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ABSTRACT 
Antibody dependent enhancement (ADE) of porcine reproductive and 
respiratory syndrome virus (PRRSV) infection as a contributing factor to viral 
pathogenesis was studied. Yield of progeny virus and infection rates of porcine 
alveolar macrophages (PAM) were increased (p<0.01) following treatment of the 
virus with subneutralizing levels of anti-PRRSV antibody. Maximum increases 
in virus yields ranged from 1.5 to 2 logio, while maximum increases in infection 
rates of PAM ranged from 7 to 53 fold. Increased yields and infection rates were 
directly correlated (r=0.95). Enhancement of virus yield in the presence of 
antibody was was blocked by Protein A, indicating that increased virus yield was 
due to enhanced uptake of virus by PAM through Fc receptors. However, the 
yield of progeny virions from individual PAM was also significantly (p<0.01) 
enhanced in the presence of antibody, suggesting that an additional mechanism 
may contribute to the increase in virus yield. 
The biological significance of ADE was assessed in two experiments. First, 
ADE of infection was demonstrated in pigs using a completely randomized block 
design (n=16). The mean level and duration of viremia were greater (p<0.05) in 
pigs injected with subneutralizing amounts of PRRSV-specific IgG prior to virus 
challenge than in control pigs injected with normal serum globulin, suggesting 
that ADE of PRRSV infection has the potential to exacerbate the severity of 
disease by amplifying virus replication in vivo. Conversely, virus replication 
was significantly (p<0.01) suppressed in pigs with a high level of neutralizing 
antibody. Second, the period of time that subneutralizing levels of passively 
supplied antibody can persist and contribute to ADE of PRRSV infection was 
estimated in 4 pigs injected with PRRSV-specific IgG to yield an initial serum-
virus neutralizing (SVN) antibody titer of 3.8 log2. Neutralizing antibody 
declined to undetectable levels by day 37 post injection (PI), while antibody 
detected by the immunoperoxidase monolayer assay continued to be detected for 
an additional 35 days. ADE activity was first detected in undiluted sera on day 20 
PI and persisted through day 62 PI, suggesting that passively immunized pigs are 
susceptible to the potential enhancing effect of ADE for a period of 5 to 6 weeks 
following the disappearance of neutralizing antibody. A similar period of 
potential susceptibility to ADE was also demonstrated by regression analysis of 
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the antibody response of 8 pigs that were infected with PRRSV by the nasal route. 
The SVN antibodies were estimated to persist for 280 days following infection, 
while non-neutralizing antibodies were estimated to persist for an additional 6 
weeks. These results strongly suggest that ADE has the potential to contribute to 
the pathogenesis of PRRSV infection in pigs with declining levels of PRRSV-
sepcific antibodies of maternal origin, or induced by vaccination or exposure to 
wild type virus. 
The western immunoblot analysis (WIA) of sera from passively 
immunized pigs revealed the presence of antibodies specific for the 15kD 
nucleocapsid and 26kD glycosylated envelope proteins in sera with ADE but no 
neutralizing activity. Because of internal location of the 15kD protein in the 
virion, the 26kD protein was concluded to be responsible for inducing antibodies 
associated with ADE. In addition, the 26kD protein appears to be also involved 
in the induction of neutralizing activity. In 8 pigs exposed to PRRSV by the nasal 
route, no SVN activity was detected until after antibodies to the 26kD protein 
was present as determined by WIA. Consequently, it is likely that the 26kD 
protein contains antigenic determinants associated with ADE and/or virus 
neutralization. 
Seventeen field isolates of PRRSV, including isolate ISU-P, were 
evaluated for their susceptibility to ADE of infection mediated by antibodies 
raised against PRRSV isolate ISU-P and were shown to vary in this respect. This 
variability was dramatically demonstrated by the neutralization of homologous 
virus by a concentration of antibody that enhanced the replication of 
heterologous isolates. These observations imply that antibodies induced by 
vaccine strains of PRRSV could also do the same in vaccinated animals that 
become infected with wild type viruses. Therefore, vaccine candidates should be 
evaluated for their ability to induce ADE activity before their use in the field. 
Furthermore, the susceptibility of PRRSV isolates to ADE was shown to be 
inversely proportional (r=0.92) to the ability of the same antibody to neutralize 
the isolates. Consequently, it may be possible to use the susceptibility of PRRSV 
isolates to neutralization by vaccine-induced antibody as a surrogate marker for 
ADE. 
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INTRODUCTION 
Dissertation Organization 
This dissertation begins with an abstract and is followed by a review of the 
literature and a statement of the problem. Three papers present the 
experimental work performed. The doctoral candidate is the principal 
investigator and senior author for all three papers. The dissertation concludes 
with a general discussion, a list of references cited in the literature review and 
general discussion, and acknowledgments. 
Literature Review 
History of PRRS 
Porcine reproductive and respiratory sjoidrome (PRRS) is a relatively new 
viral disease of swine. It was initially known as "mystery swine disease" in the 
United States (U.S.) because its etiology was unknown at the time.®^ For the 
same reason, PRRS has been identified by a variety of synonyms since the disease 
syndrome became recognized in swine populations throughout the world. Some 
examples of names used for PRRS are summarized in Table 1. The 'porcine 
reproductive and respiratory syndrome' was designated the official name at the 
First International Symposium on SIRS/PRRS held in St. Paul, Mirmesota in 
1992.195 
The first cases of PRRS were reported in the United States®5/143 a^d 
Canadai35 in 1987. In Europe, it was first reported in Germany in 1990^3 and 
subsequently in the Netherlands,3i2 Spain,240 Belgium,299 the United 
Kingdom,229 France,!"^ and Denmark^!! during 1991 and 1992. The presence of 
porcine reproductive and respiratory syndrome virus (PRRSV) has recently been 
reported in Austria,305 Asia,49/i74,270 a^d South America.^i 
Zimmerman conducted a survey of members of the American Association 
of Swine Practitioners utilizing clinical manifestations of PRRS to identify the 
approximate time of appearance of PRRS and spread of the virus in the United 
States.333 Criteria for recognizing herds infected with PRRSV included: a) 
anorexia, b) pyrexia, c) respiratory disease in yotmg pigs, d) increased stillbirths. 
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Table 1. A list of synonyms for PRRS 
Names for disease References 
abortus blauw 8 
blue ear disease 9 
blue-eared pig disease 94 
Epidemisch Spatabort der Sauen 332 
Maladie Blue du Pore 332 
Maladie Mysterieuse du Pore 332 
mystery pig disease 216 
new pig disease 216 
pig plague '89 163 
plague of 1988-1989 9 
porcine epidemic abortion and respiratory syndrome 314 
porcine viral syndrome 216 
Ratselhafte Schweinekranheit 332 
SMEDI-like syndrome 163 
Seuchenhafter Spatabort der Schweine 157 
swine infertility and respiratory syndrome 10 
swine plague 332 
swine reproductive failure syndrome 163 
swine reproductive and respiratory syndrome 332 
Syndrome dysgenesique et respiratoire du Pore 332 
Wabash syndrome 332 
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e) increased early farrowing, and f) increased numbers of mummified fetuses. 
This survey found that 1611 herds were considered to be infected in 19 states and 
that the first recognized case fitting the criteria was in 1980. Serological survey of 
banked sera collected from pigs in mid-west swine herds between 1980 and 1989 
as part of National Animal Health Monitoring System (NAHMS) revealed that 
PRRSV was present in Iowa by 1985 and in Minnesota by 1986.^28,323 
Identification of the etiologic agent 
Prior to establishing PRRSV as the cause of PRRS, a number of 
microorganisms were considered to be as the cause of PRRS. Attention was 
initially focused on porcine parvovirus, pseudorabies virus, porcine 
enteroviruses, encephalomyocarditis virus, hog cholera virus, and leptospira 
since all of these pathogens were associated with reproductive failure.^'' 
Identification of the causative agent was complicated by the isolation of one or 
more of the previously listed agents as well as mycoplasma, swine influenza 
virus, a paramyxovirus-type virus. Chlamydia psittaci, and Streptococcus suis 
from suspected cases of PRRS.i'29,38,73,78,81,144,154,208,216,236,311 Attention was also 
focused on the role of the mycotoxin, fumonisin in PRRS.12,13 
The virus that caused PRRS was first isolated in 1991 in the Netherlands299 
and subsequently in 1992 in the United States^^ and Canada.''9,80 xhe first virus 
isolates in the Netherlands and U.S. were designated Lelystad virus (LV) and 
ATCC VR-2332, respectively. Lelystad virus was isolated from specimens 
obtained from herds undergoing severe reproductive disorders utilizing porcine 
alveolar macrophage cultures, while ATCC VR-2332 was isolated from herds 
undergoing severe respiratory and reproductive problems using the proprietary 
cell line ATCC CL2621 (Boehringer Ingelheim Animal Health Inc., St. Joseph, 
Missouri). Both virus isolates were shown to reproduce reproductive and 
respiratory failures in gnotobiotic pigs that were experimentally infected by the 
nasal route.^6'289 
The virus 
Classification Porcine reproductive and respiratory syndrome virus is a 
small, enveloped RNA virus26,3io that been provisionally classified as a 
member of the Arterivirus genus of the family To^flufr/rffle.68,i97,224,30i other 
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members of the genus Arterivirus include lactate dehydrogenase elevating virus 
(LDV) of mice, equine arteritis virus (EAV) and simian hemorrhagic fever 
virus.238,239 jsjo serological cross reaction has been demonstrated between 
PRRSV and other Arteriviruses.26 
Currently, genomic studies of arteriviruses support the establishment of a 
new family independent from Togaviridae family. Arteriviridae,239 
Multiviridae,239 and Mamurnaviridae^^ have been proposed as names for the 
new family. An even more "coronavirus-like" superfamily that includes 
coronavirus, torovirus, and arterivirus has been proposed because of the high 
degree of similarity in their genomic organization and gene expression 
strategy.301 
Physicochemical properties The PRRSV is spherical in shape. The size of 
the virus ranges from 48 to 83 nm in diameter.23'26,34,i84,244,3io jt contains an 
electron dense icosahedral nucleocapsid that ranges in size from 25 to 30 nm in 
diameter.23'34,244 7^0 buoyant density of the virus ranges from 1.13 to 1.18 g/ml 
in CsCl gradients and 1.18 to 1.23 g/ml in sucrose gradients.23'6i/i84,3i4 
Three structural proteins with molecular masses of approximately 15, 19, 
and 26-30 kilodaltons (kD) have been consistently demonstrated by numerous 
independent investigators.i5'23'i84,3io Endoglycosidase treatment and 
glucosamine labeling study revealed that the 26kD protein is a N-glycosylated 
protein while the 15 and 19 kD proteins are not glycoproteins, Benfield and 
his associates have recently identified an additional viral protein with a 
molecular mass of approximately 22-23kD in lysates of cells infected with 
PRRSV.25,219 Canadian investigators have also demonstrated an additional 
glycosylated protein with a molecular mass of 42kD in virus-infected MA104 
cells.i®4 However, genomic sequence analysis suggests that PRRSV consists of as 
many as 6 proteins.^^'^^^'^^^'^^o 
Although the functions of these proteins have not been completely 
determined, a recent electron microscopic study utilizing colloidal gold labeled 
with monoclonal antibodies indicated that the 15kD protein is a nucleocapsid 
protein and the 26kD protein is an envelop protein.2i9 xhe 19kD, 22kD, and 42kD 
proteins are presumed to be components of the viral envelope.25'i84,2i9 xhe 15kD 
protein appears to be highly immunogenic since antibody specific for this protein 
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can be detected in serum from virus-infected pigs earlier than antibodies to other 
proteins.25/218 Investigators have speculated that the 26kD protein is associated 
with virus neutralization since antibody specific for this protein was detected by 
radioimmunoprecipitation (RIP) close to the time at which serum virus 
neutralizing activity was present.^s 
The PRRSV is stable for at least 1 month at 4°C and for several months at 
-70°C. Complete inactivation occurs within 48 hours at 37°C and by 45 minutes 
at 56°C.23'26 Infectivity of the virus is reduced over 90% at a pH less than 5 or 
greater than 7.^6 No chemical inactivatant except chloroform has been tested in 
vitro against PRRSV.26 In common with other members of the Arterivirus 
group, PRRSV does not hemagglutinate red blood cells from mammalian or 
avian species including sheep, goat, swine, cattle, mouse, rat, rabbit, guinea pig, 
human type O, duck, and chicken.26,314 
Genomic organization and gene expression The genome of the virus is 
polyadenylated, single-stranded positive sense jhe genome is 
approximately 15 kilobases in size and consists of 8 open-reading frames 
(ORFs).68'i^7 Each of the ORFs 2 through 7 is overlapped with neighboring ORFs 
in their organization. The ORFs la and lb are predicted to encode the RNA-
dependent RNA polymerase, whereas ORFs 2 to 6 are presumed to encode 
membrane-associated proteins and ORF 7 to encode the nucleocapsid protein. 
Comparison of the amino acid sequences encoded by each of the ORFs of PRRSV 
to that of other members of the Arterivirus group indicate that PRRSV is more 
similar to LDV than to EAV.^®'!^^ 
Genes are expressed by the production of a 3' co-terminal nested set of 7 
subgenomic mRNAs.^^'^^^ Each subgenomic RNA contains the same leader 
sequence at its 5' end. Gene expression of PRRSV is similar to that of 
Coronaviruses and Toroviruses, rather than that of Togaviruses.^S'i^'''30i It is not 
known how soon PRRSV-encoded mRNA is produced in infected cells, 
although Bautista et al. reported that viral polypeptide can be detected in infected 
cells as early as 16 hours postinoculation.^s the case of LDV, viral RNA has 
been reported to be detected as early as 8 hours after infection.239 
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Viral replication The porcine alveolar macrophage is the only cell to date 
proven to support virus replication both in vitro and in yiuo.^^'203,3i2,33i jt 
not been determined which surface molecules on the cells serve as receptors for 
the virus and how the virus is internalized into target cells. After 
internalization, viral replication occurs only in the cytoplasm of infected cells. 
The virus produces 3' co-terminal nested set of 7 subgenomic mRNAs.^®-!^^ Each 
of subgenomic mRNAs is known to encode for individual viral proteins. Viral 
RNA-dependent RNA polymerase is the only nonstructural protein identified to 
date that functions in replication of the viral genome. The nucleocapsid obtains 
an envelope by budding through the membrane of the smooth endoplasmic 
reticulum.23'242,244 Enveloped virions accumulate in the endoplasmic reticulum 
which causes its enlargement.244 in addition to enlargement of endoplasmic 
reticulum, severe disruption of mitochondria and formation of double-layered 
vesicles has also been observed in infected cells. The same changes have been 
observed in mouse macrophages infected with LDV.277 An ultrastructural study 
on PAM inoculated with PRRSV revealed that progeny virus was first observed 
in the cells at 9 to 12 hours after inoculation with a multiplicity of infection of 1, 
suggesting that the replication cycle of the virus in the cells is 9 to 12 hours.244 
Progeny viruses are released from the cell initially by exocytosis and eventually 
by cell lysis.244 Most PRRSV isolates produce cytolytic infections, but some 
investigators have reported the existence of noncytopathic PRRSV 
isolates.6i'i®4,325 
Virus propagation The virus is known to replicate preferentially in 
PAM.^1'203,312,331 Virus-specific cytopathic effects can be detected by light 
microscopy in the PAM cultures between 48 and 72 hours after inoculation. The 
virus yield from PAM ranges from 10^ to 10^ TCIDso/ml.^i Peripheral blood 
monocytes of swine have recently been demonstrated to support PRRSV 
replication in vitro, but progeny virus yield in the monocyte culture was found 
to be lower (10^ TCID50/ml) compared to virus yield obtained with PAM (10^ 
TCID5o/ml).303 More recently, Molitor et al. reported that splenic macrophages 
and brain microglial cells of swine also supported PRRSV replication in vitro.^^^ 
Virus replication has also been demonstrated in established cell lines, such 
as ATCC CL2621 cells and the African green monkey kidney cell line. 
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MA104.68/100,167 a comparative study revealed that PAM are more susceptible to 
PRRSV than the CL2621 cell in terms of the isolation rate of the virus from 
clinical specimens.!^ However, some PRRSV isolates only replicate in CL2621 or 
PAM but not both. A more susceptible subpopulation of MA104 cells (MARC-
145) has recently been cloned.i^'' The virus replication cycle in MARC-145 cells is 
48 to 72 hours when the cells are exposed to virus at a multiplicity of infection of 
0.01. Maximum progeny virus titers of lO®-^ TCIDso/O.lml have been obtained 
with this clone. 
Antigenic variation To date, marked antigenic differences have been 
demonstrated among PRRSV isolates. Broad antigenic variation is a major 
concern in the development of effective vaccines and vaccination strategies 
against PRRS. The existence of antigenic variation among PRRSV isolates was 
initially demonstrated between European and North American PRRSV using 
the immunoperoxidase monolayer assay (IPMA).3i3 Investigators evaluated the 
reactivity of polyclonal porcine antibodies raised against LV and ATCC VR-2332 
isolate with PRRSV isolates from countries arovmd the world. The investigators 
were able to distinguish between European and North American isolates based 
on IPMA antibody titers of reference antisera which were determined using each 
isolate as antigen. Significantly higher antibody titers were obtained between 
anti-LV antibody and European isolates or between anti VR-2332 antibody and 
North American isolates than between other combinations. In another study, 
837 swine sera collected from 87 herds in 18 states in the U.S. were tested by 
fluorescence microscopy for PRRSV-specific antibodies using the Lelystad and 
ATCC VR-2332 virus isolates.Approximately 58% of the samples tested 
contained PRRSV-specific antibodies and 36.1% of the samples contained 
antibodies which reacted with both viruses. Antibodies to Lelystad virus were 
found in 20.1% of the samples and antibodies to VR-2332 virus were found in 
43.8% of the samples. 
Field isolates of PRRSV have been shown to vary in their ability to be 
neutralized by antibody raised against a heterologous virus isolate. McGinley et 
al. compared 22 North American PRRSV isolates for their antigenic relationship 
by a one-way serum-virus neutralization (SVN) test using polyclonal porcine 
antibodies raised against PRRSV isolate ISU-P (ATCC VR-2402).i86 The PRRSV 
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isolates were placed in one of 3 groups based on their cross neutralization index. 
The virus isolates in groups 1, 2, and 3 were cross neutralized by the antiserum at 
a rate of 50%, 25-30%, and <15% of the homologous system, respectively. More 
recently, a similar variability in the susceptibility to neutralization was also 
observed among European isolates of PRRSV.233 
Antigenic diversity among PRRSV isolates has also been demonstrated 
using monoclonal antibodies (MAbs). Nelson et al. evaluated the reactivities of 
a panel of 3 MAbs (SD0W17, V017, EP147) directed against the 15 kD 
nucleocapsid protein.217 Sixty-three U.S. isolates originating in the midwest and 
57 European isolates representing Denmark, France, Germany, Italy, 
Luxembourg, the Netherlands, Spain, and the United Kingdom were examined 
using fluorescence microscopy. All 3 MAbs reacted with all 63 U.S. PRRSV 
isolates, while MAb SDOW17 reacted with the 57 European isolates; neither 
V017 or EP147 reacted with any European isolates. More recently, Yoon et al. 
examined the antigenic relationship of 22 U.S. PRRSV isolates from 8 different 
states (Arizona, Iowa, Illinois, Kansas, Michigan, Minnesota, North Carolina, 
Permsylvania) from 1989 through 1993.329 The antigenic relationship of the 
isolates was evaluated by fluorescence microscopy using a panel of 5 MAbs 
(SDOW17, V017, EP147, M146, M302) specific for the 15kD protein. The 22 virus 
isolates were categorized into three groups based on their reactivities to the 5 
MAbs. Eighteen of 22 isolates were recognized by all MAbs and 3 of the 
remaining isolates were detected by all MAbs except the MAb EP147. One unique 
isolate was recognized only with MAb V017. Similarly, Drew et al. evaluated the 
antigenic relationship of 18 United Kingdom and 7 continental European field 
isolates of PRRSV using a panel of 6 monoclonal antibodies specific for the 
nucleocapsid protein and observed broad antigenic variation among the 
isolates.^2 
Genomic sequence analysis of the PRRSV genome has provided genetic 
evidence for the marked antigenic diversity that was demonstrated by serological 
tests.56,160,191,192,215 By comparing partial genomic sequences. North American 
PRRSV isolates were found to have 87 to 95% homology in their nucleotide 
sequences but were only 64 to 67% similar to European isolates. In these studies, 
amino acid homology between North American and European isolates was 
shown to be 60 to 80%. 
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The antigenic variation of PRRSV with respect to virulence has also been 
evaluated by a pathological study conducted by Halbur et Groups of 
cesarean-derived colostrum-deprived pigs were infected intranasally with 
various U.S. PRRSV field isolates collected from swine herds that experienced 
different types of clinical disease outbreaks. Clinical signs associated with 
respiratory disease and rectal temperature response were monitored. In addition, 
pigs from each virus group were periodically killed through 35 days 
postinoculation, and the blood, lung, lymph nodes, brain, heart, spleen, kidney, 
and bone marrow were collected from the pigs. Subsequently, gross lung lesions 
were subjectively scored based on the area of consolidation. Microscopic lesions 
in tissues of these organs were evaluated. By comparing lesions, the 
investigators concluded that U.S. PRRSV isolates varied in their pathogenicity. 
These investigators also observed that virus isolates with lower gross lung lesion 
scores caused less severe respiratory disease than isolates with higher scores. 
However, these differences were not able to be correlated with genomic 
differences among the isolates. 
Clinical manifestations 
The clinical manifestations of PRRS vary depending upon a number of 
factors including age of the pig, health status, immune status, reproductive 
status, and herd management practices.^ The PRRSV infection of breeding 
stock is generally characterized by anorexia, fever, respiratory signs (i.e., coughing 
and dyspnea), malaise, cyanosis of the extremities in a small number of cases, 
and reproductive disorders.i63'i79 Reproductive failure associated with PRRSV 
infection in the breeding age female includes delayed return to estrus or lack of 
cycling, premature farrowing, and an increase in the number of late term 
abortions, stillborn pigs, mummified fetuses, and weakborn pigs which usually 
fail to thrive and die shortly after birth.i63,i79,289 the breeding age boar, PRRSV 
infection has shown to cause changes in semen quality.76'97,3i6 These changes 
were manifested by increases in morphological abnormalities of spermatozoa, 
and decreases in motility and number of spermatozoa following infection. As 
many as 25% of boars tested in infected herds experienced a temporary decline in 
semen quality (volume, motility and morphology of spermatozoa).^6,97,271 
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Clinical infection by PRRSV in neonates and nursery pigs is manifested 
primarily as respiratory disease.^'^^^ Nursery pigs typically present with 
coughing and "thumping" and grow poorly. Interstitial pneumonia is the 
primary cause of lung dysfunction in these pigs.^6'243 Diarrhea has also been 
associated with PRRSV infection of neonatal pigs in some herds which 
commonly results in increased early preweaning death.^O-^o infection of PRRSV 
in nursery pigs has been shown to increase the susceptibility of pigs to secondary 
bacterial infection. Infections by Streptococcus suis, Salmonella choleraesuis, 
Hemophilus parasuis, Pasteurella multocida, and Actinobacillus 
pleuropneumoniae have been implicated in early preweaning death of nursery 
pigs which were infected concurrently with PRRSV.Growers and finishers 
may also present with mild respiratory disease and poor performance.3i'32 Today, 
respiratory disease in nursery pigs appears to be the most prevalent 
manifestation of PRRSV infection (J Zimmerman, Veterinary Diagnostic 
Laboratory, Iowa State University, Ames, Iowa, personal communication). 
The clinical presentation of herds infected with PRRSV can be categorized 
into three forms: subclinical, acute (epidemic), or chronic (endemic). 
Clinical signs of reproductive and respiratory disease are not present in the 
subclinical form of PRRS. Infection can only be recognized by the detection of 
PRRSV-specific antibodies. In the acute form, naive herds infected with the 
virus have all the clinical manifestations of severe reproductive and respiratory 
disorders.^O'^i'''^ The acute phase has been reported to last anywhere from several 
weeks to several months. 144,212 the endemic form of PRRS, herds become 
infected and fail to return to the performance level of reproduction and growth 
that was present prior to infection. Early infertility problems in breeding females 
and chronic respiratory disease complicated by secondary bacterial infection in 
young pigs continue to be a problem in these herds.^i Frequently, poor 
performance in young pigs results in increased production costs to the 
producers.30'31'165 
Epidemiology 
Prevalence Porcine reproductive and respiratory syndrome virus is 
widespread in swine producing regions throughout the world. Seroprevalence 
studies conducted to assess the spread of PRRSV in the United States revealed 
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variable ir\fectior\ rates. In a survey of sera collected during the second quarter of 
1992 from cull breeding swine in 11 states, 7.3% of the samples were positive by 
the IFA test.ii In a study of U.S. herds enrolled in NAHMS during the years 1990 
and 1991, 35% of 396 herds in 17 states were seropositive for PRRSV.2i'209 
seroprevalence in herds ranged from 2% - 82% with a mean seroprevalence of 
herds within states of 33%. In another study, a total of 2787 sera obtained from 
263 pig farms in 13 midwest states during the first 6 months of 1992 were tested 
by the IFA test for antibodies specific for PRRSV.53 Approximately 54% of the 
herds tested were seropositive. Prevalence of PRRS in the U.S. swine herds was 
directly correlated with swine population density. 
In Europe, the number of clinical outbreaks of PRRS has decreased since it 
reached a peak in early to mid 1991.Although PRRSV infection appears to be 
widespread in European swine population, there is no thorough report as to 
prevalence of PRRS in Europe. 
Economic impact The widespread prevalence of PRRS throughout the 
world has created an economic hardship for swine producers. The economic 
losses to the swine producer are due to: a) death loss of pigs, b) increased costs to 
finish market hogs, c) increased costs of veterinary services and drugs, d) 
increased labor costs, and d) an increase in nonproductive sow days which creates 
the need for establishing larger sow and boar inventory to maintain maximum 
facility usage.^^'^^^ 
Typical reproductive losses that can be expected in a herd acutely infected 
with PRRSV were summarized in a study of 4 affected herds in Great Britain.i^® 
Abortion and premature farrowing rates were up to 3.3% and 20.6% of pregnant 
sows, respectively. Among pigs bom, 26.0°/) and 18.8% of the pigs were stillborn 
and mummified, respectively. Neonatal and preweaning death rates reached 
88.0%. German investigators evaluated pig losses during and after a PRRS 
outbreak in 200 sows. The mean number of pigs lost per litter rose from a pre-
outbreak level of 22.3% to a finial mortality rate of 67.0%.^! Following the 
outbreak the mean number of pigs lost per litter returned to the pre-outbreak 
level. In the United States, Keffaber investigated 11 infected herds in the 
midwest and reported that the mean number of pigs weaned per litter was 2.9 
and the mean nursery death rate was 50%.i^3 
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The economic impact of PRRSV infection in a typical U.S. herd 
undergoing an acute outbreak was evaluated.245 Assuming that infected herds 
return to normal following the outbreak, estimated losses were estimated to be 
$236 per inventoried sow. Potential chronic losses were estimated to be $502 per 
female in one severely affected herd. Reduced conception rates have also added 
to the economic impact of PRRS in some herds due to increased nonproductive 
sow days.163 
In addition to reproductive losses, productivity of growing pigs is also 
influenced by infection of PRRSV. Following infection, fattening pigs are often 
undersized and have retarded growth, Blaha studied the consequence of 
PRRSV infection in 12 finishing herds in Germany.32 The average mortality of 
finishing hogs rose from 2.2% to 4.3% and lung lesions of pigs at slaughter 
increased from 45% to 70%. Secondary bacterial infections with Salmonella 
choleraesuis, Streptococcus suis, or Hemophilus parasuis have resulted in 
mortality rates of 15-25%A^^ Increased rates of bacterial infections following a 
PRRS outbreak lead to increased vaccine and medication costs, increased labor 
costs, and decreased average daily gains.^'i^5'289 
Host species Pigs {Sus scrofa domestica) are the only known species of 
domestic animals that are susceptible to PRRSV infection and show clinical 
manifestations after infection. The presence of antibody in wild boars indicates 
that feral swine may also be susceptible to PRRSV as well (J. Zimmerman, 
Veterinary Diagnostic Laboratory, Iowa State University, Ames, Iowa, personal 
communication).227 
Experimental inoculation of various species of birds indicates that some 
birds may be susceptible to PRRSV infection.335 Muscovy ducks, guinea fowl, 
Cornish cross chickens, and mallard ducks were inoculated orally via the 
drinking water with approximately 10^ TCID50 of PRRSV per bird. Feces from the 
birds were collected for 30 days and assayed for virus. No virus was isolated from 
Muscovy duck feces. Virus was isolated from guinea fowl feces on days 5 and 12, 
and chicken feces on day 5 post inoculation (PI). PRRSV was isolated from 
Mallard duck feces at most sampling points between day 5 to 24 PI. No overt 
clinical signs or seroconversion were observed in any birds at any time during 
the collection period. Recovery of PRRSV from feces on days ^3 PI provided 
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evidence of viral replication in one or more of the systems emptying into the 
cloaca, rather than passive movement of challenge virus through the 
gastrointestinal tract. Levels of PRRSV in feces were not determined. Using 
fecal shedding of virus as the criterion for the susceptibility, Muscovy ducks were 
found to be completely resistant, guinea fowl and chickens marginally 
susceptible, and Mallard ducks highly susceptible to PRRSV infection. 
Attempts to isolate PRRSV from tissues and sera from trapped wild mice 
and rats obtained from farms with endemically infected herds were 
unsuccessful.^^'' In addition, mice and rats that were experimentally infected 
with 103 to 10^ TCIDso's by the nasal, peritoneal and oral routes did not become 
infected. No virus was isolated from sera or any of the tissues collected. Gross 
and microscopic examinations did not revealed any abnormalities. 
Transmission Direct contact with infected swine has been considered a 
major route of transmission of PRRSV between pigs, and has been incriminated 
as a cause of PRRSV outbreaks in naive herds after purchase and movement of 
infected swine.'*2,43,83,94,iio,163,189,253,255,299 jn Spain, pigs imported from Germany 
were incriminated as the source of PRRSV infection.240,241,242 Field observations 
indicate that transmission occurs when weaned pigs are exposed to older pigs.^^^ 
Young pigs which were weaned into an isolation facility did not seroconvert 
until coming into contact with older pigs. Seroconversion was also 
demonstrated when uninfected pigs were commingled under experimental 
conditions with penmates which were infected with PRRSV several weeks 
earlier.288,326,334 Seronegative finishing pigs seroconverted after they were 
commingled with experimentally infected sows 14 weeks following 
inoculation334 but not when commingled with sows 26 weeks after 
inoculation. 326 Regarding the exit portal of PRRSV, Yoon et al. reported that the 
virus was recovered from nasal secretions and feces of experimentally infected 
pigs for up to 35 days.326 in contrast. Wills et al. did not detect the virus in the 
feces of experimentally infected pigs and questioned the role of feces in 
transmission of the virus.^20 Urine^ and saliva320 have been demonstrated to 
be a source of virus transmission to naive pigs. 
It has been proposed that airborne transmission of PRRSV can occur over 
a distance of 20 kilometers.'^'^2,72,93,94,i35,i70,i7i,i89,253,254,267 However, Wills et al. 
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reported the absence of transmission of PRRSV between infected and uninfected 
pigs housed in isolation vmits with a common air source.317 in subsequent work, 
these investigators evaluated the possibility of airborne transmission in a more 
confined area.^i^ Three nursery decks were placed parallel to each other and 46 
cm apart in the same room. A aluminum partition the size of the deck side 
walls was suspended halfway between the center deck and a side deck. In 3 of 5 
trials, no transmission of virus was demonstrated from infected pigs (n=3) in the 
center deck to pigs (n=3) in the side deck separated by the barrier, although air 
flow studies showed that air moved over, under, and aroimd the barrier. In 5 of 
5 trials, however, PRRSV-free pigs commingled with infected pigs in the central 
deck, and pigs in the side deck without a barrier became viremic and 
seroconverted. The data strongly indicated that airborne transmission does not 
readily occur and, if it does occur, it does so only over a relatively short distance. 
Semen collected from clinically or subclinically infected boars is 
considered a potential source for transmission of PRRSV. Robertson reported an 
outbreak of PRRS in swine herds in Great Britain in which the only source of 
outside contact with pigs was through artificial insemination (AI).254 Yager et al. 
also suggested that fresh semen is a possible source of PRRSV in the U.S. swine 
herds.321 Experimentally, AI of 2 gilts with freshly collected unextended semen 
from experimentally infected boars resulted in the development of clinical signs 
of PRRS and seroconversion by both gilts 3 to 4 days after AI. Swenson et al. 
demonstrated the presence of viable PRRSV in semen ejaculated from boars that 
were experimentally infected by the nasal route for as long as 43 days 
postinoculation.280 This study was done by a 'swine bioassay' technique in which 
semen samples were injected into the peritoneal cavity of young pigs. Sera were 
collected from these pigs weekly for 5 weeks PI and assayed for anti-PRRSV 
antibody by the IFA test. Seroconversion was an indicative of the presence of 
infectious virus. These investigators, however, were not able to infect gilts that 
were artificially inseminated with extended semen collected from a boar 
experimentally infected with PRRSV.279 in contrast, the pregnancy rate in gilts 
receiving virus-contaminated semen was 20% compared to 67% in gilts 
inseminated with virus-free control semen. Work by Christopher-Hennings et 
al. also supports prolonged shedding of PRRSV in semen.^3 Using the 
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polymerase chain reaction (PGR), these investigators detected PRRSV in semen 
from experimentally infected boars for up to 92 days after initial exposure. 
The role of fomites in the transmission of the virus has not been 
completely evaluated. Under certain conditions, such as a high humidity or in 
the presence of high concentration of organic materials, PRRSV appears to 
survive in the environment for extended periods of time. Pigs placed in 
facilities used for PRRSV studies seroconverted after being placed in non-
disinfected rooms 3 to 4 weeks after infected pigs had been removed from the 
rooms.It was recently found that virus infectivity can be retained in well 
water for 9 days under experimental conditions.237 
A study demonstrated that some birds were susceptible to PRRSV 
infection and shed the virus for extended period of time after exposure.335 These 
observations suggest that some species of birds may have the potential to act as 
biological vectors and transmit the PRRSV over a long distance. To date, no 
insect vector has been reported to be associated with transmission of PRRSV. 
Diagnosis 
A presumptive diagnosis of PRRSV infection is based on clinical 
manifestations such as reproductive problems and chronic respiratory disease. 
The reproductive problems of PRRS are characterized by poor conception rates, 
late-term abortion, and increases in numbers of stillborn pigs, mummified 
fetuses, and weakbom pigs. However, because of the similarity of clinical 
manifestations with those induced by other viral and bacterial pathogens, a 
differential test is required for a definitive diagnosis.ii7'i20,328 Furthermore, there 
are no pathognomonic gross or histopathological lesions for the respiratory 
disease induced by PRRS virus infection, although interstitial pneumonia is a 
common finding.^o A definitive diagnosis of PRRSV infection requires the 
isolation of virus, detection of antibody, detection of viral antigen, or detection of 
genomic materials. 
Virus isolation Porcine alveolar macrophages,i^'7®'®°'230'3i2,325,330 CL2621 
cells,i9'26/ioo,i36 MA104 cells,^^'' and MARC-145 cells^^^ have been reported to 
support virus replication in vitro and used for virus isolation from tissues and 
clinical specimens. PRRSV has been isolated from the spleen,24,i 12,165,296,297 
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lungS,24,80,112,153,165,190,223,265,289,296,297 lymph nodeS,24,165,265,296,297 heart,24 
thymus,ii2,296,297 tonsil,24,112,265,296,297 nasal turbinate,24 placenta,plasma,223,265 
serum,^4,25,59,9i,ii2,i53,i65,i90,230,265,296,297 buffy coat layer of citrated blood,i^5'265 
urine,m'265 feces,265,326 sejnen,280,32i nasal swabs.23i'265,326 Saliva is found to 
be a source for virus isolation.^^o Lung and serum are samples of choice for virus 
isolation.153 particular, the presence of a long viremia in young pigs has made 
serum a good source for virus isolation.296 in cases of late-term abortion and 
early farrowing, samples should be collected from weakbom pigs rather than 
mummies, aborted, or stillborn pigs.90,i55,296,330 
The thermal susceptibility of PRRSV in specimens to different 
environmental temperature was evaluated.297 The virus isolation rate from 
positive tissues was 47%, 14%, and 7% when tissues were kept at 25°C for 24, 48, 
and 72 hours, while virus isolation rates were >85% from tissues stored at 4°C 
and -20°C for the same time periods. In contrast, virus was isolated from all but 1 
serum sample kept at 25°C even for 72 hours. This observation indicates that 
serum may have a protective effect on PRRSV. Current recommendations are 
that tissues and clinical specimens collected for virus isolation should be kept at 
refrigerator temperature during shipment to diagnostic facilities in order to 
enhance the likelihood of isolating the virus. 
Although several cells types have been reported to support PRRSV 
replication, the ability of these cells to grow virus from samples of infected pigs 
has been complicated by the fact that individual isolates do not replicate in all 
cell types. In a comparative study, 98 tissues and 73 sera were assayed for the 
presence of PRRSV utilizing PAM and CL2621 cells, Virus was recovered from 
7 of 98 (7%) and 4 of 98 (4%) tissue samples in PAM and CL2621 cultures, 
respectively. Eighteen of 73 serum samples (25%) were found to contain the 
virus using PAM, but only 2 isolations (3%) were made in CL2621 cell culture. 
Interestingly, 25 of 82 PRRSV isolates (30%) isolated in CL2621 cells did not grow 
in PAM and 28 of the isolates (34%) that grew in PAM did not produce cytopathic 
effect. Five out of 18 isolates (28%) from PAM did not grow in CL2621 cells. 
These differences demonstrate that at least 2 cell types should be used for virus 
isolation whenever possible. 
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Serology The indirect fluorescent antibody test,324 serum virus 
neutralization (SVN) test,26,2io immunoperoxidase monolayer assay,^12 ^^d 
enzyme-linked immunosorbent assay (ELISA)^ have been used for the detection 
of PRRSV-specific antibodies. Most North American veterinary diagnostic 
laboratories have extensively used the IFA test, while European laboratories 
have relied on the IPMA using PRRSV-infected PAM.^^^ jhe recent licensure of 
a commercial ELISA kit (Idexx) is changing this picture. 
The IFA and IPMA are thought to be highly specific and sensitive tests. 
Antibodies to PRRSV are usually detected by these tests between 7 and 15 days 
after infection.112,223,312,324 goth IFA and IPMA reliably detect specific antibodies 
for 2 to 3 months after infection.io°'ii2,223 jhe ELISA is also reported to be 
sensitive and specific.^'^^ One disadvantage of the ELISA was reported to be 
unacceptable background reaction in some negative pigs.^4'23i one study, 
PRRSV-specific antibodies were reported to be detected by ELISA as early as 10 
days after exposure and infected sows remained seropositive for at least 5 
months.5 The specificity and sensitivity of the commercial ELISA has not been 
evaluated. 
The SVN test is considered to be a specific test, but previous studies have 
suggested that the SVN test is less sensitive than the IFA and IPMA tests.26-2io 
This low sensitivity of the test is mainly due to the fact that neutralizing 
antibodies against PRRSV develop as late as 1 to 2 months after 
infection.27/100,112,200,210 jhe low sensitivity of the test, together with the fact that 
the test is laborious, has resulted in the SVN test being used primarily as a 
research tool. A recent report indicated that the sensitivity of the SVN test could 
be increased by adding 20% fresh normal swine serum to serum being assayed.327 
Neutralizing antibodies were detected in the serum of infected pigs at 9-11 days 
following exposure to PRRS virus using this modification of the SVN test. 
Interpretation of diagnostic information obtained from serological testing 
has been complicated by several factors. First, antigenic diversity among PRRSV 
isolates is a major concern in interpreting the serological information especially 
obtained by the IFA and IPMA tests since false negative results may be due to the 
strain of virus in use at a diagnostic laboratory.^! Secondly, lack of comparative 
information on the performance of the IFA, IPMA, ELISA and SVN tests in 
detecting PRRSV-specific antibody over time makes it difficult for diagnosticians 
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to standardize the tests in use. Thirdly, because of the high prevalence of PRRSV 
infection in herds, serological information from a single sample is not sufficient 
for evaluating PRRS status of individual animals.296 Consequently, it has been 
suggested that PRRS serology should be used primarily to determine if a herd has 
been exposed to PRRSV as opposite to virus isolation.296 
Although serological information is considered to be as a useful tool in 
tracking the progression of PRRSV infection within a population, the 
information by itself is not a good predictor of immunity. Viremia is frequently 
detected in infected pigs in the presence circulating antibody specific for 
PRRSV,^^ and persistent infection of PRRSV was observed in pigs with relatively 
high levels of SVN antibodies.319 in addition, discovery of positive antibody 
titers against PRRSV in a group of pigs during the outbreak of disease similar to 
PRRS is not direct evidence of cause in some instances.^^^ Consequently, for a 
definitive diagnosis, virus isolation and/or detection of viral antigen or genomic 
material are the tests of choice.^i'^ 
Detection of viral antigen Benfield et al. described monoclonal antibodies 
which have been used to identify PRRSV antigen in lungs of infected pigs.23 
Done et al. have also reported the use of the fluorescent antibody (FA) technique 
for detection of viral antigen in frozen spleen and lung tissues with monoclonal 
or polyclonal antibodies.^i A disadvantage of the FA technique is that the test is 
not suitable for fixed tissues. Immunohistochemical tests utilizing an 
immunoperoxidase systemii^'ii®'243 or colloidal goldi''6,i82 have been developed 
to detect PRRSV in frozen or fixed tissues. Both tests are reported to be highly 
sensitive in detecting viral antigens in a variety of tissues including heart, 
kidney, lung, lymph nodes, spleen, thymus, and tonsil. 
Detection of viral genomic material A reverse transcriptase-polymerase 
chain reaction (RT-PCR) utilizing a nested set of specific primers complementary 
to the sequences of ORF 7 has been developed to detect viral nucleic acid in 
infected cells and tissues specimens collected from infected pigs.62,278 size of 
primers designed for VR-2332 isolate of PRRSV and LV is 22- and 28-mer 
oligonucleotides, respectively. Target sequences within ORF 7 for amplification 
are located at between nucleotides 14639 and 14950 for LV, and between 
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nucleotides 2885 and 3121 for VR-2332. More recently, an in situ hybridization 
technique that utilizes a nonradiolabeled RNA probe (1000 base pairs in length) 
that is specific for a partial sequence of ORF 7 of PRRSV has been developed.i'^o 
Although experimental data indicate that the both RT-PCR and in situ 
hybridization techniques can be used as a sensitive diagnostic tool for detecting 
the presence of PRESV, specificity and sensitivity of these techniques have not 
been thoroughly evaluated. 
Prevention and control 
Prevention and control of PRRS mainly depends the implementation of 
good preventive medicine and husbandry. The initial method of prevention 
was partial or complete restriction of pig movement from herds affected by 
PRRS. For example, the European Economic Community established control 
measures for pig movement.^^^z These measures mandated that pigs could only 
be moved to slaughter 8 weeks after clinical signs had disappeared. This 
restriction applied to herds in which two of three following clinical signs were 
observed: a) abortion >8%; b) stillbirth rate > 20%; and/or c) preweaning 
mortality >25% in a 14 day period. However, this measure was largely ineffective 
because herds routinely remained infected for longer than 8 weeks.2'302 7^0 
United Kingdom introduced "draconian" measures to prevent spreading PRRS 
from affected herds by issuing the "blue-eared pig disease order".253 This method 
also adopted complete restriction of pig movement. It was effective in slowing 
down the spread of PRRS; however, at the same time, it caused economic 
hardships to owners of affected herds.30,94 
Current prevention of PRRSV infection is dependent on management 
strategies which maintain high biosecurity standards.^^/in This includes limiting 
traffic on the premise, cleaning and disinfecting transport vehicles, limiting 
access to buildings, and maintaining rodent control programs. Purchases of 
breeding stock should be done by matching donor and recipient herds with the 
same PRRS status.m Stock should preferably be purchased from a limited 
number of sources. It is recommended that all replacement pigs should be 
quarantined for 3 weeks prior to entry into the herd. In addition, the all-in/all-
out production strategies, age segregation, and multisite production have been 
successfully used to prevent PRRS.^^'m'i^s 
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The use of vaccine is being advocated to prevent and/or control PRRS. 
An experimental killed vaccine has been evaluated in sows and found to 
provide protection against reproductive disease.^®'' In this study, vaccinated sows 
delivered 23 normal and 2 stillborn pigs, while control sows delivered 36 
stillborn pigs and no normal pigs after homologous challenge by the nasal route. 
Recently, a commercial "modified" live virus vaccine has been made available to 
the swine industry (NOBL Laboratories). This vaccine has not yet been critically 
evaluated for efficacy and safety by independent investigators. However, field 
observations indicate that the efficacy of this vaccine varies from being effective, 
to occasionally contributing to the disease problem (B Thacker, Iowa State 
University, Ames, Iowa, personal communication; G Erickson, personal 
communication). 
The control of PRRSV following infection of a herd is primarily based on 
symptomatic treatment and management practices which reduce stress, 
minimize exposure to secondary pathogens, and prevent exposure of naive pigs 
to infected pigs. Use of electrolytes, anti-inflammatory drugs, and antibiotics has 
been recommended for symptomatic treatment.ii0'i79,2i2 Management practices 
designed to reduce stress and minimize secondary infection include: 
maintaining adequate and clean environmental conditions (temperature, 
humidity, drafts, and ventilation), feeding good quality feed, preventing 
exposure to older pigs, widespread use of antibiotics, and vaccination against 
pathogens found on the farm.i^i'i''9,2i3,3i6 Management of the breeding herd is 
another key area in the control of PRRS.®^ Strategies such as partial 
depopulation, depopulation/repopulation, test and removal, and modified 
medicated early weaning have also been evaluated and appear to be useful in 
eliminating PRRSV from infected herds.®3-85,iii However, the long range success 
of these strategies for eradication of PRRSV is tmknown. 
Pathogenesis 
Introduction Pigs can be experimentally infected with the virus via oral, 
nasal, intramuscular, intrauterine, intravenous, and intraperitoneal routes.^'' 
Minimum infectious dose of the virus is estimated to be 10 virions when pigs 
are exposed to the virus intramuscularly or by the nasal route (M McGinely, 
Bayer Corporation-Agricultural Division, Shawnee Mission, Kansas, personal 
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communication). Following nasal challenge with PRRSV, the virus is detected 
in plasma or serum of the pigs 24 to 36 hours laterOne study revealed that 
pigs that are experimentally infected at 3 days of age became viremic at 12 hours 
after exposure.24 Viremia persists approximately for 4 weeks and occasionally for 
up to 8 weeks.9'^'1^^'274 All sites of PRRSV replication have not been identified. 
The extended period of transmissibility of PRRSV from infected pigs 
raised questions as to where the virus localizes in the body and whether pigs 
become latent/chronic carriers of the virus. Regarding the possibility that 
PRRSV may induce latency in infected pigs, corticosteroid-induced 
immunosuppression studies failed to reactivate latent virus in experimentally 
infected pigs at 12 weeks postinoculation.326 in contrast, Albina et al. found that 
movement stress and administration of prednisolone resulted in transmission 
of PRRS by animals that had seroconverted to PRRSV 15 weeks earlier.^ More 
recently. Wills et al. demonstrated the presence of PRRSV in oropharyngeal 
scraping samples collected from experimentally infected pigs for up to 157 days 
postinoculation.3i^ Overt clinical signs of PRRS were not observed in any of 
these pigs, indicating chronic infection of PRRSV. These data strongly support 
field observations that the virus can persist in infected pigs for relatively long 
periods of time after initial exposure. The investigators suspect that the virus 
may localize in tonsils of infected pigs. 
Initial clinical signs manifested by anorexia, lethargy, and fever appear 
within 3 to 5 days.^^'^^^ In some herds, pigs show transient blue discoloration of 
ears, vulva, tails, abdomens and snouts. Vascular lesions including swollen 
endothelial cells and thrombi have been suggested to play a role in the transient 
blue discoloration of extremities.^o® It is possible that the subcutaneous^i^ and 
periorbital edema^^o which have occasionally been observed in affected pigs may 
also be attributed to vascular lesions. The initial phase of disease is followed by 
clinical manifestations associated with respiratory distress and reproductive 
disorders.24 Such clinical signs appear within 1 to 2 weeks after infection. 
Respiratory disease Clinical PRRSV infection of neonates and nursery pigs 
is manifested primarily as respiratory disease in the field.64,179 Clinical signs are 
coughing and "thumping". Lungs of affected pigs may appear grossly normal 
unless infection is complicated with secondary pathogens.^^'^^'^o Interstitial 
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pneumonia is a common observation in infected pigs.66,243 Microscopic lesions 
are characterized by thickening of alveolar septa and accumulation of 
degenerating cells and proteinaceous debris in alveolar spaces.^^^ 
Although respiratory disease is a major clinical component of PRRSV 
infection in the field, it has been difficult to consistently reproduce it 
experimentally even though histological lesions compatible with those observed 
in field cases of PRRSV infection were present in experimentally infected 
pigs 66,98,243 Failure to reproduce respiratory disease in pigs may be due to several 
factors. First, reproduction of PRRSV-induced respiratory signs may require a 
synergistic interaction with other respiratory pathogens. For example, Collins et 
al. were able to demonstrate respiratory signs in 10-day old SPF pigs 7 days after 
concurrent infection with both PRRSV and Streptococcus suis but not with 
PRRSV alone.^5 Secondly, the genetic constitution of pigs could also influence 
the response to PRRSV infection. Halbur et al. infected 5-week-old Meishan pigs 
(n=4) and Yorkshire x Hampshire crossbred pigs (n=4) with two different PRRSV 
isolates that varied in virulence and evaluated gross and microscopic lesions of 
lungs and heart collected at 3,5,10, and 28 days post infection.^^^ They observed 
that the severity of respiratory disease caused by PRRSV infection was always 
greater in Meishan pigs than in Yorkshire x Hampshire crossbred pigs, regardless 
of the virulence of virus isolates used. 
The presence of antibody might influence the severity of a PRRSV 
infection. A preliminary in vitro study has shown that it was possible to 
enhance infection of PAM by PRRSV by treating the virus with optimally diluted 
anti-PRRSV swine sera prior to inoculating the virus to PAM.^^ Yields of 
progeny virus were enhanced 10 to 100 times and the proportion of PAM 
infected was increased 2 to 10 fold, as compared to control group that were not 
treated with antiserum. An in vivo study conducted by Christiansen et al. 
supported antibody dependent enhancement (ADE) of PRRSV infection.^s 
Fetuses of sows between 40 and 45 days of gestation were exposed in utero to 
PRRSV mixed with antibody or the virus without antibody. Although no 
difference in clinical responses, such as fetal death rate, was observed between 
two groups, higher titers of the virus were demonstrated in fetuses received 
antibody-virus mixture than fetuses that were injected only with virus. 
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Antibody-mediated disease enhancement has been demonstrated in 
several viral infections in other speciesi''3,i85 g^d may occur in pigs infected with 
PRRSV. For example, field observations indicate that pigs at 3 to 5 weeks of age 
are highly susceptible to PRRSV infection and often develop a severe respiratory 
clinical manifestations of PRRS.^^'^^^ This clinical manifestation is referred to as 
'post weaning PRRS.' The time period in which post weaning PRRS commonly 
occurs corresponds to the time period that the level of maternal antibody specific 
for PRRSV approaches the lower limits of detection. Maternal antibodies specific 
for PRRSV are generally detected in pigs at 4 to 8 weeks of age.^'^'^^fi 
Consequently, it is possible that maternal antibodies at subneutralizing levels 
may contribute to the severity of PRRSV-induced respiratory disease in weaning 
pigs. 
Reproductive disease Effects of PRRSV on female reproductive 
performance have been extensively studied by inoculating sows and evaluating 
the effect on the fetus, or by inoculating the fetus directly. It is not known if the 
reproductive effects seen with PRRSV infection are due to maternal, fetal, or an 
interaction of maternal and fetal changes. Inflammatory and degenerative 
changes in the placenta have been reported and virus-like structures has been 
identified in endothelial cells of fetal and maternal placental capillaries. These 
changes suggest the potential for placental passage of virus from dam to 
offspring.275 The PRRSV has also been isolated from the placenta of a sow 
experimentally infected intranasally with the virus.^® Moreover, the potential 
for placental transfer of PRRSV to the fetus was proven when the virus was 
isolated from piglets born to sows that were infected with PRRSV by the nasal 
route during 45-50 or 84 days of gestation and anti-PRRSV antibody was detected 
in precolostral blood samples or ascitic fluids of the piglets.5®'289 
Studies on the effect of PRRSV infection in different stages of gestation 
indicate that the age of the fetus determines its susceptibility to PRRSV-induced 
disease. In one study, sows were inoculated intranasally with PRRSV between 45 
and 50 days of gestation.^s Fetuses were collected from inoculated sows on days 7, 
14 and 21 postinoculation and piglets were obtained at term of pregnancy. No 
PRRSV was present in the fetuses, while the virus was isolated from live bom 
piglets. These data suggest that PRRSV is able to cross the placenta and to infect 
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fetuses after mid-gestation. In contrast. Lager et al. evaluated the effect of PRRSV 
on fetuses by directly injecting the virus to amniotic cavity. These investigators 
reported that virus was isolated from fetuses in all stages of gestation.^^s The 
investigators also observed that PRRSV replicated in younger fetuses without 
gross changes until midgestation and the fetuses began to die thereafter. 
Similarly, Mengeling et al. inoculated pregnant gilts at various stages of gestation 
with PRRSV by the oro-nasal route and monitored the transplacental infection 
of fetuses.1^3 Fetuses at any stages of gestation were shown to be transplacentally 
infected with PRRSV. However, the incidence of transplacental infection was 
significantly greater when gilts were exposed to the virus relatively late in 
gestation, compared with earlier exposure in gestation. Hypotheses as to the 
cause of age-dependent susceptibility include; a) failure of cells at the maternal-
fetal junction to support virus replication until late in gestation, b) development 
of a susceptible fetal cell population during midgestation, and c) a fetal immune 
component which enhances viral replication such as antibody.5®'i75,i93 
Little is known about the pathogenesis of PRRSV infection in the boar. 
Epidemiological and experimental studies have indicated that semen can be a 
source of PRRSV to naive herds.^2,63,254,255,271,280,321 However, the presence of 
PRRSV in boar reproductive tract has not been described, even though 
Wensvoort reported isolation of PRRSV from the genital tract of a boar killed 2 
weeks after exposure.^^^ The effect of PRRSV infection on boar reproductive 
function has not been understood completely, although a decrease in semen 
volume and an increase in morphological abnormality of spermatozoa have 
been observed in infected boars.^'^'^^-^i^ Post-infection changes in semen quality 
and virus shedding in semen have been implicated as a cause of increased 
returns to estrus seen in the breeding age female following PRRSV infection.279 
It was not clear if this early infertility is due to the inability of spermatozoa to 
fertilize eggs or due to viral effects resulting in death of the embryo. However, 
Swenson et al. recently demonstrated that conception occurred in gilts that had 
been artificially inseminated with PRRSV-contaminated semen.^si 
Furthermore, these investigators found the presence of PRRSV in ovaries of 
these gilts. 
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Immunology 
Pigs develop both humoral and cell-mediated immunity after PRRSV 
infection. Humoral immunity appears to develop approximately 7 to 14 days 
after infection, based on initial appearance of detectable circulating 
antibodies.312,324 Relatively high levels of normeutralizing antibodies to 
PRRSV are produced in the early stage of infection. Neutralizing antibodies 
develop approximately 1 to 2 months following exposure, although antibody 
titers are relatively low.^oo-^io Field observations suggested that PRRSV-specific 
antibodies may persist for 1 year after initial exposure.^^^-^^^ 
Cell-mediated immunity has been reported to develop following infection 
of PRRSV. Bautista et al. monitored the T-cell mediated immune response in 
pigs exposed to PRRSV using lymphocyte blastogenesis assay and a skin test.^^'^'' 
The study revealed that PRRSV induces an antigen-specific cell-mediated 
immune response in infected pigs. Antigen-specific lymphocyte proliferation 
response to the virus was initially detected in virus-infected animals at 28 days 
following exposure and continued to be detected through 77 days after infection. 
The skin test revealed that infected animals also develop a virus-specific delayed 
type hypersensitivity reaction. Induction of virus-specific cytotoxic T 
lymphocytes by PRRSV infection has not been studied. Although humoral and 
cell-mediated immunity are known to be induced in infected pigs, the relative 
importance of humoral and cell-mediated immimity has not been evaluated. 
The development of protective immunity to PRRSV has been shown to 
occur in naturally and in experimentally infected pigs.2i/42,99,i09,24i,294 an 
experimental challenge study, 8 gilts were initially exposed intranasally to 
PRRSV at 86-96 days of gestation and gave birth to an average of 5.8 live pigs, 0.6 
stillborn pigs, and 2.1 mummified fetuses.^"^ Five months after initial exposure, 
the same females were bred and subsequently challenged again at 93 days of 
gestation (7-8 months after first challenge). These sows gave birth to an average 
of 10.8 live pigs, 0.5 stillborn pigs, and 0.3 mummified fetuses, indicating that 
they had recovered from the initial infection and had acquired immunity to 
subsequent infection. Freese and Joo investigated two herds that had a previous 
history of PRRS outbreak by serological monitoring and virus isolation attempt 
for 6 months after initial, outbreaks.^^ The investigators observed that PRRSV 
infection spontaneously ceased in one of the two farms investigated. However, 
26 
some herds have chronic or cyclic problems of PRRS following initial exposure 
to PRRSV indicating that virus continues to circulate in the herd.274 Recent 
studies by several investigators have indicated that PRRSV can be persistently 
present in infected pigs in the presence of circulating antibodies.^'28-3i9,326 These 
observations put in question the protective role of humoral immtmity against 
virus. 
Frequent outbreaks of secondary infections, particularly by bacterial agents 
following PRRS outbreak in the field suggest that PRRSV may suppress the 
immune system.®9'i65'203'274,289,3i5 por example, Keffaber et al. reported that the 
nursery death rate increased to an additional 25% over the rate normally caused 
by PRRS only in the presence of secondary infections, particularly with 
Salmonella choleraesuis, Streptococcus suis, and Hemophilus parasuisA^^ 
Stevenson et al. also reported a severe systemic salmonellosis in two herds 
following PRRSV outbreak, suggesting that PRRSV renders pigs more 
susceptible to salmonella infection.274 These field observations have been 
supported by results of controlled experiments. Galina et al. reported that 
PRRSV predisposes pigs to Streptococcus suis meningitis.i^'^ In the study, specific 
pathogen free pigs of 4 groups received PRRSV (group 1), PRRSV (group 2), 
media (group 3), and S. suis (group 4), respectively. Four days later, pigs in 
groups 1, 2, 3, and 4 received media, S. suis , S. suis , or PRRSV, respectively. 
Development of clinical central nervous signs typical of S. suis infection were 
evident only in the group 2 pigs which had been previously infected with 
PRRSV. In contrast, recent studies failed to demonstrate such a synergistic 
interaction between PRRSV and Hemophilus, Pasteurella or Salmonella in the 
pig under experimental conditions.47-69,273 
The potential for PRRSV to modulate the host immune system is 
supported by the fact that the virus replicates preferentially in PAM and results 
in the destruction of these cells.244,312 a significant decrease in the proportion of 
lung alveolar macrophages has been observed in pigs following PRRSV 
infection.203'331 Under experimental conditions, the proportion of PAM in lung 
lavage was decreased from >95% of total cells collected to approximately 50% by 
day 7 post challenge. In addition, alterations in functions of PAM were also 
observed after PRRSV infection. The production of inflammatory cytokines, 
such as IL-1 and TNF, in PAM was enhanced and nonspecific bactericidal activity 
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of the cells was suppressed.^^i Depletion of lymphocytes from lymphoid tissues, 
such as splenic periarteriolar lymphoid sheaths, tonsillar crjrpts, mesenteric 
lymph nodes and the thymic cortex, and decreases in peripheral blood leukocytes 
after challenge of PRRSV may also lead to the increased susceptibility of infected 
pigs to secondary infections.243,265,331 
Experimental studies have been performed to evaluate the interaction of 
PRRSV with the host immune system. Flow cytometric analysis revealed a 
down regulation or loss of antigen expression on the surface of infected PAM.223 
This observation may explain why PRRSV is not easily cleared from infected pigs 
by cell-mediated immune surveillance in the presence of circulating antibodies, 
resulting in prolonged viremia and persistent infection. In another study, 3 
groups of pigs were evaluated at 1, 4, and 10 week of age for their ability to 
respond to foreign antigen following challenge with PRRSV.203 The humoral 
immune responses of pigs that were previously infected with PRRSV to Brucella 
abortus, Escherichia coli pili antigens, and killed pseudorabies virus were 
enhanced compared to control pigs. Cell-mediated immune responses to 
dinitrofluorobenzene, as measured by the delayed type hypersensitivity, were 
also enhanced in infected pigs compared to control pigs. Consequently, 
investigators concluded that there was no evidence for systemic 
immunosuppression by PRRSV infection. Instead, these investigators suggested 
that PRRSV infection induces polyclonal B- and T-cell activation. A similar 
observation has been made with respect to infection of mice with another 
arterivirus, LDV.177 
Very little is known about the role of colostrum-derived maternal 
antibody in PRRSV infection. Specific antibodies have been demonstrated in the 
colostrum from experimentally infected sows.^^^ Albina et al. reported that 
passive maternal antibody was detected in the serum of piglet as early as 4 days 
after birth.^ The investigators also observed some instances in which no 
maternal antibody was detected in sera of piglets bom to infected dams after 
ingestion of colostrum. Maternal antibody specific for PRRSV has been reported 
to persist until 4 to 8 weeks of age and occasionally up to 16 weeks of age in pigs 
nursing immune dams.m'296 Although passive immunity is believed to be 
protective against infection, Molitor reported that pigs from nonimmune dams 
were not protected following challenge when they were passively given PRRSV 
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antibodies, while challenged pigs bom to immune dams were protected.^oi This 
observation suggests that antibody alone may not be able to protect pigs from 
disease and that cell mediated immimity might plays an important role in 
protecting pigs from PRRS. 
Antibody dependent enhancement 
Introduction In general, virus-specific antibodies are considered antiviral 
and play an important role in the control of virus infections in a number of 
ways. Antibodies neutralize virus, thereby preventing virus infections of target 
cells. Antibodies also bind to virus-irifected cells and subsequently mediate cell 
lysis through complement activation or antibody-dependent cell-mediated 
cytotoxicity mediated by natural killer cells, monocytes/macrophages, and 
neutrophils.266 However, in some instances, the presence of specific antibodies 
can be beneficial to the virus. This activity is known as antibody dependent 
enhancement (ADE) of virus infection. 
Antibody dependent enhancement of virus infection is a phenomenon in 
which virus-specific antibodies enhance the entry of virus, and in some cases the 
replication of virus, into monocytes/macrophages and granulocytic cells through 
interaction with Fc and/or complement receptors-'^^-^^'^'i^^,232,249,259 ^ ^ ^s first 
described by Hawkes in 1964 who reported that it was possible to increase the 
total yield of a variety of flaviviruses including Japanese encephalitis virus, 
Murray Valley encephalitis virus, and Getah virus in chick embryo cell cultures 
by first exposing the viruses to high dilutions of homologous antibody.^^s 
Subsequently ADE has been described for a variety of viruses representing 12 
different families. Some examples are: rabbitpox virus,i39 dengue virus 
(DV),130,131 yellow fever virus,268 feline infectious peritonitis virus (FIPV),309 
Sindbis virus,^® LDV of mice,Bunyamwera virus,reovirus,^! rabies 
virus,i68 murine cytomegalovirus,i49 influenza virus,22i,285 human 
immunodeficiency virus type 1 (HIV-l),i46,26i,284 respiratory syncytial virus 
(RSV),105 Hantavirus^o^ and Aleutian disease virus (ADV) of mink.i58 
Common features of the viruses described above are that: a) they replicate, 
in part or exclusively, in macrophages;i27,i5i,185,225,269,277,290 b) they induce the 
production of large amount of antibodies that neutralize even homologous 
virus poorlyi27,i85 ^^d c) they cause persistent infections which are commonly 
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characterized by viremia of long duration. Antigenic diversity among isolates is 
also a common feature of these viruses, which renders them partially resistant to 
neutralization by antibody raised against heterologous isolates.^^?,185,249 
Mechanism of APE Although the precise mechanism of ADE is not 
completely understood, it is generally assumed that the increased yields of virus 
are primarily due to a greater number of susceptible cells being 
infected.''0'105'127,158,225 jhig increase in infection rate of cells is shown to be 
mediated by receptors, most notably Fc receptor (FcR), which facilitate the uptake 
of virus-antibody complexes. However, studies also suggested that other 
mechanism(s) could also account for increased virus yields. Antibody may also 
increase the efficiency of virus replication, either a) by facilitating the uptake of 
infectious antibody-virus complexes or b) by increasing the synthesis of viral 
protein and nucleic acid. For example, Collins et al. demonstrated that antibody 
increases the numbers of West Nile virus (WNV) attached to mouse 
macrophage-like cells by comparing radioactivity counts associated with cells 
infected with radiolabeled WNV in the presence of antibody to that in the 
absence of antibody.106,107 Robinson et al. demonstrated that replication of HIV-1 
was initiated sooner in cells when the virus was pretreated with HIV specific 
antibody, as opposed to when the virus was not treated with antibody.259 
Progeny virus was released sooner from treated cells than from non-treated cells, 
as well. They also found that protein and RNA synthesis were increased in cells 
that were infected with HIV-1 treated with antibody. In contrast, Olsen and Scott 
studied the kinetics of FIPV infection in individual feline peritoneal 
macrophages in the presence and absence of antibody utilizing in situ 
hybridization.226 They demonstrated that the number of infected cells was 
increased in the presence of antibody. However, based on the relative intensity 
of-radiograms of individual cells, they did not find any evidence that the 
efficiency of viral replication within the cell was enhanced. 
Generally, interaction between virus-antibody complexes and FcR on 
monocytes/macrophages or granulocytes induces signal transduction, resulting 
in phagocytosis, release of cytokines, a superoxide burst, and antibody-dependent 
cell-mediated cytotoxicity.263 These responses are considered antiviral. It is not 
known how this interaction results in enhanced infection. However, since these 
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viruses are known to replicate in part or exclusively in these cells, it is assumed 
they have the ability to modulate antiviral mechanisms of the cells either by 
utilizing their own products or by interfering with metabolic pathways of cells. It 
is also possible that infections by virus-antibody complexes are restricted to 
immunologically immature subpopulation of the cells.^27 Halstead and his 
associates found that human monocytes cultured more than 1 day prior to being 
infected with DV-antibody mixture became increasingly less permissive to 
infection. This loss of permissiveness may have been due to increased lysosomal 
activity. 130/132 These observations explains why high virus titers are produced in 
bone marrow explant culture in which young monocytes are continuously 
produced. 127 Restriction of virus infection to immunological immature cells was 
also demonstrated in mice that were persistently infected with LDV.276 
Interaction of virus, antibody and receptor in APE 
Antibodies mediating APE Enhancement of virus infection has been 
demonstrated using various sources of antibodies. These sources include 
polyclonal antisera generated in natural host and other animals, mouse ascitic 
fluids containing MAbs to the virus of interest, and immunoglobulin isolated 
from antiserum. The mechanism by which APE is mediated is known to be 
primarily through the interaction of the Fc region of virus-specific IgG and Fc 
receptors on the surface of monocytes/macrophages and granulocytic 
cells. 130,232,249 Halstead and O'Rourke fractionated IgG and IgM from antisera of 
PV-immunized monkeys and evaluated which fraction increased the yield of 
progeny virus. 130 Enhancement was observed only with the IgG fraction, while 
virus that was exposed to the IgM fraction was neutralized. Similar observations 
were made by Olsen et al. who evaluated the ability of mouse MAbs specific for 
the spike (S) protein of FIPV to mediate APE in feline peritoneal macrophages.225 
Only IgG class MAbs enhanced FIPV infection, while IgM class MAbs did not 
mediate APE. To date, it is not known whether or not other subtypes of 
antibodies (IgA, IgP and IgE) can mediate APE. 
Pifferent isotypes (subclasses) of IgG have also been evaluated for their 
ability to mediate APE. In the case of PV, murine IgGl, IgG2a, and IgG2b 
monoclonal antibodies specific for the E envelope protein of PV serotypes 2 and 
4 are reported to enhance infection of the virus when cells with compatible Fc 
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receptors were used as targets.^^^'^o^ No information is available about the role of 
IgG3 in ADE of DV infection. In contrast, Corapi et al. evaluated the ability of 19 
mouse monoclonal antibodies specific for the S envelope protein of FIPV to 
induce ADE in feline peritoneal macrophages.'''' All MAbs were capable of 
neutralizing the ability of virus to infect a permissive cell line. Fifteen of 19 
MAbs induced ADE of infection in macrophages, and all but one were of the 
IgG2a subclass. The remaining 4 MAbs that did not induce ADE were IgGl. The 
difference in the isotypes between neutralizing MAbs that induced ADE and 
those that did not induce ADE suggested that there may be a restriction in the 
subclasses capable of mediating ADE. It is also possible that the difference in the 
ability of FlPV-specific murine IgG isotypes to mediate ADE is due to differences 
in the binding affinity of murine isotypes to FcR on feline macrophages.^^s The 
ability of the different isotypes of human and other mammalian IgG to enhance 
virus infection has not been evaluated. 
Receptors involved in ADE Several cell surface molecules, including 
the FcR, complement receptor (CR), p2-microglobulin, and some CD molecules, 
have been reported to play a role, or at least to be involved, in mediating ADE of 
virus infection.i^S/iss Antibody-FcR interaction is known to play a key role in 
ADE. The FcR-mediated mechanism of ADE was first suggested by Halstead et al. 
who reported that F(ab')2 fragments prepared from IgG did not enhance infection 
of DV in human peripheral blood leukocyte cultures while whole IgG did so.i^o 
This was indirect evidence which suggested that interaction of virus-IgG 
complexes with FcR on the cell surface may be necessary for ADE of virus 
infection. Other indirect evidence for this interaction was shown by Daughaday 
et al..74 These investigators found that ADE of DV infection in monocytes was 
inhibited by first treating the cells with immunoglobulin prior to exposing cells 
to virus-antibody mixtures. Peiris et al. conclusively demonstrated that the 
interaction between virus-antibody and FcR is essential for the ADE of virus 
infection.232 They were able to block ADE of WNV infection in a macrophage-
like cell line (P388D1) by pretreating the cells with anti-FcR MAb prior to 
exposing cells to a virus-antibody mixture. Other investigators were also able to 
block infection of cells by virus-antibody complexes by first treating virus-
antibody mixture with Protein A which binds to the Fc portion of antibody.i58'225 
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In humans, there are 3 types of Fc receptors which bind human IgG: FcyRI, 
FcyRII, and FcyRIII.'''252,293 jhe FcyRI is present exclusively on 
monocytes/macrophages and binds human IgG with high avidity. It has higher 
specificity for IgGl and IgG3 isotypes than for IgG2 and IgG4 isotjq^es. The two 
other receptors, FcyRII and FcyRIII, are found on monocytes, macrophages, 
eosinophils, neutrophils, natural killer cells, B lymphocytes, and T lymphocytes. 
These two receptors have relatively low avidity for IgG compared to FcyRI. 
Kontny et al. showed that FcyRI mediated ADE of DV infections in U937 cells. 
In a related study, FcyRII was also reported to mediate ADE of DV infection in a 
human erythroleukemic cell line (K562) which has only FcyRII. 1^8 xhe role of 
FcyRIII in ADE of DV infection is not known. 
Mouse macrophages are known to have two types of Fc receptors, 
designated FcRI and FcRII, which bind IgG. The FcRI is tr5^sin-sensitive and 
binds IgG2a, while the FcRII is trypsin-resistant and binds IgG2b and IgGl 
complexes.®® Feiris et al. studied the inhibitory effect of anti-mouse FcRII 
antibody on the ADE of WNV infection mediated by anti-WNV MAbs of 
subclasses IgGl or IgG2a.232 Pretreatment of P388D1 cells with anti-FcRII antibody 
completely inhibited enhancement of virus infection mediated by both IgGl and 
IgG2a anti-WNV MAbs. Enhancement of WNV infection, however, was 
independently achieved with anti-WNV MAbs of both subclasses. Other 
investigators found that intact anti-FcRII antibody interfered with both FcRI and 
FcRII in a macrophage rosetting assay,292 suggesting that both Fc receptors on 
mouse macrophages can mediate ADE of virus infection. 
Since ADE of virus infection results from the interaction of virus, 
antibody, and FcR, changes in any of these three components may modulate the 
ADE. Of the three components, the FcR can be most easily modulated within 
relatively short periods of time by treating FcR-bearing cells with certain 
cytokines or proteolytic enzymes. A quantitative (i.e., number) change or a 
qualitative (i.e., avidity for Fc portion of IgG) change in FcR expressed on cells 
may influence the ADE of virus infection. For example, gamma interferon 
(IFNy) is known to increase the number of FcyRI without changing in the affinity 
of each FcyRI for the Fc portion of IgG.234,264 Kontny et al. reported that 
pretreatment of human monocytic cells with IFNy augmented ADE of DV 
infection and that the level of enhancement correlated with the increase in the 
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number of FcyRI on the cells. 1^2 in another case, Halstead and O'Rourke found 
that pretreatment of monocytes with pronase, trypsin, and protease augmented 
ADE of DV infection.130 Zoellner et al. have also suggested that protease may 
play a role as a cofactor in ADE of HIV infection.336 More recently, Mady et al. 
examined the effects of neuraminidase on ADE of DV infection mediated by the 
low-affinity FcyRII in vitroA^'^ They found that neuraminidase treatment of the 
K562 cells that have only FcyRII increased the degree of ADE of DV infection by 
human anti-DV antibodies. It is known that treatment of FcyRII with enzymes 
such as pronase, trypsin, elastase, and neuraminidase increases the avidity of 
receptors for IgG but does not increase the number of the receptor expressed on 
cell surface.®2/298 
Besides FcR, complement receptors have also been implicated in ADE of 
virus infection.'^6'262 Cardosa et al. found that infection of P388D1 cells by WNV 
is enhanced in the presence of virus-specific IgM by supplementing fresh mouse 
serum containing complement to virus-IgM mixtures prior to inoculation.^^ 
However, the magnitude of enhancement of WNV infection mediated by 
complement was less than IgG-mediated ADE of virus infection. Complement-
dependent ADE of HTV infections has also been reported.ii3,i56,204,260„262 
Subneutralizing levels of HIV-specific antibody enhance virus replication in 
several human neoplastic cell lines which express CR and CD4, as well as FcR, in 
the presence and the absence of complement. The magnitude of the enhancing 
effect was greater in complement-mediated ADE of HIV replication than 
enhancement mediated by the presence of antibody only.i®^ Furthermore, 
Robinson et al. reported that replication of HIV was initiated sooner and the 
efficiency of replication (e.g., protein and RNA synthesis) was enhanced through 
the mechanism of complement-mediated ADE.259 
Several cell surface molecules are known to enhance virus infections or to 
be involved in ADE.i^O'i®^ Takeda et al. demonstrated that ADE of HIV infection 
in monocytic cells via FcR was blocked by pretreatment of cells with monoclonal 
antibodies to CD4 molecule, as well as to FcyRI.283 Robinson et al. also reported 
that enhanced infection of HIV through complement-mediated ADE required 
not only complement receptors, but also CD4 molecules on the surface of cells.262 
These observations indicate that the presence of the CD4 molecule on the cell 
surface may be a requirement for both the FcR-mediated and complement-
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mediated ADE of HIV-1 infection. In the case of DV infection, Mady et al. used 
bispecific antibodies which were prepared by chemically cross-linking anti-DV 
antibodies to antibodies specific for one of three Fc receptors or non-FcR 
molecules, and demonstrated that DV infection could be erihanced by non-FcR 
molecules such as p2-microglobulin, CD15 or CD33.i®o 
Viral proteins/epitopes associated with ADE Viral antigenic 
determinants associated with envelope protein(s) induce antibodies which 
mediate ADE.^^'^o,105,141,225,256,285 Scott and his associates conducted extensive 
studies utilizing monoclonal antibodies specific for the nucleocapsid protein, 
matrix protein (M), and the S protein of FIPV. ADE-associated epitopes were 
only found on the S protein70'225 xhe same observations have also been made 
for envelope proteins of other viruses for which ADE has been reported. Specific 
examples are: the E protein of DV,i4i gpl20 and gp41 of HIV,257,258,282 f^A protein 
of influenza virus,222,285 d and G2 proteins of hantavirus,322 and the F protein of 
RSV.105 To date, no internal proteins of enveloped viruses have been reported 
to be associated with the induction of enhancing antibody, with the exception of 
pre-M protein, an immature matrix protein of dengue virus, Reovirus is the 
only nonenveloped virus for which ADE was reported. Enhancement of 
reovirus infection in the P388D1 cells was demonstrated to be mediated mainly 
by monoclonal antibodies specific for the a-1 protein, a major outer capsid 
protein which determines the serotype of reoviruses.^i In addition, monoclonal 
antibody specific for other capsid proteins, such as |j,lc protein, was also reported 
to mediate the ADE of reovirus. No protein of the inner capsid of reovirus was 
found to be associated with ADE. 
Since viruses in the same genus or family may share common antigenic 
determinants, ADE of virus infections can be mediated by antibodies raised not 
only against heterologous strains but also different serotypes of the viruses or 
even against closely related viruses in the same genus or family. This 
observation suggests that enhancing antibodies may not be highly specific for a 
specific virus. For example, studies using polyclonal antibody revealed that DV 
infection can be enhanced by antisera raised against heterologous serotypes of DV 
and also by antisera specific for other flaviviruses, suggesting that not only 
serotype-specific but also serotype- and flavivirus-cross reactive epitopes are 
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associated with ADE.130,133,134 xhere was a difference in the magnitude of 
enhancement mediated by homologous sera as compared to heterologous sera. 
A similar observation has also been made utilizing monoclonal 
antibodies.36434,141,207 These studies revealed that infections of DV type 2 (DV-2) 
could be enhanced by monoclonal antibodies directed against heterologous DV-2 
isolates and against DV type 4. Likewise, Tamura et al. found that infection by 
influenza A virus was augmented by pretreating the virus with antisera raised 
against different subtypes of the virus.286 in the case of FIPV, virus infection in 
feline peritoneal macrophages was enhanced by monoclonal antibodies 
generated against transmissible gastroenteritis virus of swine which, like FIPV, 
belongs to the family CoronaviridaeP-'^^ 
Since antigenically distinct strains of virus may have different 
quantitative and/or qualitative profiles of epitopes associated with ADE, 
differences in epitopic profiles may influence augmentation of virus infection in 
the presence of antibodies directed against heterologous strains or viruses. 
Consequently, strains vary in their susceptibility to ADE and/or ability to induce 
ADE.i®5'205 Halstead and others evaluated anti-DV sera from naturally infected 
humans or produced in various species of animals (mouse, rabbit, monkey) 
against 4 different serotypes of DV for their ability to cross-neutralize DV-2 and to 
mediate ADE of DV-2 infections.^30''34,205,207 xheir studies revealed that 
heterotypic antisera neutralized DV-2 infectivity for continuous cell lines very 
poorly, but both homotypic and heterotypic antisera enhanced DV-2 infection in 
human peripheral blood leukocyte cultures. The degree of ADE of DV-2 
infection mediated by either homotypic or heterotypic antisera varied. Higher 
ADE activity for DV-2 infection was detected in the heterotypic antisera than in 
the homotypic serum. Further, the magnitude of maximum ADE of DV-2 
infections mediated by heterotypic antisera varied among the antisera, as well as 
the serum dilution at which the maximum ADE activity for DV-2 was observed. 
These results suggested that DV serotypes and field isolates varied in their 
susceptibility to ADE mediated by antibody raised against heterologous serotypes 
or isolates, and probably also varied in their ability to induce enhancing 
antibodies. The variability in ADE response among the DV-2 isolates was 
attributed to difference in epitopic profiles of isolates. 
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In related work with FIPV, Olsen et al. evaluated the biological function of 
MAbs raised against the S protein of the virus and discovered that specific 
epitopes of the S protein vary in their ability to induce ADE-associated 
antibodies.225 They were able to categorize the monoclonal antibodies that 
represent the epitopes of the envelop S protein into 3 groups according to their 
ability to a) only neutralize, b) both neutralize and enhance, and c) only erihance 
FIPV infection. Furthermore, monoclonal antibodies with specificity for 
different FIPV antigenic determinants varied in their ability to enhance virus 
infection, suggesting that epitopes are either or strongly and weakly associated 
with ADE.''0'225 These finding are particularly noteworthy because they suggest 
that it may be possible to develop vaccines with strong neutralizing and weak 
ADE inducing characteristics. Similar variability in the susceptibility of HIV-1 
isolates to ADE and/or in the ability to induce ADE also believed to exist because 
a great deal of genomic diversity has been demonstrated among HIV isolates.i®^ 
Currently, variation in the susceptibility of isolates to ADE and in the ability to 
induce ADE are a great concern in developing vaccines against viruses for which 
ADE and antigenic diversity have been reported. 
Assays of ADE activity Antibody dependent enhancement of virus 
infection can be studied either in vitro or in vivo. Although in vivo study may 
have more clinical relevance, in vitro assays utilizing various sources of virus-
specific antibody, such as antisera, mouse monoclonal antibodies, fractionated 
immunoglobulin, are generally performed to determine the ability of antibody to 
enhance specific virus infections.127,185,249 Two types of ADE assays have been 
developed for in vitro study to quantitate enhancing activity. One assay is to 
assess the increase in the production of progeny virus from cells exposed to 
virus-antibody mixtures.^^o,131,138 The other assay measures the increase in the 
proportion of cells being infected after exposure to virus-antibody mixtures.io^'225 
Both ADE assays are conducted by first exposing the virus of interest to antibody 
at different levels of concentration or to an appropriate antibody-free control 
serum. Permissive cells are then inoculated with these mixtures. After an 
appropriate period of incubation, progeny virus yield or numbers of infected cells 
are determined and compared. The virus yield is usually determined by 
microtiter infectivity assay or plaque assay using permissive cell lines.i27 
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Fluorescence microscopy/O'225 in situ hybridization,226 or infectious foci center 
assayi®^ have also been used to measure the proportion of cells infected with 
virus. 
Morens and Halstead proposed that the occurrence of ADE of virus 
infections can be recognized by the following observations: a) a significant 
increase in virus production as measured by quantitative assays at different 
points on the growth curve; b) 'enhancement profiles' which are characterized by 
the appearance, peak, decline, and disappearance of infection enhancement 
produced over at least a lO'^ fold dilution range when the virus output is assayed 
in cells infected with mixtures of constant amounts of virus and serial dilutions 
of antibody source; c) the dilution of antibody source at which maximal 
enhancement is observed is related to other serological measures of binding to 
virus components; d) infection enhancement is detected with different antibody 
sources and virus strains tested over a range of multiplicity of infection; and e) 
other causes of enhanced virus production could be ruled out.206 
Using an in vitro ADE assay, the ADE activity of antibody source can be 
expressed in several ways, including endpoint titers, peak enhancement titer and 
'enhancement power.' The endpoint titer of enhancing antibody is by definition 
the highest dilution of serum producing a significant enhancement of infection 
compared to controls.127,169 The peak enhancement titer is a serum dilution at 
which virus yield or proportion of infected cells is maximal for the antibody 
source tested.^^^ The 'enhancement power or ratio' can be calculated by dividing 
the virus yield or proportion of infected cells in antibody-supplemented group by 
the yield or proportion if uninfected cells in control cultures at a selected 
dilution of serum, or on a selected comparison day if a single dilution of serum 
is used.127,169,249 
The method of measuring and expressing ADE activity can be of critical 
importance in attempting to correlate in vitro ADE with an in vivo effect. For 
instance, in secondary dengue infections, enhancing activity in undiluted sera 
was a significant risk factor for severe dengue illness when human peripheral 
blood mononuclear cells were used as indicator cells. In contrast, endpoint ADE 
titer, such as the highest serum dilution showing enhancing activity was not 
predictive and paradoxically was higher in children without severe illness.^^^ 
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Role of APE in disease Antibody dependent enhancement of virus 
infection has been suggested as a disease enhancing factor for several human and 
animal viral diseases.Specific examples include Aleutian mink disease virus, 
dengue virus, feline infectious peritonitis virus, and respiratory syncytial 
virus.50'51 In addition, ADE has also been implicated as a major obstacle to the 
development of specific virus vaccines, such as ADV,248 bluetongue virus,^^ 
DV,35 FIPV,300 influenza virus,306 lentiviruses,i88,304 measles virus,37,25i rabies 
virus,272 and RSV.159 in all cases, the presence of antibodies induced by 
vaccinat ion increased the suscept ibi l i ty  to  subsequent  virus  infect ions and/or  
exacerbated the severity of clinical disease by virus challenge in vaccinated 
individuals. 
Respiratory syncytial virus In general, RSV infections are not always 
considered serious. However, individuals who develop pneumonia from RSV 
infection are required to be hospitalized. Chanock et al. reported that naturally 
acquired severe RSV infections were almost always seen in the first 6 months of 
life when children had circulating maternal anti-RSV antibodies.^i In another 
study, infants with maternally acquired RSV antibody not only failed to be 
protected from RSV infections, but the rate of severe disease was higher in these 
infants when compared to infants without maternal antibodies.^o These 
observations led to the speculation that RSV-specific antibody may contribute to 
the severity of clinical manifestations of disease caused by RSV. A recent study 
demonstrated that infection of mouse macrophage cell line by RSV is enhanced 
in the presence of virus-specific antibody. This observation supports the 
hypothesis that immune-mediated enhancement of disease does occur in 
human RSV infection and may contribute to the pathogenesis of the disease. 
Immune-mediated enhancement of disease has also been described in 
human infants and children vaccinated against RSV. Several epidemiological 
and experimental studies found that immunization with an inactivated whole 
virion RSV vaccine led to development of antibody response, but did not 
prevent infection with wild-type RSV in children less than 2 years of 
age.52,103,159,166 More importantly, subsequent natural infection by wild-type RSV 
resulted in an extremely high frequency (52-69% of infected children) of severe 
lower respiratory tract disease (i.e., pneumonia) in the vaccinated group, whereas 
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only 9-10% of infected children became pneumonic in the nonvaccinated 
group.Furthermore, the duration of illness was longer^o^ and the severity 
of illness was greater in the vaccinated children compared with nonvaccinated 
children.52 Results from these studies indicated that children were at increased 
risk to severe RSV disease following immunization. 
Dengue virus infection Dengue viruses belong to the genus Flavivirus 
of the family Flaviviridae. There are 4 serotypes: dengue virus types 1, 2, 3, and 
4.125 Dengue virus infections are considered a serious health problems in many 
areas of the world. Dengue virus infection can be asymptomatic or cause two 
forms of disease.125 Iri many cases, DV infection causes a febrile disease referred 
to as 'dengue fever' which is characterized by fever, retroorbital pain, muscle 
aches, bone pain, and petechiae. Patients recover in 7 to 10 days without 
complications. In some instances, patients infected with DV leak plasma into 
interstitial spaces resulting in hypovolemia and sometimes circulatory collapse. 
This severe and life-threatening syndrome, which is always accompanied by 
thrombocytopenia and sometimes by frank hemorrhage is termed dengue 
hemorrhagic fever (DHF). More severe clinical manifestations of DHF in which 
plasma leakage is so profoimd that shock occurs, are referred to as dengue shock 
syndrome (DSS). 
Although the pathogenesis of DHF/DSS is not clearly understood, the 
association between ADE and the severity of disease has been extensively 
studied. This association was first described by Halstead and co-workers who 
observed that the severity of dengue fever was significantly greater in children 
with maternal antibody specific for DV than in children with no DV specific 
maternal antibody.i23,i26,i29 Experimentally, these investigators demonstrated in 
rhesus monkeys that anti-DV maternal antibody enhances DV infection.i^^ The 
Investigators injected monkeys intravenously with small amounts of human 
cord blood containing anti-DV antibody and immediately challenged them with 
DV. The monkeys that were injected with DV antibody developed higher levels 
of viremia for a longer period than control monkeys. 
It was also found that DV produced a more severe clinical manifestation 
in older individuals who had subneutralizing levels of antibodies which were 
induced by previous DV infections than in individuals who had no previous 
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exposure to the virus.125,128 These severe clinical manifestations were more 
frequently observed in individuals who have antibody against one serotype of 
DV and were subsequently exposed to a different serotype of DV than in 
individuals challenged with an homologous serotype. Recent prospective case-
control studies conducted by Burke et al.^o and Kliks et al.^^^ demonstrated that 
presence of DV antibodies is a significant risk factor for increased severity of 
disease by subsequent DV infection. In these studies, individuals were 
categorized into the case and control based on the presence and absence of anti-
DV antibody. Decay of DV antibody was monitored for the case group and 
correlated to ADE activity in imdiluted sera. Both groups were also monitored 
for subsequent clinical event with respect to natural DV infection. The 
investigators observed that the morbidity of DV infection was significantly 
higher in the case than the control. Mortality due to DHF/DSS was also higher 
in the case group than the control. 
Feline infectious peritonitis Feline infectious peritonitis virus is a 
coronavirus that causes peritonitis and occasionally a fatal pyogranulomatous 
disease in kittens and cats.30'',308 Antibody dependent enhancement has been 
incriminated as a disease enhancing factor of feline infectious peritonitis.235,309 
Cats with active or maternal immunity to FIPV often develop an accelerated and 
more fulminant disease following challenge with FIPV than seronegative cats. 
The role of antibodies in mediating more severe disease following challenge has 
been also documented in cats that were injected with FlPV-reactive immune sera 
or purified immvmoglobulin and subsequently challenged with the virus.^o^ 
Furthermore, immune-mediated disease enhancement has been demonstrated 
in kittens who had vaccine-derived humoral immunity directed against the 
spike protein of FIPV. These kittens died earlier than did control animals.300 
Similarly, kittens immunized with a recombinant vaccinia virus expressing the 
spike protein of FIPV died earlier than control animals.^"" 
Aleutian mink disease Aleutian disease virus is a parvovirus and is 
know to exist in blood principally as immune complexes which are fully 
infectious both in vivo and in vitroM^ Consequently, viral infection causes a 
fatal glomerulonephritis in mink due to deposition of soluble immune 
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complexes on renal glomerular membrane or wall of capillary blood vessel 
which causes tissue damage by mononuclear cells and complement and 
consequently results in impairment of renal filtration. Besides formation of 
soluble immune complexes, ADE of infection has also been suggested as a 
potential contributing factor to the pathogenesis of Initially, Porter et 
al. found that ADV replicated in macrophages and large amounts of non-
neutralizing antibody were produced in mink infected with ADV.247 They 
speculated that the early formation of non-neutralizing antibody might lead to 
virus-antibody complex formation. They further speculated that phagocytosis of 
these complexes by macrophages could lead to increased infection of the cells by 
ADV resulting in increased production of progeny virus. In related work. Porter 
et al. demonstrated that passive transfer of virus-specific antibody at the peak of 
viral replication resulted in foci of necrosis around virus-infected cells. The 
investigator concluded that this pathological reaction was due to erihanced 
complement-mediated cytolysis, suggesting that antibody has the potential to 
contribute to the severity of disease by ADV.^^s ^ recent in vitro study by Kano 
et al. demonstrated that infection of mink peritoneal macrophages by ADE is 
enhanced by anti-ADV antibody.^^s 
In a trial with an experimental ADV vaccine, the immunization regimen 
even failed to produce any detectable neutralizing antibody to ADV. However, 
following challenge with a standardized infectious does of virus by the oral 
route, higher levels of circulating antibodies were detected in vaccinated mink 
than in challenged control animals .248 Moreover, 8 of 10 vaccinated mink, but 
none of control animals, developed Aleutian disease. Cumulatively, these 
observations provide strong evidence that vaccine-induced humoral immunity 
can lead to a more severe disease course through ADE. 
Lentiviral diseases Equine infectious anemia is a lentiviral infection of 
horses that generally causes a syndrome of fever, anorexia, and anemia with 
cyclic recurrence during the first year of disease. Subsequently, horses may 
become asymptomatic or develop a chronic wasting syndrome. Several studies 
were conducted to evaluate the efficacy of vaccines against equine infectious 
anemia virus (EIAV) as a model for evaluating AIDS vaccine strategies.^^^-^o^ 
These studies clearly illustrated that enhanced severity of disease in vaccinated 
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animals was due to the presence of vaccine-induced antibody. Issel et al. used 
viremia as a criteria of disease and demonstrated that inactivated whole virus 
vaccines elicited 100% protection against homologous challenge with avirulent 
EIAV.1^2 In contrast the vaccines failed to prevent viremia following 
heterologous challenge with a virulent strain of EIAV. However, the vaccine 
did protect ponies from the subsequent development of clinical symptoms after 
challenge with the virulent strain. Using viremia as criteria of disease these 
investigators also evaluated the efficacy of a subunit vaccine composed of lectin 
affinity-purified viral envelope glycoproteins. This vaccine failed to prevent not 
only viremia but also the development of subsequent clinical symptoms 
following challenge with the heterologous virus, while the vaccine provided 
100% protection against infection by the homologous virus challenge. In a 
subsequent study, Wang et al. evaluated a recombinant subunit vaccine 
consisting of a baculovirus-expressed surface glycoprotein of EIAV in groups of 8 
ponies each.304 Horses immunized with the recombinant vaccine were not 
protected from challenge with either homologous or heterologous strains of 
EIAV. Vaccination resulted in significantly higher levels of viremia that 
persisted for longer period of time. In addition, the severity of disease in 
vaccinated ponies was greater than in unvaccinated controls following challenge 
with the virulent heterologous strain Exacerbation of disease severity in 
vaccinated animals has also been observed with vaccine for other members of 
the Antiviruses. Currently a similar concern about immune-mediated disease 
enhancement in HIV vaccine trials is being raised because ADE of HIV infection 
in human peripheral blood mononuclear cells has been demonstrated in vitro 
with sera from HIV-infected individuals or animals vaccinated with 
experimental vaccines.^^'^^^'^®^ 
Other viral diseases Adverse affects of ADE have also been reported in 
animals vaccinated with experimental rabies or influenza virus vaccines. Sikes 
et al. evaluated a large number of licensed and experimental rabies vaccines in 
monkeys.272 Vaccines were administered either 36 and 73 days prior to challenge 
or within 6 hours after challenge. Monkeys were injected with lO^-^-lO^-S mouse 
lethal doses of rabies virus into cervical muscles. Monkeys vaccinated either 
before or after challenge, as well as another group of monkeys given with anti-
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rabies serum, died 6-13 days (meari 11 days) after challenge, while 14 of 17 control 
animals died 14-63 days (mean 25 days) after challenge. The investigators 
subsequently coined the term 'early death' phenomenon to describe these 
observations. The same phenomenon has also been demonstrated in mice 
inoculated intracerebrally with rabies virus 2-4 days after a rabies vaccine was 
administered intraperitoneally.^^ Later, it was suggested that the 'early death' 
phenomenon was attributed to ADE of rabies virus infection mediated by 
vaccine-induced humoral immunity. 1^8,250 
In work with an experimental influenza virus vaccine, Webster and 
Askonas found that mice inoculated with one or two doses of inactivated whole 
virus or subunit vaccines of influenza virus A/USSR/90/77 (HlNl) showed 
enhanced growth of influenza virus in the lung following intranasal challenge 
with homologous or heterologous (X-31, H3N2) strains at varying intervals after 
immunization.306 
Disease enhancement due to ADE has also been documented in children 
vaccinated against measles virus.3''/i02,ii4,25i Some children immunized with 
formalin-inactivated, alum-precipitated measles vaccine developed severe, 
atypical disease following exposure to wild-tj^e measles virus approximately 2 to 
2.5 years and up to 14 years after initial immimization. 
Statement of the Problem 
Porcine reproductive and respiratory syndrome is a relatively new viral 
disease of swine. It continues to be an economically significant problem in swine 
producing regions throughout the world. The use of vaccines to control and 
prevent the disease is being advocated in response to the widespread incidence 
and economic significance of PRRS. However, antigenic diversity among 
PRRSV field isolates has posed a significant obstacle to vaccine development. 
Field and experimental observations to date suggest that the humoral immunity 
may not provide protection from PRRSV infection and has the potential to 
contribute to the disease problem. In addition, preliminary studies suggest that a 
phenomenon known as ADE of virus infection could present obstacles to the 
development of effective immunization strategies for PRRS. Antibody 
dependent enhancement has been implicated as a disease erihancing factor in 
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several viral diseases of humans and animals and recognized as a major obstacle 
in the development of vaccination strategies against these viruses. 
Consequently, it was important to know whether or not the same potential exists 
in PRRSV infection. The work presented here was conducted to determine 
whether or not PRRSV-specific antibody is a contributing factor to the 
pathogenesis of PRRS. Specific aims were: a) to determine and characterize ADE 
of PRRSV infection; b) to evaluate the biological significance of ADE with respect 
to the pathogenesis of PRRSV; c) to determine if ADE has the potential to 
interfere with immunization strategies for PRRS; and d) to determine which 
viral proteins are responsible for the induction of antibodies that mediate ADE. 
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ANTIBODY DENEPDENT ENHANCEMENT OF PORCINE REPRODCUTIVE 
AND RESPIRATORY SYNDROME VIRUS INFECTION IN PIGS 
A paper accepted in Viral Immunology 
Kyoung-Jin Yoon, Lie-Ling Wu, Jeffrey J. Zimmerman, Howard T. Hill, and 
Kenneth B. Piatt 
ABSTRACT 
Infection of porcine alveolar macrophages by the porcine reproductive and 
respiratory syndrome virus (PRRSV) was significantly enhanced in vitro by 
antibody raised against the PRRSV isolate ISU-P (p<0.01). Increased yields and 
infection rates were highly correlated (r=0.95) and the ratio of yield to infection 
rate was greater than 1.4, suggesting that more than one mechanism was 
responsible for enhanced infection. Antibody dependent enhancement (ADE) of 
infection was also demonstrated in vivo using a completely randomized block 
design (n=16). The mean level and duration of viremia was greater (p<0.05) in 
pigs injected with subneutralizing amounts of PRRSV-specific IgG prior to virus 
challenge than in control pigs injected with normal IgG. In contrast, virus 
replication was significantly (p<0.01) iiihibited in pigs with neutralizing antibody 
titers of 4 log2. The period of time that subneutralizing levels of antibody can 
persist and contribute to ADE of PRRSV infection was estimated in 4 pigs 
injected with PRRSV-specific IgG to yield an initial neutralizing antibody titer of 
3.8 log2. Neutralizing activity declined to undetectable levels by day 37 post 
injection (PI). ADE activity was first detected in undiluted sera on day 20 PI and 
persisted through day 62 PI. Western immunoblot analysis of sera collected 
between days 37 and 62 PI detected antibodies specific for the 15kD nucleocapsid 
and 26kD glycosylated envelope proteins. These results strongly suggest that 
ADE has the potential to contribute to the pathogenesis of PRRSV infection and 
is mediated by antibody specific for the 26kD envelope protein. 
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INTRODUCTION 
Porcine reproductive and respiratory syndrome (PRRS) is an economically 
significant viral disease of swine world wide. The sjmdrome was initially 
observed in the United States in 1987 (15) and subsequently in Europe in 1990 (3). 
The porcine reproductive and respiratory syndrome virus (PRRSV) was isolated 
from infected swine in 1991 (36) and has been provisionally placed in the 
Arterivirus genus of the family Togaviridae (23)- Broad antigenic variations 
among PRRSV isolates have been demonstrated by serological assays using 
polyclonal (22,37) and monoclonal antibodies (25,39). 
The PRRSV causes reproductive failure in sexually mature pigs and 
respiratory disease characterized by interstitial pneumonia in pigs of all ages (6). 
Respiratory disease is particularly severe in pigs 3 to 5 weeks of age (15,30,41). 
This corresponds to the time period when PRRSV-specific maternal antibodies 
are relatively low. Colostrum-derived antibody specific for the virus is generally 
detected in young pigs through 4 to 8 weeks of age by the indirect fluorescent 
antibody test and the enzyme-linked immimosorbent assay (1,6,35). This 
observation has led to the speculation that antibody dependent erihancement 
(ADE) of PRRSV infection may play a role in the pathogenesis of the disease. 
This hypothesis is supported by the work of Choi et al. which demonstrated that 
virus production could be enhanced in vitro in the presence of subneutralizing 
levels of PRRSV-specific antiserum (2). 
Enhancement of virus infection by antibody has been demonstrated for 
several different viruses representing 12 different families (18). Specific 
examples include feline infectious peritonitis virus (FIPV), Aleutian disease 
virus (ADV) of mink, equine infectious anemia virus (EIAV) and dengue virus 
(DV) of humans. The role of ADE in viral pathogenesis has been particularly 
well characterized for DV. It is recognized that DV-induced disease is more 
severe in individuals who have subneutralizing levels of antibodies induced by 
previous infection with the same or different DV serotypes than in individuals 
infected with DV for the first time (7,8,9). In addition, ADE has also interfered 
with the development of vaccines. Cats, horses, and mink that have been 
immunized with experimental FIPV, EIAV, and ADV killed vaccines 
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respectively, developed a more severe disease tharv unvaccinated control 
animals following challenge with homologous virulent strains of virus (21). 
There is a significant effort currently underway to develop effective 
immunization strategies to control PRRS. If PRRSV infection is enhanced by 
antibody, then ADE must be taken into consideration in the development of 
these strategies. The following studies evaluated the potential of PRRSV-
induced antibody to enhance PRRSV infection in pigs. 
MATERIALS AND METHODS 
Media and reagents. All growth, maintenance and cell freezing media were 
supplemented with fetal bovine serum (Sigma Chemical Co., St. Louis, MO) at a 
rate of 10%, 2%, and 20%, respectively. Each of these media contained lOmM of 
HEPES and a mixture of antibiotic-antimycotic agents consisting of lOOIU/ml 
penicillin, 10|j,g/ml streptomycin, 50|ig/ml gentamicin, and 0.25|J,g/ml 
amphotericin B. In addition, the freezing media contained 10% DMSO (Sigma 
Chemical Co., St. Louis, MO). 
Protein A was prepared by dissolving staphylococcal protein A (Sigma 
Chemical Co., St Louis, MO) in Hanks' balanced salt solution (HBSS, Sigma 
Chemical Co., St. Louis, MO) at a concentration of 0.1% (w/v). The solution was 
filtered through a 0.22|Lim membrane filter (Coming Glass Works, Corning, NY) 
and stored at -70°C until used. 
Swine anti-PRRSV sera for use in ADE assays were prepared from blood 
collected from nine 14- to 28-week-old pigs 55 to 69 days after nasal inoculation 
with approximately 10^ to 10'^ TCIDso's of the PRRSV isolate ISU-P. The virus 
neutralizing and the immunoperoxidase monolayer assay (IPMA) antibody titers 
of these 9 sera ranged from 1:8 to 1:64 and from 1:256 to 1:1280, respectively. 
PRRSV-specific polyclonal immunoglobulin (IgG) for in vivo studies was 
prepared by salt precipitation using saturated ammonium sulfate aqueous 
solution (16) from a heat inactivated serum pool consisting of equal parts of the 
above sera. Normal swine serum globulin was prepared in the same marmer 
from 2 control pigs that were not infected with PRRSV. Aliquots of PRRSV-
specific and normal globulin were further purified by DEAE cellulose 
chromatography (16) and concentrated by ultrafiltration for in vitro use. Total 
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protein concentration was estimated using the BCA protein assay kit (Pierce, 
Rockford, IL). 
Cells and virus. Porcine alveolar macrophages (PAM) were used for ADE 
assays and virus isolation. The cells were collected from limgs of 4- to 6-week-
old PRRSV-free pigs by limg lavage (38). In brief, lungs were removed from pigs 
immediately following death and lavaged with cold HBSS containing the 
antibiotic-antimycotic mixture. Cells were pelleted by centrifugation at 800 x g for 
10 minutes, washed 3 times in HBSS, suspended in freezing media at a 
concentration of 5 x 10^ cells/ml, and stored at -70°C imtil used. The total 
number of viable cells was determined by dye exclusion using a 0.04% tr)^an 
blue solution (12). The proportion of PAM among total viable cells was 
determined by a nonspecific esterase test (14). Frozen cells were reconstituted for 
use by rapid thawing at 37°C, pelleted by centrifugation, and resuspended in 
RPMI-1640 growth media to contain 2 x 10^ viable PAM per ml. The cells were 
incubated for 24 hours at 37°C in a humidified 5% CO2 atmosphere prior to use. 
The MARC-145 clone (17) of the African monkey kidney cell line, MA 104 was 
used for virus titration and for the production of PRRSV antigen for use in 
serological assays and western immunoblotting. The cells were grown in 
Dulbecco's modified Eagle's media (DMEM, Sigma Chemical Co., St. Louis, MO). 
The PRRSV isolate ISU-P (ATCC VR-2402) was used for all assays and in vivo 
studies (39). This virus was initially isolated in 1992 from an homogenate 
prepared from a pool of lungs collected from young pigs in a herd that was 
undergoing an acute outbreak of respiratory disease in the state of Illinois, USA. 
Porcine alveolar macrophages were used for the initial isolation. The isolate was 
cloned by 3 rounds of limiting dilutions in PAM and twice by plaquing in MAI 04 
cells. The working stock of virus used in the present study represents the fourth 
passage in MA104 cells. 
Virus isolation and assay. Virus was isolated from serum samples using 24-
hour cultures of PAM maintained in 48 well cell culture plates (Costar Corp., 
Cambridge, MA). The cells in individual wells were inoculated by adding 0.2 ml 
aliquots of undiluted swine serum directly to the media contained in the well. 
The cell cultures were incubated at 37°C for 7 days or until visible CPE was 
observed. Two blind passages were made for each sample before the sample was 
considered negative. Confirmation of PRRSV infection was made by inoculating 
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media containing suspect virus onto 24 hour-old MARC-145 cell monolayers 
prepared on 8-chamber glass slides (Nunc Inc., Naperville, IL). The inoculum 
was removed after a 1 hour adsorption period and replaced with maintenance 
media. The cell cultures were incubated at 37°C for 48 hours and then examined 
by the indirect fluorescence antibody technique using a PRRSV-specific 
monoclonal antibody, SDOW17, specific for the 15kD nucleocapsid protein (25). 
Virus was assayed in 96-well microtiter plates (Corning Glass Works, 
Corning, NY) containing MARC-145 cell monolayers. MARC-145 cells were used 
in place of PAM because the yield of PAM from individual pigs was relatively 
small. Serum and cell culture samples to be assayed were serially diluted 10-fold 
in growth media. Media was removed from individual wells which were 
inoculated in triplicate with 0.1ml of each serial dilution of sample. One 
hundred )il of maintenance media were added to each well after a 1 hour 
adsorption period. The cell cultures were then incubated at 37°C and observed 
for CPE for 7 days. Virus titers were determined by the method of Reed and 
Muench (31) and expressed as TCIDso/ml. 
Serological assays. The serum virus neutralization (SVN) test was performed 
in 96-well microtiter cell culture plates using MARC-145 cell monolayers as 
previously described (41). Titers were expressed as the log2 of the reciprocal of the 
highest serum dilution in which no CPE was observed at the end of a 5 day 
incubation period. The immunoperoxidase monolayer assay was conducted 
utilizing a biotin-streptavidin horseradish peroxidase system with 
diaminobenzidine tetrachloride substrate (Kirkagaard and Perry Laboratories Inc., 
Gaithersburg, MD) as previously described (40). IPMA antibody titers were 
expressed as the log2 of the reciprocal of the highest serum dilution in which a 
specific color reaction was observed. 
Experimental animals. Four- to five-week-old white crossbred pigs were used 
as sources of PAM, for the production of PRRSV-specific antibody, and for 
experiments in which the effect and duration of ADE in pigs was evaluated. All 
pigs were serologically tested for PRRSV-specific antibody by the IPMA at least 
two times before being used for specific purposes, then again on the day of use. 
Pigs were obtained from sows that were medicated 9 days prior to farrowing to 
minimize the possibility of transmitting respiratory pathogens to piglets. 
Individual piglets were weaned at 14 days of age and maintained on medicated 
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rations for the duration of experiments. All pigs were serologically tested for 
pseudorabies virus, swine influenza virus, porcine parvovirus, and 
transmissible gastroenteritis virus at the end of each experiment. 
Assays for detecting ADE activity. Antibody dependent erihancement of 
PRRSV infection was assessed both by measuring increases in virus yield and by 
determining infection rates of PAM in the presence of subneutralizing levels of 
PRRSV-specific antibody. Two assays were used to measure increases in progeny 
virus yield: the standard ADE assay and the modified ADE assay. Increases in the 
infection rates of PAM were determined by indirect fluorescent antibody 
microscopy. 
The standard ADE assay was a modification of the assay described by Moren 
and Halstead (24). In brief, test and negative control sera were heat-inactivated at 
56°C for 45 minutes. Individual sera were serially diluted 2- and 10-fold in RPMI 
growth media over a range beyond that in which SVN activity was present. One 
and a half ml of each dilution of the test serum, the negative control serum, and 
RPMI growth media alone were separately mixed with an equal volume of 
RPMI-1640 containing lO^ ^ TCIDso's/ml PRRSV. These mixtures were incubated 
at 37°C for 60 minutes. Subsequently, 1 ml aliquots of each mixture were 
inoculated in triplicate into individual wells of 48-well cell culture plates that 
had been inoculated one day earlier with 10^ PAM. The plates were again 
incubated at 37°C for 60 minutes. Inoculums were replaced with 0.5 ml of RPMI 
growth media and the cultures were incubated for an additional 48 hours at 37°C 
in a humidified 5% CO2 atmosphere. The virus-infected cell cultures were 
frozen to -70°C, thawed rapidly in a 37°C water bath, then clarified by 
centrifugation at 1000 x g for 10 minutes. The supernatant from each well was 
harvested and assayed for virus activity. The difference in virus yields at each 
dilution of test and control serum was calculated by the following formula: 
Yield difference = ( Yts - ) or (Yes - ); 
where Yts = yield of virus in the presence of test serum, Y^ = yield of virus in the 
presence of RPMI alone, and Yes = yield of virus in the presence of negative 
control serum. The yield difference was modeled for each test and control serum 
by regression on serum dilutions. The general linear test (27) was used to 
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compare the yield of virus at all dilutions of test serum to the yield of virus 
generated following treatment with identical dilutions of control serum. 
Differences significant at p<0.05 were considered indicative of ADE of virus 
infection. 
The modified ADE assay was a variation of the standard ADE assay described 
above and was conducted in the same manner with the exception that PRRSV 
was treated with undiluted serum or a specific dilution of PRRSV-specific IgG. 
Student's t test was used to compare the increase in virus yield following 
treatment with undiluted serum or IgG preparation to the increase in virus yield 
following treatment with control serum or a normal serum globulin 
preparation. Differences significant at p<0.05 were considered indicative of ADE 
of virus infection. 
Antibody dependent enhancing activity as reflected by increases in the 
infection rates of PAM following treatment with PRRSV-specific antibody was 
assessed using modification of the protocol described by Olsen et al. (28). The 
assay was conducted in the same manner as the standard ADE assay through the 
end of the 48 hour incubation period. At this point, PAM cultures in the 48-well 
cell culture plates were fixed in cold acetone:methanol (70:30) for 10 minutes. 
The proportion of cells infected with PRRSV was then determined by indirect 
fluorescence microscopy using the PRRSV-specific monoclonal antibody 
SDOW17 and goat anti-mouse IgG conjugated to fluorescein isothiocyanate 
(Kirkagaard and Perry Laboratories Inc., Gaithersburg, MD). Significant 
differences (p<0.05) between the infection rates of PAM infected with treated and 
non-treated PRRSV were considered indicative of ADE activity. 
Western immunoblotting. Western immunoblot analysis (WIA) was done as 
previously described (40). In brief, MARC-145 cells were infected at a multiplicity 
of infection (m.o.i.) of 0.01 and harvested when CPE was present in >95% of the 
cell monolayer which generally occurred in 3 to 4 days. Virus-infected cell and 
uninfected control cell preparations were solubilized in a lysis buffer (pH 8.0, 
0.05M Tris, 0.15M NaCl, 0.002M EDTA, 0.5% deoxycholate, 0.1% SDS, 1% NP-40, 
0.1% sodium azide, 0.1% gelatin, and 0.1% bovine serum albumin) and clarified 
by centrifugation at 600 x g for 10 minutes. Viral and cellular proteins were then 
separated by SDS-PAGE using a modified Lammeli procedure (19) on a 
discontinuous slab gel (70 x 80 x 0.75mm) consisting of a 5% stacking gel and a 
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14% resolving gel, cross-linked with bis-acrylamide at a ratio of 30:0.8. The 
separated proteins were electrophoretically transferred from the gel to 0.45|Lim 
nitrocellulose membranes (Bio-Rad Laboratories, Richmond, CA). The 
membranes were then immersed overnight in cold (4°C) Tris-buffered saline 
(TBS, pH 7.5; 20mM Tris,.500mM NaCl) containing 1% gelatin. The membranes 
were washed for 10 to 15 minutes in gently agitated TBS, then cut into 0.7 cm-
wide strips. Duplicate strips containing viral and cellular antigens were reacted 
with test, control, and reference sera diluted 1:10 in TBS containing 0.05% Tween 
20. Antigen-antibody reactions were visualized by immunostaining with 
peroxidase labeled goat anti-swine IgG (H+L) and subsequent treatment with 
TMB (3,3',5,5'-tetramethylbenzidine) membrane peroxidase substrate (Kirkagaard 
and Perry Laboratories Inc., Gaithersburg, MD). Approximate molecular weights 
of proteins were determined by comparison with protein standards (GIBCO/BRL 
Life Technologies, Gaithersburg, MD) using linear regression. 
Demonstration of ADE activity in swine sera. Sera were collected from 9 pigs 
55 to 69 days following nasal inoculation with 10^ to 10^ TCIDso's of PRRSV 
isolate ISU-P. Each of the sera was paired randomly with a PRRSV antibody-free 
control serum collected from 9 different pigs of similar age. Each pair of test and 
control sera was assayed in triplicate for ADE activity using the standard ADE 
assay for detecting differences in progeny virus yield and indirect fluorescence 
microscopy to detect differences in infection rates of PAM. Both assays were 
performed concurrently for each pair of test and control sera. The assays were 
repeated 3 times on each of 3 separate days using the same lot of PAM. The 
general linear test was used to compare the differences in virus yield and 
infection rates of PAM for all dilutions of each pair of test and control sera. The 
relationship between the infection rate of PAM and the yield of progeny virus 
was then determined by correlation analysis. 
The effect of protein A on ADE of ERRS virus infection. The Fc receptor of 
macrophages has been shown to be an essential component in the ADE of 
several viral infections (10,13,29). Protein A binds to the Fc portion of IgG. 
Consequently, reacting protein A with PRRSV-specific IgG prior to infection of 
PAM should significantly reduce virus yield if ADE of PRRSV infection is 
mediated in whole or in part by Fc receptors. The effect of protein A on ADE of 
PRRSV infection was assessed as previously described (13) by the modified ADE 
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assay using a 3 x 2 factorial design in which PRRSV was treated with 
homologous IgG, normal serum globulin, or RPMI-1640 in the presence and 
absence of protein A. The concentration of IgG used in the study was selected 
based on its ability to optimally enhance the yield of PRRSV in the standard ADE 
assay. Each experiment was done 3 times on 3 different days using 4 different 
concentrations of protein A, i.e., 25, 50,100, and 200 fig/ml. Virus yields for all 
treatments were compared by analysis of variance (ANOVA). A blocking effect 
of protein A was considered to exist if significant reductions in virus yield 
(p<0.05) were observed at one or more concentrations of protein A. 
The effect of ADE on the duration and level of viremia in pigs. The ability of 
PRRSV-induced antibody to enhance virus infection in pigs was evaluated in 16 
pigs using a completely randomized block design. Pigs were randomly assigned 
to one of 4 treatment groups of 4 pigs each. One pig from each treatment group 
were housed in 4 separate rooms. Sera were collected from all 16 pigs prior to 
treatment and used as controls. Pigs in groups 1, 2, and 3 were injected 
intraperitoneally with salt precipitated PRRSV-specific IgG at a rate calculated to 
yield SVN antibody titers of <1, 2, and 4 log2, respectively. Group 4 pigs were 
injected with an amout of normal serum globulin which was equivalent to the 
amount of IgG received by pigs in group 1. Seven days later, all pigs were 
challenged intramuscularly with 10^ TCIDso's of PRRSV. 
Response of treatment groups to virus challenge was assessed by determining 
the duration and level of viremia. For this purpose, serum was collected from 
all pigs daily for 7 days beginning on the day of challenge, then every other day 
through day 28 post challenge (PC). Sera collected on the day of challenge were 
also assayed for SVN and ADE activity. ADE activity in undiluted serum was 
determined by the modified ADE assay. In addition, the peripheral blood 
leukocyte (PBL) profile was monitored in all pigs during this period. Pigs were 
also observed for signs of respiratory distress and inappetence. All data were 
analyzed by ANOVA to determine treatment effect, with the exception of data 
representing changes in virus titers in serum and PBL over time, which were 
analyzed by the general linear test. 
Duration of ADE activity in pigs following the decline of antibodies below 
neutralizing levels. Six 4- to 5-week-old pigs were housed in the same room. 
Four of the 6 pigs were injected intraperitoneally with salt precipitated PRRSV-
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specific IgG at a rate calculated to yield an SVN antibody titer of 4 log2. The 2 
remaining pigs were injected with an amount of salt precipitated normal swine 
serum globulin that was equivalent to the amount of IgG received by the other 4 
pigs. Sera were collected from each pig 2 to 3 times weekly over a 79 day period. 
All serum samples were assayed for PRRSV-specific antibody by the IPMA and 
the SVN test. The ADE activity in each undiluted serum was determined by the 
modified ADE assay. Sera collected on day 0 (the day of injection), day 1, and 
approximately every 10 days postinjection were also analyzed by western 
immunoblotting to determine the PRRSV protein specificity of antibody 
associated with ADE. 
RESULTS 
Presence of ADE activity in swine sera. Serum samples were collected from 9 
pigs 55 to 69 days following nasal inoculation with PRRSV isolates ISU-P. Each 
of these sera and a corresponding control serum were assayed for ADE activity by 
comparing their ability to mediate increases in virus yields and PAM infection 
rates. Results are summarized in Figure 1. 
Antibody dependent enhancement activity induced by PRRSV infection was 
demonstrated in sera collected from all 9 infected pigs. Significant increases 
(p<0.01) in both progeny virus yield and in the infection rates of PAM occurred 
when PAM were infected with PRRSV at a m.o.i. of 0.01 following treatment of 
the virus with all 9 PRRSV-specific antisera at dilutions that did not possess 
detectable viral neutralizing activity. Maximum increases in virus yields and 
infection rates of PAM mediated by a specific dilution of each of the 9 sera ranged 
from 1.43 to 1.97 logio, and 0.14% to 1.1% respectively. This increase in infection 
rates represented a 7 to 53 fold increase. In contrast, no difference in virus yield 
or infection rates of PAM was observed when PRRSV was treated with control 
sera or only media. 
The mean yield of infectious progeny virus in infected alveolar macrophages 
was 4.0 virions per infected cell following treatment of PRRSV with control sera 
or only media. In contrast, the yield of infectious progeny virus per individual 
PAM was significantly increased following treatment of the virus with the 9 
antisera at dilutions in which ADE activity was detected. Under these 
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Figure 1. Antibody dependent enhancement of PRRSV infection revealed by (A) increases in virus yields 
as determined by the standard ADE assay and (B) increases in infection rates of porcine alveolar 
macrophages (PAM) 
— = fitted curve 
O = mean of 3 estimates with each of 9 PRRSV-specific antiserums 
A = mean of 3 estimates with 9 control serums 
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conditions, the mean yield per infected cell ranged from 5.1 to 10.7 virions 
(Figure 2), suggesting that increased efficiency of virus replication occurred in. the 
cells. 
The relationship between increases in virus yields and infection rates of PAM 
in culture is summarized in Figure 3. The correlation coefficient between virus 
yield and infection rates was 0.95, which is highly suggestive of a direct 
relationship between these two parameters of ADE. The relationship between 
the two parameters is also represented by the equation: Y = 1.43X-0.53. The slope 
of the equation is significantly (p<0.01) greater than 1, which suggests that one or 
more additional factors besides enhanced infection rate of PAM, such as 
enhanced efficiency of virus production, may account for the increases in virus 
yield. 
The effect of protein A on ADE of PRRSV infection. An optimum dilution 
(1:128) of salt precipitated polyclonal IgG specific for PRRSV was treated with 
varying concentrations of Protein A to determine if ADE of PRRSV infection of 
PAM could be inhibited as determined by the modified ADE assay. The results of 
this experiment are summarized in Figure 4. The mean yield of progeny virus 
following infection of PAM with PRRSV at an m.o.i. of 0.01 after treatment of 
virus with normal serum globulin and media alone was 2.94 ± 0.16 and 2.93 ± 
0.16 logio, respectively. The addition of Protein A to normal serum globulin or 
media did not affect these virus yields. The yield of progeny virus increased 
significantly (p<0.01) to 4.97 ± 0.17 logio when the virus was treated with PRRSV-
specific IgG in the absence of Protein A. In contrast, the virus yield was 
progressively reduced to 4.63 ± 0.09 (p<0.05), 3.36 ± 0.11 (p<0.001), 1.67 ± 0.14 
(p<0.001), 1.79 ± 0.08 (p<0.001), and 1.71 ± 0.13 logio (p<0.001) following the 
addition of Protein A to PRRSV-specific IgG at concentrations of 25, 50, 100, 150, 
and 200|j,g/ml, respectively. 
The effect of ADE on the duration and level of viremia in pigs. The potential 
of PRRSV-induced antibody to erUiance virus infection in vivo was evaluated 
using a completely randomized block design in which 16 pigs were equally and 
randomly assigned to 4 groups. Three groups were injected with quantities of 
polyclonal PRRSV-specific IgG to yield SVN antibody titers of <1 log2 (Group 1), 2 
log2 (Group 2), and 4 log2 (Group 3). A fourth group injected with normal serum 
globulin served as an untreated control. 
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Figure 2. Mean yield of infectious progeny PRRSV produced in individual 
porcine alveolar macrophages (PAM) infected with the ISU-P 
isolate of PRRSV in the presence and absence of homologous 
antibody 
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Figure 3. The relationship between enhanced virus yields and infection rates 
of porcine alveolar macrophages (PAM) following treatment of 
PRRSV isolate ISU-P with 9 individual swine serums raised against 
isolate ISU-P 
- = fitted curve 
~ = 99% confidence interval 
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Figure 4. Blocking effect of staphylococcal protein A on the enhancement 
of PRRSV infection of porcine alveolar macrophages mediated 
by virus-specific polyclonal immunoglobulin (IgG) 
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Serum virus neutralizing and IPMA antibody titers together with ADE 
activity in undiluted serum on the day of virus challenge is summarized for all 
groups in Table 1. Significant ADE activity was detected in the imdiluted sera of 
all pigs in Group 1 and in one pig in Group 2. No ADE activity was 
demonstrated in the undiluted sera of Group 3 pigs. The mean SVN titers of 
Groups 2 and 3 was 1.6 and 3.4 log2, respectively. No SVN activity was detected 
among Group 1 pigs. 
The response of each group with respect to the duration and the level of 
viremia following intramuscular challenge with isolate ISU-P are summarized 
in Figure 5. Both the mean duration and the mean level of viremia were 
significantly lower (p<0.05) for Group 3 than for all other groups, indicating that 
high SVN antibody titers suppress virus replication in the pig. In contrast, the 
mean duration and the mean level of viremia were significantly greater (p<0.05) 
for Group 1 than for the control group or Group 3, indicating that 
subneutralizing levels of antibody enhance virus replication. In addition, no 
significant differences were observed between Group 2 and the control group 
with respect to the duration and the level of viremia. 
The response of all 4 groups following PRRSV challenge with respect to PBL 
profile is summarized in Figure 6. A transient leukopenia occurred in all groups 
and ranged in duration from 9 to 11 days. The maximum level of PBL 
depression occurred between 3 and 4 days following challenge. No significant 
differences were detected between groups (p>0.05). No signs of respiratory 
distress or inappetence were observed in any pig during the course of the 
experiment. 
Duration of ADE activity in pigs following the decline of antibodies below 
neutralizing levels. The length of time that ADE activity may persist in pigs 
with declining levels of maternal or vaccine-induced PRRSV-specific antibodies 
was estimated in 4 pigs which were injected with polyclonal PRRSV-specific IgG. 
Serum virus neutralizing activity, IPMA antibody titers, and ADE activity in 
undiluted serum were subsequently monitored for an 80 day period. Results are 
summarized in Figure 7. The mean SVN antibody titer on day 1 post injection 
(PI) was 3.8 log2 which subsequently declined to undetectable levels by day 37 PI. 
The mean IPMA antibody titer was 7.42 log2 on day 1 PI and declined slowly 
thereafter until becoming undetectable by day 72 PI. Mean ADE activity was first 
Table 1, Antibody dependent enhancement (ADE) activity, serum virus neutralization (SVN) 
antibody titers, and inununoperoxidase monolayer assay (IPMA) antibody titers in 
4 groups of pigs on the day of challenge v*/ith PRRSV isolate ISU-P 
Treatment groups ADE activity^ SVN activity^ Mean SVN titer Mean IPMA titer 
(log2) (logz) 
Group 1 4/4 0/4 N/Ad 5.32 
Group 2 1/4 4/4 1.60 6.13 
Group 3 0/4 4/4 3.32 7.32 
Group 4 0/4 0/4 N/A N/A 
3 Each group contained 4 pigs each. Groups 1, 2, and 3 were injected with PRRSV-specific 
polyclonal immunoglobulin at a rate calculated to yield SVN antibody titers of <;1, 2, and 
4 log2, respectively seven days before virus challenge. Group 4 was injected with normal 
swine serum globulin. 
^ Number of pigs in which ADE activity was detected in undiluted serum. 
Number of pigs in which SVN activity was detected. 
NA= not applicable 
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Figure 5. The effect of neutralizing and subneutralizing levels of PRRSV-specific antibody on the 
(A) duration and (B) levels of viremia in pigs challenged by intramuscular injection of 
10^ TCID50 of PRRSV isolate ISU-P. Groups 1,2, and 3 were injected with salt-precipitated 
PRRSV-specific polyclonal immunoglobulin at a rate to yield serum virus neutralizing 
antibody titers of ^1,2, and 4 log2. Group 4 was injected with normal swine serum globulin. 
N = 4 for all groups 
* significant difference at p<0.05 
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Figure 6. The peripheral blood leukocyte response in pigs that were 
injected with PRRSV-specific polyclonal immunoglobulin (IgG) 
and challenged 7 days later by intramuscular injection of 10 
TCID50 of PRRSV isolate ISU-P. Groups 1,2, and 3 were injected 
with concentrations of IgG to yield serum virus neutralizing 
antibody titers of ^1,2, and 4 log2. Group 4 was injected with 
normal swine serum globulin. N = 4 for all groups 
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Figure 7. Antibody dependent enhancement (ADE) activity, serum virus 
neutralizing (SVN) antibody titers and immunoperoxidase monolayer 
assay (IPMA) antibody titers of 4 pigs that were initially injected 
intrapeiitoneally with PRRSV-specific polyclonal immunoglobulin 
at a rate to yield a SVN titer of 4 logj and monitored for a 79 day period 
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observed in undiluted serum at day 20 PI when the mean SVN antibody titer was 
less than 1.6 log2. The mean ADE activity peaked at day 41 PI, then slowly 
declined at approximately the same rate as the mean IPMA antibody titer until 
becoming undetectable at day 62 PI. 
Identification of PRRSV protein(s) associated with ADE. Sera that were 
collected from the 4 passively immunized pigs described above were analyzed by 
western immunoblot to determined the specificity of the antibodies associated 
with ADE. Results of this analysis are summarized in Table 2. Antibodies 
specific for proteins with molecular masses of 15,19, 23, and 26kD were detected 
in all 4 pigs through day 20 PI when ADE activity was first detected. The mean 
SVN antibody titer on day 20 PI was 1.6 log2. By day 51 PI, immunoblotting only 
detected antibodies specific for the 15kD and the 26kD proteiris. Antibody specific 
for the 26kD protein continued to be detected in all 4 treated pigs through day 72 
PI, while antibodies specific for the 15kD protein persisted in all 4 pigs until day 
51 PI and in 3 pigs until day 62 PI. 
DISCUSSION 
A preliminary study indicated that infection of PAM by PRRSV could be 
enhanced by treating the virus with subneutralizing levels of antibody prior to 
infecting PAM (2). Because ADE of virus infection has been shown to contribute 
to several other viral diseases and to interfere with immunization strategies for 
viruses such as dengue virus, feline infectious peritonitis virus, Aleutian disease 
virus of mink, and equine infectious anemia virus (21), it was important to 
know if ADE has the potential to contribute to the pathogenesis of PRRSV 
infection and to interefere with immunization strategies for PRRS. 
In the work reported here, infection of PAM by the PRRSV was significantly 
ervhanced in vitro by the presence of antibody raised against the PRRSV isolate 
ISU-P (p<0.01), indicating that PRRSV' induces antibodies which are capable of 
enhancing PRRSV infection (Figure 1). Antibody dependent enhancement of 
virus infection was also demonstrated in vivo. The mean level and duration of 
viremia was greater in pigs injected with subneutralizing amounts of PRRSV-
specific IgG prior to virus challenge than in control pigs injected with normal 
serum globulin (Figure 5). In a separate experiment, the time period that pigs 
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Table 2. Western immunoblot analysis of serums collected from 4 pigs 
over a 79 day period following injection of PRRSV-specific 
immunoglobulin (IgG) at a rate to yield a serum virus neutralization 
antibody titer of 4 log2 
PRRSV Days following injection of IgG 
proteins 0 1 9 20 30 41 51 62 72 79 
26 kD 0 4a 4 4 4 4 4 4 3 0 
23 kD 0 4 4 4 3 0 0 0 0 0 
19 kD 0 4 4 4 3 2 0 0 0 0 
15 kD 0 4 4 4 4 4 4 3 0 0 
3 Number of pigs in which antibody specific for each protein was detected. 
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with declining levels of PRRSV-specific antibodies could be expected to be 
susceptible to ADE was estimated using 4 pigs that were injected with virus 
specific IgG. Antibody dependent enhancement activity was first detected in 
undiluted sera when SVN antibody titers droped below 2 log2 and persisted in 
undiluted sera of the pigs for periods that ranged from 5 to 6 weeks, thereafter 
(Figure 7). Collectively, these observations strongly suggest that ADE of PRRSV 
infection has the potential to enhance the severity of disease and possibly the 
susceptibility to PRRSV infection in pigs with declining levels of PRRSV-specific 
antibodies of maternal origin, or antibodies induced by exposure to wild type or 
vacine PRRSV. 
In the present study, a direct correlation (r=0.95) was demonstrated between 
increased virus yields and infection rates of PAM that were mediated by PRRSV-
specific antibody. In addition, the ratio between increases in virus yield and 
infection rate was greater than 1.4 (Figure 3). These observations suggest that 
more than one mechanism contributed to the enhancement of virus yield in the 
presence of virus-specific antibody. This conclusion is consistent with the 
observations that not only was the infection rate of PAM increased but also the 
yield of progeny virions from individual PAM (Figure 2). The primary 
mechanism responsible for increased virus yields appears to have been due to an 
increase in the infection rates of PAM which was facilitated by an interaction 
between Fc receptors of PAM and virus-antibody complexes. We base this 
conclusion on the observation that virus yields were significantly reduced when 
virus/antibody preparations were treated with Protein A prior to exposing PAM 
to virus (Figure 4). Similar observations have been made by other investigators 
who shidied ADE of DV (10), FIPV (28), West Nile virus (WNV) (29), and ADV 
infection (13). Increased efficiency of virus production in individual cells in the 
presence of antibody may have also contributed to increased yields of PRRSV in 
PAM. This possibility has bee previously reported for other viral infections. For 
example, Robbinson et al. (32) observed higher production of viral components 
in cells that were infected with human immunodeficiency virus in the presence 
of virus-specific antibody than in the absence of antibody. The mechanism 
responsible for the enhanced production of viral components in individual cells 
was not determined. However, Collins et al. (5) who studied ADE of WNV 
presented data that suggest that multiple viral infection of individual cells could 
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increase virus production. We do not believe that multiple viral infection of 
individual PAM was responsible for the increased efficiency of virus production 
in our study because a low m.o.i., i.e., 0.01 was used and infection rates were 
significantly increased. Nonetheless, the specific mechanism for ADE of PRRSV 
infection remains to be determined. 
Western immunoblot analysis revealed the presence of antibody specific for 
the 15kD nucleocapsid protein (26) and the envelope-associated 26kD 
glycoprotein (26) throughout the period that ADE activity was present in 
undiluted serum of pigs that were injected with PRRSV-specific IgG (Table 2). 
The location of the 26kD protein in the viral envelope suggests that antibodies 
induced by this protein are associated with ADE. Other investigators have 
reported that ADE of other virus infections is also mediated by antibodies 
induced by envelope-associated proteins (4,11,28,33,34). It is also possible that 
other envelope-associated proteins of PRRSV that were not detected by our assay, 
such as the 43kD glycoprotein described by Madassi et al. (20), may induce 
antibodies that contribute to ADE. The internal location of the 15kD 
nucleocapsid protein within the virion leads us to believe that antibodies 
induced by this protein were not associated with ADE even though they were 
detected throughout the period that ADE activity was detected in undiluted 
serum. However, it is conceivable that antibody specific for the 15kD protein 
could contribute to enhancement of PRRSV infection if the integrity of the viral 
envelope is compromised by host defense mechanisms. 
The above study indicates that ADE of PRRSV infection has the potential to 
contribute to the severity of disease and possibly to increase the susceptibility of 
pigs to infection by PRRSV. These possibilities are of particular concern with 
respect to young pigs with declining levels of maternal antibodies since these 
young pigs are highly susceptible to respiratory disease caused by PRRSV 
(15,30,41). Results of our study also showed that virus replication was 
significantly suppressed in pigs with virus neutralizing antibody titers greater 
than 3.4 log2 and that ADE activity was not detected in undiluted serum until the 
SVN titers fell below 2 log2. Consequently, potential adverse affects mediated by 
ADE might be avoided by designing immunization strategies that maintain high 
serum virus neutralizing activity in young pigs. 
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FIELD ISOLATES OF PORCINE REPRODUCTIVE AND RESPIRATORY 
SYNDROME VIRUS VARY IN THEIR SUSCEPTIBILITY TO ANTIBODY 
DEPENDENT ENHANCEMENT OF INFECITON 
A paper accepted in Veterinary Microbiology 
Kyoung-Jin Yoon, Lie-Ling Wu, Jeffrey J. Zimmerman, Kermeth B. Piatt 
Abstract 
Seventeen porcine reproductive and respiratory syndrome virus (PRRSV) 
field isolates, including isolate ISU-P, were evaluated for their susceptibility to 
antibody dependent erihancement (ADE) of infection mediated by antibodies 
raised against PRRSV isolate ISU-P. Progeny virus yields of ISU-P and 4 of 16 
field isolates in porcine alveolar macrophages (PAM) were reduced following 
treatment with a concentration of antibody that neutralized ISU-P (p<0.01). In 
contrast, the yields of 12 of 17 field isolates were enhanced (p<0.01). Treatment of 
all isolates with a 10-fold lower concentration of this antibody significantly 
(p<0.01) increased virus yields of all isolates in PAM. However, the degree of 
enhancement varied among the isolates when compared to the enhancement of 
the yield of ISU-P. While no differences in enhancement were observed among 
ISU-P and 9 field isolates, yield enhancement of 6 and 1 isolates were less than 
and more than the yield enhancement of ISU-P, respectively (p<0.05). The 
degree of enhancement mediated by a high concentration of antibody raised 
against ISU-P was inversely proportional to the ability of the antibody to 
neutralize the isolates (r=0.92). In contrast, no direct correlation (r=0,32) was 
observed between the degree of enhancement mediated by a low concentration of 
antibody and the ability of the antibody to neutralize the isolates. These data 
suggest that the variability in the susceptibility of PRRSV isolates to ADE arise 
from quantitative and/or qualitative differences in the antigenic determinants 
associated with virus neutralization and/or ADE. The antigenic diversity and 
the wide range in the susceptibility to ADE that exists among field isolates 
indicate that ADE should be taken into consideration in the development of 
effective immunization strategies for PRRS. 
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1. Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is a highly contagious 
disease of swine manifested by reproductive failure in breeding age swine and 
respiratory disease in young pigs (Christiansen and Joo, 1994). It is caused by an 
enveloped, single-stranded RNA virus that has been provisionally classified as a 
member of the Arterivirus genus of the family Togaviridae (Meulenburg et al., 
1993). Currently, the use of vaccines are being advocated to control this disease. 
However, field observations suggest that the use of a vaccine may exacerbate the 
clinical manifestations of PRRS in some herds (B. Thacker, personal 
communication; G. Erickson, personal communication). One possible 
explanation for these observations is antibody dependent enhancement (ADE) of 
virus infection in which antibodies of maternal origin or induced by vaccination 
increase the susceptibility of pigs to vaccine or endemic strains of porcine 
reproductive and respiratory syndrome virus (PRRSV) as well as contribute to 
the severity of infection. This possibility has been suggested by results of an 
earlier study in which that the level and duration of viremia was significantly 
greater in pigs that were infected with virus following the injection of 
subneutralizing levels of polyclonal PRRSV-specific IgG than in PRRSV 
antibody-free control pigs (Yoon et al., 1995c). 
Antibody dependent enhancement of virus infection has been reported for 
several other viruses, most notably dengue virus (DV) of humans (Kurane et al., 
1992). More importantly, ADE has been implicated as a significant obstacle to the 
development of effective vaccines and vaccination strategies for several viruses, 
including DV, feline infectious peritonitis virus (FIPV), equine infectious 
anemia virus (EIAV), and Aleutian disease virus of mink (Mascolar et al., 1993). 
A common characteristic of these viruses is their antigenic variability which has 
been shown to contribute to not only their susceptibility to ADE but, in some 
cases, to their ability to induce ADE activity. For example, Halstead and his co­
workers (1977 and 1984) have demonstrated that different DV serotypes, as well 
as different strains within the same serotype, varied in their susceptibility to ADE 
and in their ability to induce antibodies associated with ADE. Similar 
observations have been reported by Scott and his associates with respect to FIPV 
(Corapi et al., 1992; Olsen et al., 1992). Broad antigenic variation among PRRSV 
isolates has also been demonstrated by several investigators (McGinley et al.. 
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1993; Nelson et al, 1993; Wensvoort et al., 1992; Yoon et al., 1995a). 
Consequently, the possibility exists that PRRSV isolates may also vary in their 
susceptibility to ADE. The following study was conducted to determine if such 
variations exist among field isolates of PRRSV which could interfere with 
immunization strategies. 
2. Materials and methods 
2.1 Media and reagents 
All growth, maintenance, and freezing media were supplemented with fetal 
bovine serum (Sigma Chemical Co., St. Louis, MO, USA) at a rate of 10%, 2%, 
and 20%, respectively. Each of these media contained lOmM of HEPES and a 
mixture of antibiotic-antimycotic agents (Sigma Chemical Co., St. Louis, MO, 
USA) consisting of lOOIU/ml penicillin, 10|xg/ml streptomycin, 50fig/ml 
gentamicin, and 0.25|xg/ml amphotericin B. In addition, freezing media 
contained 10% DMSO. 
2.2 Anti-PRRSV reference serum 
Sera were obtained from 3 pigs at 60 to 63 days following nasal inoculation 
with 10'^ TCIDso/ml of PRRSV isolate ISU-P. The virus neutralizing antibody 
titers of the 3 sera ranged from 5 to 6 log2. Antibody titers that were determined 
by the immunoperoxidase monolayer assay ranged from 8.32 to 10.3 log2. 
Control sera were obtained from PRRSV antibody-free SPF pigs of similar age. 
Each of the 3 reference antisera was paired randomly with a control serum. Each 
pair of antibody-positive and control sera constituted one set. 
2.3 Cells 
Porcine alveolar macrophages (PAM) were used for ADE assays. The cells 
were collected from lungs of 4- to 6-week-old PRRSV-free pigs by lung lavage 
using Hanks' balanced salt solution (Sigma Chemical Co., St. Louis, MO, USA) 
and harvested by centrifugation as previously described (Yoon et al., 1995c). 
Harvested cells were suspended in freezing media at a concentration of 5 x 10'' 
cells/ml and stored at -70°C until used. Immediately prior to use, frozen cells 
were rapidly thawed in a 37°C water bath and suspended in RPMI-1640 growth 
media at a concentration of 2 x 10^ viable PAM per ml. The total number of 
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viable cells was determined by dye exclusion (Kaltenbach et al., 1958) using a 
0.04% trypan blue solution. The proportion of PAM in the viable cell population 
was determined by a nonspecific esterase test (Kasplow, 1981). 
The MARC-145 clone (Kim et al., 1993) of the African green monkey kidney 
cell line, MA104 was used for virus assays and the serum virus neutralization 
(SVN) test. These cells were grown in Dulbecco's modified Eagle's media (Sigma 
Chemical Co., St. Louis, MO, USA). 
2.4 Virus 
A total of 17 PRRSV isolates were evaluated in the study. The PRRSV isolate 
ISU-P (ATCC VR-2402) was included among these isolates and used as a 
reference strain for all comparisons. This virus was initially isolated in 1992 
from an homogenate prepared from a pool of lungs collected from yoimg pigs in 
a herd in which an acute PRRS outbreak was occurring in the state of Illinois, 
USA. The isolate was cloned by 3 rounds of limiting dilution in PAM and 
subsequently plaque cloned twice in MA104 cells. Sixteen PRRSV field isolates 
were obtained from the National Veterinary Services Laboratories, Ames, Iowa. 
These isolates represented the states of Arizona (AZ), Iowa (lA), Illinois (IL), 
Kansas (KS), Michigan (MI), Minnesota (MN), and North Carolina (NC) and 
were isolated from field specimens during the years 1989 through 1993. Field 
isolates were not cloned. The working stock of all virus isolates used in the 
study represented the third or fourth passage in MA104 cells. 
2.5 Virus assay 
Virus titration was performed in 96-weIl microtiter plates (Corning Costar 
Corp., Cambridge, MA USA) using MARC-145 cells as previously described 
(Yoon et al., 1995b). Virus titers were determined by the method of Reed and 
Muench(1938) and expressed as TCIDso/ml. 
2.6 ADE assays 
A standard and a modified ADE assay were used to determine the relative 
susceptibility of different PRRSV isolates to ADE. The standard assay was 
conducted as previously described (Yoon et al., 1995c). In brief, each set of 
PRRSV-specific antibody-positive and antibody-free sera was heat-inactivated at 
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56°C for 45 minutes and serially diluted 2- and 10-fold in RPMI growth media 
over a range beyond detectable SVN activity. One and a half ml of each dilution 
of the 3 serum sets and RPMI growth media alone were separately mixed with an 
equal volume of RPMI-1640 media containing lO^-^ TCIDso/ml of a specific 
PRRSV isolate. These mixtures were incubated for 60 minutes at 37°C. 
Subsequently, 1 ml aliquots of each mixture were inoculated in triplicate into 
individual wells of 48-well cell culture plates (Coming Costar Corp., Cambridge, 
MA USA) that had been inoculated with 10^ PAM one day earlier. The plates 
were again incubated at 37°C for 60 minutes. Inoculums were replaced with 0.5 
ml RPMI growth media and the cultures were incubated for an additional 48 
hours at 37°C. The virus-infected cell cultures were then frozen and thawed 
once at -70°C and 37°C, respectively, and clarified by centrifugation at 1000 x g for 
10 minutes. The supernatant from each well was harvested and assayed for 
virus activity using MARC 145 cells. The increased yield of virus mediated by 
PRRSV-specific antibody was determined for each dilution using the formula: 
Yield difference = (Yts - Ym ) - (Yes - Ym ); 
where Yts = yield of virus in the presence of PRRSV specific antibody, Ym = yield 
of virus in the presence of RPMI alone, and Yes = yield of virus in the presence of 
PRRSV specific antibody-free control serum. 
The modified ADE assay was conducted in the same manner as the standard 
ADE assay with the exception that individual PRRSV isolates were individually 
treated with a 10"^ and a 10-2 dilution of each set of sera. Increased virus yields 
were determined for each isolate as described above. 
2.7 Serum virus neutralization 
The SVN test was used in one-way format to determine SVN indices of the 17 
PRRSV isolates. The SVN test was conducted as previously described in 96-well 
microtiter plates using MARC-145 cell monolayers (Yoon et al., 1995b). The titers 
of all 3 antisera described above in which each isolate was used separately as 
antigen were determined in duplicate on the same day. This procedure was 
repeated on 3 separate days and geometric mean (GM) titers were calculated. 
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2.8 Experimental design 
Two experiments were conducted. In the first experiment, 16 PRRSV field 
isolates were evaluated by the modified ADE assay to determine their relative 
susceptibility to ADE with respect to that of PRRSV isolate ISU-P. All isolates 
were coded to avoid test bias and assayed for ADE in triplicate using 2 different 
dilutions of each set of antibody-positive and negative control sera. The assay 
was repeated on 3 separate days using the same lot of PAM. Yield differences of 
each isolate were compared to the yield difference of PRRSV isolate ISU-P by 
Student's t test. Subsequently, Duncan's multiple range test was used to 
determine the relatedness of PRRSV isolates in terms of their relative 
susceptibility to ADE. 
Two PRRSV isolates, AZ-1 and KS-1, were identified by the modified assay as 
being the most and the least affected by ADE. The susceptibility of these 2 isolates 
and ISU-P to ADE was further evaluated by the standard ADE assay. The assay 
was repeated on 3 separate days using the same lot of PAM. Yield differences 
following treatment with the 3 sets of antibody-positive and control sera were 
modeled for each isolate by regression on serum dilutions and compared by the 
general linear test (Neter et al., 1990). Subsequently, the area under the fitted 
curves which represented ADE of virus yields was determined for each isolate by 
integration and compared by analysis of variance (ANOVA). 
In the second experiment, the relationship between susceptibility of an isolate 
to both neutralization and ADE was determined. For this purpose, we conducted 
the one-way SVN test using the same 3 reference antisera that were used in the 
first experiment and determined the SVN indices as described by McGinley et al. 
(1993) for 17 isolates including isolate ISU-P. The SVN index of an individual 
isolate was defined as: 
SVN index (%) = GM titer determined with individual isolate x 100 
CM titer determined with isolate ISU-P 
The relative sensitivity of individual isolates to neutralization was determined 
by comparing SVN indices using ANOVA. Subsequently, the relationship 
between susceptibility to neutralization and to ADE which was assessed by the 
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modified ADE assay in the first experiment was determined by correlation 
analysis. 
3. Results 
3.1 Variability in the susceptibility of PRRSV field isolates to ADE 
Seventeen PRRSV field isolates, including isolate ISU-P, were evaluated to 
determine their relative susceptibility to ADE mediated by a high and a low 
concentration of antibody raised against PRRSV isolate ISU-P. Results of this 
experiment are summarized in Figure 1. Treatment of isolates with a high 
concentration of antibody raised against PRRSV isolate ISU-P prior to infecting 
PAM resulted in a reduction of virus yield of ISU-P and 4 additional isolates (lA-
7, IA-2, NC-1, IA-3). The virus yields of these isolates were reduced by 0.61 ± 0.08, 
0.32 ± 0.08, 0.24 ± 0.14, 0.13 ± 0.07 logio, respectively. In contrast, virus yields of 
the remaining 12 isolates were increased by treating with the same concentration 
of the antibody. Increases in virus yields ranged from 0.24 ± 0.00 logio for isolate 
IL-1, to 0.76 ± 0.14 logio for isolate NC-8 (Figure lA). No increases or reductions 
in virus yields were observed among the 16 isolates when they were treated in 
the same maimer with normal control serum. 
No reduction in virus yields of any isolate occurred when individual isolates 
were treated with a 10-fold lower concentration of antibody. Increases in virus 
yields varied among the isolates (p<0.01) and ranged from 0.16 ± 0.08 logio for 
isolate KS-1 to 1.83 ± 0.17 logic for isolate AZ-1 (Figure IB). Yield increase of 1 
isolate (AZ-1) was greater than the yield increase of ISU-P (p<0.01), while yield 
increases of 6 isolates were significantly less than the yield increase of ISU-P 
(p<0.01). No differences in yield increase were observed among the remaining 9 
isolates and ISU-P. 
The 2 isolates showing the most (AZ-1) and the least (KS-1) susceptibility to 
ADE in the modified assay and isolate ISU-P were further evaluated by the 
standard ADE assay. Results of this experiment are summarized in Figure 2. 
Treatment of the 3 isolates with PRRSV-specific antiserum prior to infecting 
PAM significantly (p<0.01) increased the yield of progeny virus of each isolate. 
The areas described by the fitted curves which are proportional to the virus yields 
for isolates KS-1, ISU-P, and AZ-1 were 1.56 ± 0.05,4.17 ± 0.02, and 10.02 ± 0.04, 
respectively. These results support the finding revealed by the modified ADE 
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Figure 1. Variability in the susceptibility of 17 North American PRRSV isolates to antibody 
dependent enhancement mediated by (A) high and (B) low concentrations of porcine 
antibody raised against PRRSV isolate ISU-P 
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Figure 2. Comparison of antibody dependent enhancement of infection 
of 3 PRRSV field isolates AZ-1, ISU-P, and KS-1 in porcine 
alveolar macrophages following treatment with porcine antibodies 
raised against the PRRSV isolate ISU-P. Symbols are observations 
(n=9) and lines are fitted curves for each of the 3 isolates: 
AZ-1: Y = -0.0085X^ + 0.0443X^ + 0.3898X -t- 2.5671 
ISU-P: Y = -O.OllSX^ -h 0.1126X^ + 0.0927X + 1.7215 
KS-1: Y = 0.0056X^ - 0.1137X^ + 0.6293X + 2.2277 
Control: Y = 2.833 
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assay that PRRSV field isolaets vary widely with respect to their susceptibility to 
ADE. 
3.2 The relationship between the relative susceptibility of PRRSV isolates to 
neutralization and ADE 
The 17 PRRSV isolates were compared by a one-way SVN assay for their 
susceptibility to neutralization by antibodies raised against ISU-P. Results are 
summarized in Figure 3. The relative difference in the susceptibility of 
individual isolates to neutralization is reflected by the SVN antibody titers which 
were determined by the SVN assay using each individual isolate as antigen. The 
mean SVN antibody titer determined with isolate ISU-P was 5.3 log2. In contrast, 
the mean SVN antibody titer of the same antiserum that was determined with 
each of the 16 different isolates ranged from 0.7 (isolate AZ-1) to 4.3 log2 (isolate 
IA-3). SVN indices of these 16 isolates ranged from 13.2 to 81.1%, indicating that 
the isolates vary in their susceptibility to neutralization (p<0.01). 
The SVN indices of individual isolates were highly correlated (r=0.95), but 
inversely related to the virus yields of the isolates following treatment with a 
high concentration of antibody (Figure 4A). This observation indicates that 
PRRSV isolates with low SVN indices are more susceptible to ADE of infection 
than isolates with high SVN indices. A similar relationship was observed 
between SVN indices and the susceptibility to ADE among isolates treated with a 
10-fold lower concentration of the same antibody. However, the degree of 
correlation was markedly lower (r=0.32) because 5 of the 16 isolates fell outside of 
the 99% confidence interval. The exclusion of these 5 isolates from the analysis 
also revealed a high degree of correlation (r=0.91) between susceptibility to 
neutralization and ADE. The lack of correlation between SVN indices and the 
susceptibility to ADE among 5 isolates could be a reflection of quantitative and 
qualitative differences in the antigenic determinants of the 5 isolates. 
4. Discussion 
The primary objective of the above study was to determine if field isolates of 
PRRSV vary in their susceptibility to ADE. Such a variation could have an 
adverse effect on immunization strategies for PRRS. Our results clearly indicate 
that field isolates do vary in this respect. This characteristic of PRRSV was 
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Figure 3. Antigenic variation of PRRSV field isolates from 7 different 
states in United States of America as revealed by a one-way 
serum virus neutralization assay using porcine antibody 
raised against PRRSV isolate ISU-P 
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Figure 4. The relationship between the relative susceptibility of individual PRRSV isolates to neutralization 
and antibody dependent enhancement in the presence of (A) high and (B) low concentrations of 
porcine antibody raised against PRRSV isolate ISU-P 
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dramatically illustrated by the neutralization of ISU-P by a concentration of 
homologous antibody that significantly (p<0.01) enhanced the replication of 12 of 
16 other field isolates tested (Figure lA). This observation suggests that 
antibodies induced by vaccine strains of PRRSV could also erUiance the 
replication of PRRSV field isolates in vaccinated animals. In addition, our 
findings suggest that the replication of vaccine virus in the host could also be 
enhanced by maternal antibody specific for field isolates of PRRSV. Both of these 
possibilities could be contributing to the exacerbation of PRRS that is occasionally 
observed in North American swine herds in which vaccine is being used. 
Results of an earlier study in which the potential of ADE of PRRSV infection 
to contribute to disease was demonstrated (Yoon et al., 1995c) and the preceding 
study suggests that vaccine candidates should be evaluated for their ability to 
induce ADE activity prior to their use in the field. In the present study, we 
demonstrated that isolates with high SVN indices are less susceptible to ADE 
than isolates with low SVN indices (Figure 4). Consequently, it may be possible 
to use SVN indices of field isolates, that are determined with antiserum specific 
for individual vaccine candidates, as surrogate markers for ADE. 
The apparent lack of correlation between susceptibility to SVN and ADE 
mediated by a low concentration of antibody associated with 5 PRRSV isolates 
(Figure 4B) suggests that ADE can also be mediated by antibody specific for 
antigenic determinants that are only partially associated with SVN or not 
associated at all. Studies of FIPV (Corapi et al., 1992) and DV (Henchal et al., 1985; 
Morens et al., 1987) have revealed the existence of such antigenic determinants. 
Consequently, the identification of these antigenic determinants in PRRSV and 
their exclusion from vaccines may be beneficial. 
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CHARACTERIZATION OF THE HUMORAL IMMUNE RESPONSE TO 
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS 
INFECTION 
A paper published in the Journal of Veterinary Diagnostic Investigation 
(Volume 7, pages 305-312, 1995) 
Kyoung-Jin Yoon, Jeffrey J. Zimmerman, Sabrina L. Swenson, Michael J. 
McGinley, Ken A. Eemisse, Andy Brevik, Lydia L. Rhinehart, Merwin L. Frey, 
Howard T. Hill, and Kermeth B. Piatt 
ABSTRACT 
The development of the humoral immune response against porcine 
reproductive and respiratory syndrome virus (PRRSV) was monitored by an 
indirect fluorescent antibody (IFA) test, immunoperoxidase monolayer assay 
(IPMA), enzyme-linked immunosorbent assay (ELISA), and serum virus 
neutralization (SVN) test over a 105-day period in 8 pigs experimentally infected 
with ATCC strain VR-2402. Specific antibodies against PRRSV were first detected 
by the IFA, IPMA, ELISA, and the SVN test 9-11, 5-9, 9-13, and 9-28 days 
postinoculation (PI) and reached their maximum values by 4-5, 5-6, 4-6, and 10-11 
weeks PI, respectively, thereafter. After reaching maximum value, all assays 
showed a decline in antibody levels. Assuming a constant rate of antibody decay, 
it was estimated by regression analysis that the ELISA, IFA, IPMA, and SVN 
antibody titers would approach the lower limits of detection by approximately 
days 137,158, 324, and 356 PI, respectively. In this study, the immunoperoxidase 
monolayer assay appeared to offer slightly better performance relative to IFA, 
ELISA, and SVN in terms of earlier detection and slower rate of decline in 
antibody titers. 
Western immunoblot analysis revealed that antibody specific for the 15 
kilodaltons (kD) viral protein was present in all pigs by 7 days PI and persisted 
throughout the 105-day observation period. Initial detection of antibodies to the 
19, 23, and 26 kD proteins varied among pigs, ranging from 9- to 35-days PI. 
Thereafter, the antibody responses to these 3 viral proteins of PRRSV continued 
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to be detected throughout the 105-day study period. Among these 3 proteins, 
antibodies specific for the 26kD protein were present immediately before or at the 
time the SVN activity was detected. These results clearly indicate that the 15 kD 
protein is the most immunogenic of the 4 viral proteins identified and may 
provide the antigenic basis for the development of improved diagnostic tests for 
the detection of PRRSV antibodies. The 26kD protein appears to be highly 
associated with the induction of neutralizing antibody. 
INTRODUCTION 
Porcine reproductive and respiratory syndrome (PRRS) is a relatively new 
viral disease of swine. In 1987, PRRS was reported as a new, devastating disease 
of swine in the United States.!^ It continues to be an economically significant 
health problem in swine producing regions throughout the world due to losses 
from respiratory disease in neonates and nursery pigs, and reproductive losses in 
breeding stock.®'i3 In response to the economic importance of PRRS, a significant 
research effort has been mounted to develop reliable diagnostic tests and 
effective vaccines. 
An enveloped RNA virus was identified as the causative agent for PRRS 
and provisionally assigned to the Arterivirus genus of the family Togaviridae on 
the basis of morphological and biological characteristics, genomic organization, 
and the strategy of gene expression.4'9,i5,24,25 Although genomic sequence 
analysis has suggested that the virus may contain as many as 6 structural 
proteins,9'i5 only 3 structural proteins with molecular masses of approximately 
15, 19, and 26 kilodaltons (kD) have been consistently demonstrated.^'^^ The 
functions of these proteins have not been completely determined, but current 
evidence indicates that the 15kD protein is a nucleocapsid protein, whereas the 
19 and 26kD proteins are presumed to be components of the viral envelope.3'9,i5 
The immunobiological roles of the viral proteins have not been characterized, 
although researchers have speculated that the 26kD protein may be associated 
with induction of serum neutralizing antibodies against porcine reproductive 
and respiratory syndrome virus (PRRSV).7 
The indirect fluorescent antibody (IFA) test,26 serum virus neutralization 
(SVN) test,^'i6 immunoperoxidase monolayer assay (IPMA),^^ and enzyme-
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linked immunosorbent assay (ELISA)i have been described for the detection of 
specific antibodies against PRRSV. Currently, most North American veterinary 
diagnostic laboratories are using the IFA test and/or the SVN test to detect 
PRRSV-specific antibodies, while European laboratories have relied on the IPMA 
using PRRSV-infected porcine alveolar macrophages (PAM).®'29 The recent 
licensure of a commercial ELISA kit (IDEXX) will probably change this picture. 
The IFA and IPMA are thought to be highly specific and sensitive tests.24'26 
Antibodies to PRRSV are usually detected by these tests between 7 and 15 days 
after infection. Both IFA and IPMA appear to be accurate for 2 to 3 months after 
infection, but may lose their ability to detect antibodies against PRRS virus as 
soon as 3 to 6 months after exposure to PRRSV.iO'i®'^^ The ELISA format is also 
reported to be sensitive and specific. ^  One study found that PRRSV-specific 
antibodies could be detected by ELISA as early as 10 days after exposure.^ As yet, 
the performance of the commercial ELISA has not been reported. The SVN test 
is also considered to be a specific test, but previous studies have suggested that 
the SVN test is less sensitive than the IFA and IPMA tests.3'5,ii Neutralizing 
antibodies against PRRSV may develop as late as 1 to 2 months after 
infection. However, a recent report indicated that the sensitivity of the 
SVN test could be increased by adding fresh normal swine serum to serum being 
assayed.27 Although difference in the performance is believed to exist among the 
4 PRRS serologic tests described above, lack of comparative information on the 
performance of PRRS serological tests makes it difficult for diagnosticians to 
standardize the test in use. 
Field observations suggest that humoral immunity against PRRSV 
persists in pigs as long as 1 year after initial outbreak, Field observations 
have also revealed that some herds experience 'cyclic' recurrence of PRRS 
approximately every 6 to 10 months after initial outbreak.23 One possible 
explanation for this observation may be antibody dependent enhancement (ADE) 
of virus infection. A recent study in our laboratory has demonstrated that 
PRRSV infection can be enhanced in vitro and in vivo by the presence of 
subneutralizing levels of virus-specific antibodies.28 This study also indicated 
that ADE potential may persist for 5 to 6 weeks in passively immunized pigs after 
SVN antibody titers fell below 1:4, suggesting that pigs with declining levels of 
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PRRSV-specific antibodies may be at increased risk for increased susceptibility to 
infection and a severe clinical manifestation of PRRS. 
The following study was conducted to both characterize the ontogeny of 
humoral immune response of pigs to PRRSV and to compare the performance 
of the IFA, IPMA, ELISA and SVN test using sera collected from a homogeneous 
group of pigs over a 105 day period following nasal inoculation with the ISU-P 
PRRSV isolate (ATCC VR-2402). Duration of humoral immunity against 
PRRSV was also estimated to determine if ADE potential exists in pigs with 
declining level of antibody induced by previous exposure to the virus. In 
addition, the viral protein specificity of the antibody response of these pigs was 
determined by western immunoblotting. 
MATERIALS AND METHODS 
Experimental design Eight 5- to 6-week-old crossbred pigs were obtained 
from a PRRSV-free herd. Pigs were numbered and randomly assigned to 2 
separately housed groups of 4 pigs each. All pigs were intranasally inoculated 
with 104-5 TCIDso of PRRSV. Serum samples were collected from each pig prior 
to inoculation, every other day during the first 15 days postinoculation (PI), and 
weekly thereafter through day 105. All sera were aliquoted and stored at -20°C 
until assayed for PRRS virus-specific antibodies by the IFA, IPMA, ELISA, and 
SVN tests. Aliquots of each serum sample were stored at -70°C until assayed for 
the presence of virus. Prior to performing the serological tests, serum samples 
were randomized and re-numbered. Results from the serological assays were 
compared by curvilinear regression.22 
The viral protein specificity of the antibody response was determined by 
western immunoblotting in 7 pigs using the same serum samples described 
above. Pigs were selected for the assay based on the time that neutralizing 
antibody were first detected, i.e., early responders (3 pigs) in which neutralizing 
antibodies appeared on days 9 or 11, and late responders (4 pigs) in which 
neutralizing antibodies were first detected on days 21 or 28 PI. Serum virus 
neutralizing antibody was not detected in one of the 8 pigs until day 15 PI which 
prevented its classification as an early or late responder. Consequently sera from 
this pig were not assayed by western immunoblotting. 
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Virus A cytopathic field isolate of the PRRSV designated ISU-P (ATCC VR-
2402) was used in the study. The virus was originally isolated from pigs in a herd 
undergoing an acute outbreak of PRRS using virus-free porcine alveolar 
macrophages (PAM). The isolate was purified by limiting dilution in PAM 
culture and plaque-cloned twice in MAI04 cells. The virus reproduced clinical 
disease compatible with PRRS in experimentally infected pigs and was 
recognized by PRRSV-specific monoclonal antibody, SDOW17a and polyclonal 
swine serum raised against PRRSV ATCC VR-2332.b In addition, electron 
microscopy and western immunoblotting revealed a morphological structure 
and protein composition similar to that reported by other investigators (Pol J and 
Wagenaar F: 1992, Am Assoc Swine Pract Newsl 4{A):29)M^ 
Virus isolation Serum samples were diluted 1:5 in RPMI-1640 medium'^ 
supplemented with 10% fetal bovine serum (FBS),<^ lOmM HEPES,'^ and an 
antibiotic-antimycotic mixture (lOOU/ml penicillin, 100^,g/ml streptomycin, 
gentamicin 50|ig/ml, 0. 25\ig/ml amphotericin B).*^ Diluted samples (0.2 ml) 
were inoculated onto 24-hour-old PAM cultures prepared in 48-well plates.<^ The 
inoculated cells were incubated at 37°C and observed for the cytopathic effect 
(CPE) typical of the virus for up to 7 days PI. The presence of PRRS virus in the 
cultures showing CPE was confirmed by subinoculating onto MAI 04 cell 
monolayers prepared on 8-chambered glass slides,® incubating for 48 hours, and 
staining with SDOW17 conjugated with fluorescein isothiocyanate.® A sample 
was considered negative after 2 blind passages in PAM. 
Indirect fluorescent antibody test The IFA test was performed using a 
protocol developed at the National Veterinary Services Laboratories, Ames, lA 
(Frey M, Eernisse K, Landgraf J, et al.: 1992, Am Assoc Swine Pract Newsl 
4(4):31).io In brief, MA104 cells were placed in 8-chambered glass slides and 
incubated in Dulbecco's modified Eagle's medium (DMEM)"^ supplemented with 
10% FBS and the antibiotic-antimycotic mixture for 48 to 72 hours at 37°C in a 
humidified 5% CO2 atmosphere. PRRSV-infected MA104 cell monolayers were 
prepared by inoculating culture medium with sufficient PRRS virus to produce 
15 to 20 plaque-forming units and incubating for 20 hours at 37°C. The 
monolayers were then fixed by immersion in 100% acetone for 10 minutes, air 
dried, and stored at -70°C until used. Viral antigen-free cell controls were 
prepared in an identical maimer. Sera to be tested were serially diluted 2-fold in 
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O.OIM phosphate-buffered saline, pH 7.2 (PBS) beginning with 1:20 dilution. 
Individual chambers were inoculated with 50p,l of each serum dilution and 
incubated at 37°C for 30 minutes in a humid environment. The preparations 
were then washed 3 times for 10 minutes each with PBS. Antigen-antibody 
reactions were visualized by reacting potential antigen-antibody complexes with 
optimally diluted goat anti-swine IgG conjugated with fluorescein 
isothiocyanate^ for 30 minutes at 37°C in a humid environment. Indirect 
fluorescent antibody titers were recorded as the reciprocal of the highest serum 
dilution in which tj^pical cytoplasmic fluorescence was observed. 
Immunoperoxidase monolayer assay Porcine reproductive and respiratory 
syndrome virus-infected MA104 cell monolayers were prepared in 96-well 
microtitration platesS by replacing DMEM supplemented with 10% FBS, lOmM 
HEPES, antibiotic-antimycotic mixture on confluent 1-day-old monolayers with 
the media (50|Lil/well) containing 10^ TCID50 of virus. After 1 hour incubation at 
37°C, 100|il of the media were added to individual wells. Microtitration plates 
containing both infected and uninfected (control) cell monolayers were 
maintained at 37°C for 2 days, fixed with cold acetone:methanol (70:30) for 10 
minutes, and stored at -20°C until used. Serum samples were serially diluted 2-
fold in O.IM Tris-HCl buffer (pH 7.6) beginning at 1:20. Immediately prior to use, 
fixed cell monolayers were treated with commercially supplied, pre-diluted, 
normal goat serume for 30 minutes at ambient temperature to block non-specific 
binding sites. Subsequently, duplicate SOfxl aliquot of each serum dilution were 
added to individual wells. The preparations were then incubated at 37°C for 30 
minutes and washed 3 times with Tris-HCl buffer. Antigen-antibody reactions 
were visualized with a biotin-streptavidin horseradish peroxidase system^i using 
the protocol provided by the manufacturer. In brief, SO^il of biotinylated goat 
anti-swine IgG conjugatee were added to individual wells and permitted to react 
with potential antibody-antigen complexes for 30 minutes at 37°C in a humidity 
chamber. The plates were washed as described above and excess buffer removed. 
Fifty |J,1 of streptavidin conjugated to peroxidasee was then added to individual 
wells and incubated at ambient temperature for 30 minutes. The plates were 
washed as described above, and antigen-antibody reactions were visualized by 
adding 100|Hl of diaminobenzidine tetrachloride substrate^ to individual wells 
and incubating for 5 to 10 minutes at ambient temperature. The color reaction 
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was stopped by washing with distilled, deionized water three times. 
Immunoperoxidase monolayer assay antibody titers were recorded as the 
reciprocal of the highest serum dilution in which a specific color reaction was 
observed. 
Enzyme-linked immunosorbent assay The ELISA was performed using a 
commercial kit (HerdChek®:PRRS)h as directed by manufacturer. All reagents 
necessary for performing the assay were provided with the kit, and the assay was 
conducted at ambient temperature. In brief, serum samples were diluted 1:40 in 
a sample diluent. One hundred |xl of each diluted sample was added to duplicate 
wells coated with proprietary PRRS viral antigen or normal cell antigen. 
Reference positive and negative pig sera, pre-diluted by the manufacturer, were 
also included in each plate. The plates containing reference and test sera were 
incubated for 30 minutes, then washed 3 to 5 times with a phosphate buffered 
wash solution containing Tween (300^1/well). Excess wash solutions were 
removed and 100|li1 of anti-porcine IgG conjugated with horseradish peroxidase 
were added into each well. After a 30 minute incubation, the conjugate was 
removed and the plates were rinsed as described above. Potential antigen-
antibody reactions were visualized by adding lOOfxl of TMB (3,3',5,5'-
tetramethylbenzidine) substrate solution and incubating for 15 minutes. Color 
reactions were then stopped by adding 100|il of a stop solution containing 
hydrofluoric acid into each well. Optical density (OD) of each well was measured 
at 630 nm of wavelength using a computerized microplate reader. The presence 
or absence of antibody to PRRS was determined by calculating the sample to 
positive (S/P) ratio as following: 
S/P = (AOD of test serum between viral and control antigen) ^ 
(AOD of positive reference between viral and control antigen) 
Samples were considered to be positive for PRRSV-specific antibody if the S/P 
ratio was greater than 0.4. 
Serum virus neutralization test The SVN test was performed in 96-well 
microtitration plates using MA104 cells. Serum samples were heat inactivated at 
56°C for 35 minutes prior to performing the test and serially diluted 2-fold in 
DMEM supplemented with 10% FBS, lOmM HEPES, and the antibiotic-
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antimycotic mixture. Each dilution of serum was mixed with an equal volume 
of PRRS virus containing 10^ TCID50 per 0.1ml and incubated at 37°C for 60 
minutes. Two himdred microliters of each mixture were added to a 
microtitration plate well containing 24-hour-old confluent MA104 cell 
monolayers and incubated at 37°C. Monolayers were observed at the end of 5 
days and antibody titers expressed as the reciprocal of the highest serum dilution 
in which no CPE was observed. Each sample was run in triplicate. 
Preparation of PRRSV antigens for the western immunoblot assay 
Confluent MAI 04 cell monolayers were infected with PRRSV at a concentration 
of 10^ TCID50 per 75-cm2 flask and incubated for 3-4 days at 37°C. Virus-infected 
cells were harvested and pelleted by centrifugation at 1000 x g for 10 minutes. 
The cell pellet was resuspended and disrupted in a lysis buffer (pH 8.0, 0.05M 
Tris, 0.15M NaCl, 0.002M EDTA, 0.5% deoxycholate, 0.1% SDS, 1% NP-40, 0.1% 
sodium azide, 0.1% gelatin, and 0.1% bovine serum albumin) at a rate of 1ml 
buffer per 0.1ml of cell pellet. The lysis buffer also contained protease iiihibitors 
as described previously. The suspension was stirred overnight at 4°C, then 
centrifuged at 600 x g for 10 minutes. The supernatant was saved as crude viral 
antigen, aliquoted, and stored at -70° C. Control antigen was prepared in the 
same manner using uninfected MAI 04 cells. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) A 
modified Laemmli procedure^^ used to separate proteins on a discontinuous 
slab gel (70 x 80 x 0.75mm) consisting of 5% stacking gel and 14% resolving gel, 
cross-linked with bis-acrylamide at a ratio of 30:0.8. Proteins were solubilized in 
sample buffer (pH 6.8) containing 0.0625M Tris, 2% SDS, 5% 2-mercaptoethanol, 
0.05% bromophenol blue, and 10% glycerol at 100°C for 5 minutes. Ten 
microliters of each denatured sample (20ng proteins) and 5^-1 of prestained SDS-
PAGE molecular standards' were loaded in alternate lanes on the gel. The 
molecular weight standard contained 6 proteins with molecular masses of 
approximately 43, 29,18,14.3, 6.2, and 3kD. Electrophoresis was carried out using 
a vertical mini-gel apparatusi as directed by the manufacturer. All gels were 
electrophoresed at 100 volts (Model 1000/500 power supply)) until samples 
reached the stacking/separating gel interface. Sample separation was then 
completed by electrophoresis at a constant voltage of 200 volts until the dye front 
98 
reached 0.5cm from the bottom. This migration hmit was imposed on all 
separations in an attempt to standardize protein migration patterns. 
Electrophoretic transfer of proteins A mini-trans-blot electrophoretic 
transfer cell) was used by following the recommended procedure of the 
manufacturer. Viral and cellular proteins, along with the standard molecular 
weight markers separated in gels, were electrophoretically transferred to 0.45iJ.m 
nitrocellulose membranes) immediately following SDS-PAGE. Transfer was 
carried out at 4°C for 60 minutes at 250 milliamperes in transfer buffer (pH 8.3) 
consisting of 25mM Tris, 192mM glycine, and 20% (v/v) methanol. 
Western immunoblot assay Nitrocellulose membranes containing viral 
and control cellular antigens were blocked overnight at 4°C with 1% gelatin 
dissolved in Tris-buffered saline (TBS, pH 7.5) containing 500mM NaCl and 
20mM Tris. The membranes were then washed for 10-15 minutes in gently 
agitating TBS and cut into strips containing viral and cellular antigens and 
molecular weight standards. Pig serum samples and reference sera were diluted 
1:10 and 1:50 in TBS containing 0.05% Tween 20 (TTBS) and 1% gelatin. The 
source of the positive reference serum was a serum collected from 3 month-old 
pig approximately 55 days after it had been experimentally infected with PRRSV 
isolate ISU-P by nasal inoculation. Normal reference serum was collected from 
an age-matched pig free of PRRS virus infection. Each diluted serum sample was 
added to a single membrane strip and incubated for 2 hours at 37°C in a 
humidified chamber. Following incubation, the membranes were washed 3 
times in gently agitating TTBS for 5 minutes. Antigen-antibody reactions were 
visualized with optimally diluted goat anti-swine IgG (H+L) labeled with 
horseradish peroxidase and TMB membrane peroxidase substrate.^ The color 
reaction was stopped by three brief washes in deionized water. Appearance of 
virus-specific reactivity was assessed by comparing the antibody responses to 
viral and cellular antigens. Approximate molecular weights were determined by 
comparison with the protein standards using linear regression. 
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RESULTS 
All pigs inoculated with PRRSV remained clinically normal over the 
course of the study. Viremia was first detected 3-5 days PI and persisted through 
days 9-15 PI. The antibody response over time, as indicated by the IF A, IPMA, 
ELISA, and SVN tests, is summarized in Table 1 and Figure 1. 
Porcine reproductive and respiratory syndrome virus-specific antibodies 
were first detected by the IFA test on day 9 PI in 4 of 8 pigs. The remaining 4 pigs 
seroconverted by day 11. The IFA titers rose to >640 by 28 days PI in all pigs, then 
began to decline. Antibody titers in 2 of 8 pigs had fallen below detectable limits 
by day 105 PI and ranged from 40 to 160 in the remaining 6 pigs. 
Specific antibodies were first detected by the IPMA on day 5 PI in 4 of 8 
pigs. The remaining 4 pigs seroconverted by day 9 PI. The IPMA antibody titers 
ranged from 640 to >1280 between 28 and 42 days PI. Thereafter, IPMA titers 
declined slowly, as compared to the IFA titers, ranging from 40 to >1280 on day 
105 PI. 
Antibodies specific for PRRSV were first detected by the ELISA on day 9 PI 
in 3 of 8 pigs. Four more pigs seroconverted on day 11 PI and the remaining pig 
seroconverted on day 13 PI. Based on the S/P ratio, ELISA titers rose to 
maximum value (2.0-3.0 S/P ratio) by 28 to 42 days PI, then began to decline. All 
8 pigs remained seropositive through day 105 PI and the S/P ratios ranged 
between 0.8 to 1.4. 
Serum virus neutralizing antibodies were slow to appear relative to 
antibodies detected by the other three tests. Neutralizing antibodies were first 
detected in 1 pig on day 9,2 pigs on day 11, and a fourth pig on day 15 PI. The 
remaining 4 pigs seroconverted by day 28 PI. Neutralizing antibody titers rose 
slowly for 63-77 days PI in 6 pigs and then began to decline. However, SVN 
antibodies in 2 of 8 pigs continued to rise through day 105 PI. Maximum SVN 
antibody titers ranged from 64 to >256 during the 105-day study period. On day 
105 PI, neutralizing antibody titers ranged from 8 to ^56. Assuming a constant 
rate of antibody decay from peak levels, ELISA, IFA, IPMA, and SVN antibody 
titers were estimated by regression analysis to drop below the detectable limits of 
the tests at approximately 137,158, 324, and 356 days PI, respectively. 
Table 1. The antibody response of 8 pigs after intranasal inoculation with PRRSV 
isolate ISU-P as detected by the indirect fluorescent antibody (IFA) test, the 
immunoperoxidase monolayer assay (IPMA), the enzyme-linked immuno­
sorbent assay (ELISA) and the serum virus neutralization (SVN) test 
Days postinoculation 
Test 0 3 5 7 9 11 13 15 21 28-98a 105 
IFA^O Ob 0 0 0 4 8 8 8 8 8 6 
IPMA ^20 0 0 4 6 8 8 8 8 8 8 8 
ELISA ^0.4c 0 0 0 0 3 7 8 8 8 8 8 
SVN 0 0 0 0 1 3 3 4 6 8 8 
^Represents identical responses from samples collected at 7-day intervals 28-98 days PI. 
''Number of pigs positive by each test where n = 8. 
•Presence or absence of specific antibodies was determined by calculating the 
sample-to-positive (S/P) ratio of optical densities at 1:40 dilution of samples. 
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Figure 1. Antibody responses of 8 pigs to PRRS virus infection by the indirect 
fluorescent antibody test (A), the immunoperoxidase monolayer assay (B), 
the serum-virus neutralization test (C), and the enzyme-linked immuno­
sorbent assay (D) (The line on each graph represents curve-fitting and dots 
show distribution of serologic response) 
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Western immunoblot analysis of early and late neutralizing antibody 
responders are summarized in Table 2 and Figure 2. Four PRRS viral proteins 
with molecular masses of approximately 15, 19, 23, and 26kD were consistently 
identified by western immunoblot (Figure 2). Antibodies specific for the 15 kd 
protein were first detected in all 3 early responder pigs on day 5 PI. In contrast, 
antibodies to the 19, 23, and 26kD proteins first appeared 11-15,15, and 9-11 days 
PI, respectively. Following their initial detection, antibodies against specific viral 
proteins were present through the remainder of the study. 
No response to viral protein was detected in the 4 late responders until 
day 7 PI. Antibody to the 15kD protein was detected in all 4 pigs on day 7 PI. 
Antibody specific for the 26kD protein was first detected 15-28 days PI. Antibodies 
specific for the 19 and 23kD proteins appeared 21-28 and 28-42 days PI, 
respectively. As in the early responders, antibodies against specific viral proteins 
persisted until the end of the study following their initial detection. 
Viremia, initial detection of neutralizing antibody, and first appearance of 
antibodies against each PRRS viral protein are given in Table 3 for individual 
pigs. Viremia was first detected in all early responders on day 3 and all late 
responders on day 5 PI. The mean duration of viremia in early responders was 
10.3 days PI, in contrast to 14.0 days PI in late responders. The mean onset of 
neutralizing antibody in early responders was 10.3 days PI versus 24.5 days PI in 
late responders. The mean onset of antibodies to the 15,19, 23, and 26 kd viral 
proteins as determined by western immunoblot was 5.0,12.3,15.0, and 10.3 days 
PI in early responders, and 7.0,24.5, 33.3, and 19.8 days PI in the late responders. 
DISCUSSION 
The objective of this study was to characterize the ontogeny of the 
humoral immune response in pigs to PRRS virus infection. The antibody 
response was monitored using four serological tests routinely used to detect 
PRRS virus-specific antibodies (IFA, IPMA, ELISA, and SVN). The viral antigen 
specificity of the antibody response was further characterized by western 
immunoblot analysis. The period of time for which PRRSV-specific antibodies 
persist in pigs after infection was estimated by regression analysis. 
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Figure 2. Representative western immunoblot analysis of the antibody 
response of pigs to PRRSV infection using pooled sera from 3 
early SVN responders in which neutralizing antibodies were 
first detected between 9 and 11 days PI, and 4 late SVN 
responders in which neutralizing antibodies were initially 
detected between 21 and 28 days PI 
lane 1: positive reference serum on viral antigen 
lane 2: positive reference serum on control antigen 
lane 3: early and late responders prior to infection' 
lane 4: early responders on day 7 PI 
lane 5: early responders on day 15 PI 
lane 6: late responders on day 7 PI 
lane 7; late responders on day 15 PI 
lane 8: late responders on day 28 PI 
Table 2. A comparison of PRRSV protein specificity of antibodies in pigs (n=7) following nasal inoculation 
with PRRSV isolate ISU-P as determined by western inravunoblot analysis 
Days postinoculation 
First detectable SVN response Viral protein 0 3 5 7 9 11 15 21 28 35 42-105^ 
Early responders^ 15 kD Oc 0 3 3 3 3 3 3 3 3 3 
19 kD 0 0 0 0 0 2 3 3 3 3 3 
23 kD 0 0 0 0 0 0 3 3 3 3 3 
26 kD 0 0 0 0 1 3 3 3 3 3 3 
Late responders'^ 15 kD 0 0 0 4 4 4 4 4 4 4 4 
19 kD 0 0 0 0 0 0 0 2 4 4 4 
23 kD 0 0 0 0 0 0 0 0 2 3 4 
26 kD 0 0 0 0 0 0 2 3 4 4 4 
^Represents identical responses from samples collected at 7-day intervals 42-98 days PI. 
''SVN response first detected on day 9 or 11 postinoculation (n = 3). 
^Number of pigs with detectable antibody against each viral protein. 
'^SVN response first detected on day 21 or 28 postinoculation (n = 4). 
Table 3. The chronological appearance of virus, serum virus neutralizing (SVN) activity and 
antibodies specific for virus proteins in 7 pigs following nasal inoculation with PRRSV 
isolate ISU-P 
Pig Detection of viremia Appearance of Appearance of antibody against viral proteins 
First day Last day SVN activity 15 kP 19 kP 23 kP 26 kP 
1 3® 9 9 5 11 15 9 
2 3 11 11 5 11 15 11 
3 3 11 11 5 15 15 11 
4 5 13 21 7 21 28 15 
5 5 13 21 7 21 28 15 
6 5 15 28 7 28 42 21 
7 5 15 28 7 28 35 28 
^Number of days after inoculation with PRRSV. 
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Porcine reproductive and respiratory syndrome virus-specific antibodies 
were first detected 5-to-9 (IPMA) 9-to-ll (IFA), 9-to-13 (ELISA), and 9-to-28 (SVN) 
days PI and, assuming a constant antibody decay rate, were predicted to decline to 
the lower limits of detection by approximately 137 (ELISA), 158 (IFA), 324 (IPMA), 
and 356 (SVN) days PI. The initial antibody responses of pigs to PRRS virus 
infection as revealed by the four tests (IFA, IPMA, ELISA, SVN) evaluated in this 
study are in general agreement with the findings of other investigators who 
reported that PRRSV-specific antibodies were initially detected by the IFA test, 
IPMA and ELISA 7 to 10 days PI in contrast to detection by the SVN test which 
did not occur tmtil days 28 to 35 PL2/10,16,18,23,24,26 xhe results suggest marked 
differences in the kinetics involved in the 4 tests. Overall, the IPMA appeared to 
provide the best overall performance based on its ability to detect antibodies in 
both early and late infections, as well as the relatively short tum-around time of 
the test. However, sensitivity and specificity comparisons must be carried out 
before concluding which is actually the best test. It is also possible that the 
antibody response of the experimentally infected pigs as detected by the 4 
serological tests could have been different if the pigs were infected at an earlier or 
later age, were of a different genetic background, or were infected with a different 
PRRSV isolate. 
The estimated decay of PRRSV-specific antibodies in pigs after initial 
infection in our study is compatible with field observations suggesting that anti-
PRRSV antibodies persist for approximately 1 year in pigs which had been 
exposed to the virus. Although recovered pigs are considered to be immune, 
recurrence of PRRS every 6 to 10 months after initial outbreak has been observed 
in some swine herds.23 Recently investigators monitored decay of passive 
antibody specific for PRRSV in pigs injected with polyclonal immimoglobulin 
and correlated it to the presence of ADE activity in undiluted serum.^^ Results of 
the study suggested that pigs with declining levels of virus-specific antibody are 
susceptible to the potential enhancing effect of ADE for a period of 5 to 6 weeks 
after the SVN antibody titers in these pigs drop below 1:4. A similar period of 
potential susceptibility to ADE may also exit in pigs with declining level of anti-
PRRSV antibody induced by exposure to wild type virus. In the present study, 
the SVN antibody titers in infected pigs are predicted to fall to 1:3 or lower by 280 
day PI, while nonneutralizing antibody as measure by IPMA are estimated to 
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persist for additional 44 days. The potential period of increased susceptibility 
may be an explanation of the cyclic recurrence of PRRS in the i'ieid. 
The PRRSV consists of at least 3 structural proteins with molecular masses 
of approximately 15,19, and 26kD In our study we consistently detected 15,19, 
23, and 26 kD viral proteins by western immunoblot (Figure 2). Investigators 
recently described the detection of 15,16,19, 22, and 26kD proteir\s by 
radioimmunoprecipitation.5 The detection of an additional protein (16kD) is 
consistent with genomic studies of the PRRSV indicating that as many as 6 
structural proteins may be encoded by the viral genome.^'^'^ The failure to detect 
the 16kD protein in our study may have been due to conformational changes of 
this protein brought about by the reducing conditions that the viral preparation 
was subjected to during processing for western immunoblotting. In the current 
study, antibodies specific for the 15 kD protein were detected in all pigs by day 7 PI 
and persisted through day 105 PI (Table 2). Antibodies to the remaining 3 
proteins (19, 23, and 26kD) were not detected until 15 days PI in any early SVN 
antibody producing pigs. Antibodies to these 3 proteins were not detected in any 
late SVN antibody producing pigs until day 42 PI. These results clearly indicate 
that the 15kD protein is the most immunogenic of the PRRSV structural 
proteins and may provide the antigenic basis for the development of improved 
diagnostic tests for the detection of PRRS virus specific antibodies. 
The data summarized in Tables 2 and 3 also indicate that the 15kD protein 
is not associated with neutralizing activity since antibody to this protein was 
present in 4 of 8 pigs for 14 to 21 days prior to the initial detection of neutralizing 
antibody. In contrast. The 26kD protein appears to be involved in the induction 
of neutralizing activity. This conclusion is based on the fact that no SVN activity 
was detected in any of the 4 late responding pigs until after antibodies to the 26kD 
protein were present. Further work needs to be done to address the potential 
role that antibodies specific for the 19 and 23kD proteins may play in viral 
neutralization. In addition, a previous study has indicated that the 26kD protein 
is highly associated with the induction of antibody associated with ADE.29 
Consequently, it requires further study to identify antigenic determinants of 
PRRSV which are responsible for the induction of ADE and/or SVN activity. 
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GENERAL DISCUSSION 
Introduction 
Porcine reproductive and respiratory s3mdrome is a relatively new viral 
disease of swine. The disease is manifested by reproductive failure in breeding 
age swine and respiratory disease in young pigs. Field observations have 
indicated that pigs at 3 to 5 weeks of age are highly susceptible to PRRSV 
infection and often develop a severe respiratory clinical manifestation of PRRS. 
The high incidence of PRRS and the increased severity of disease seen in pigs of 
this age group has lead to the coining of the term, 'post weaning PRRS.' The 
time period in which post weaning PRRS commonly occurs corresponds to the 
time period that the level of maternal antibody specific for PRRSV approaches 
the lower limits of detection. The apparent correlation between time of 
occurrance of the post weaning syndrome and low maternal antibody levels has 
raised the question of whether or not ADE contributes to the pathogenesis of 
PRRS. 
Antibody dependent enhancement of infection has been shown to 
contribute to disease caused by other viruses, such as dengue virus (DV), feline 
infectious peritonitis virus (FIPV), Aleutian disease virus (ADV) of mink, and 
equine infectious anemia virus. Antibody dependent enhancement has also 
been shown to interfere with the development of effective immunization 
strategies for these viruses. Recent field observations suggest that ADE may also 
interfere with immunization for PRRS. Enhanced clinical manifestation of 
PRRS has frequently been observed in herds after a modified live virus PRRS 
vaccine was introduced to control the problem. Consequently, the main purpose 
of this study was to determine if ADE of PRRSV infection is biologically 
significant and whether or not ADE has the potential to interfere with effective 
immunization strategies. 
Summary of findings 
The preceeding study demonstrated that infection of PAM by PRRSV is 
significantly enhanced in vitro in the presence of subneutralizing levels of virus-
specific antibody. A similar enhancement of PRRSV infection in the presence of 
antibody was also observed in vivo. The mean level and duration of viremia 
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was significantly greater in pigs that were injected with subneutraUzing amounts 
of virus-specific IgG prior to virus challenge than in control pigs which were 
injected with normal serum globulin. In addition, an experiment in which the 
rate of decline of injected polyclonal PRRSV-specific antibody was monitored 
and correlated to ADE suggested that pigs are susceptible to the potential 
enhancing effect of ADE for a period of 5 to 6 weeks following the disappearance 
of SVN antibody. A similar period of potential susceptibility to ADE was 
observed in pigs that were infected with PRRSV by the nasal route. The antibody 
response of these pigs was monitored by the IFA test, IPMA, ELISA, and the SVN 
test for 105 days post inoculation. Regression analysis of data indicated that 
neutralizing antibodies persist for 280 days following infection while non-
neutralizing antibodies were estimated to persist for an additional 6 weeks. The 
study also revealed that field isolates of PRRSV vary in their susceptibility to 
ADE of infection. This variability was dramatically demonstrated by the 
neutralization of homologous virus by a concentration of antibody that 
enhanced the replication of heterologous isolates. Collectively, these 
observations clearly suggest that ADE of PRRSV infection has the potential to 
contribute to the pathogenesis of PRRS and to interfere with immimization 
strategies. 
ADE assays 
Antibody dependent enhancement of PRRSV infection was assessed by 
measuring increases in virus yield and by determining infection rates of PAM in 
the presence of PRRSV-specific antibody. All ADE assays used in the present 
study to measure these two parameters were highly reproducible because no 
significant variation was observed in results obtained between days on which the 
assays were performed. In addition. The agreement between two assays in 
detecting ADE activity in all sera tested was 100%, indicating that the two assays 
are compatible for detection of virus infection enhancing activity in serum. 
Two assays were used to measure increases in progeny virus yield: the 
standard ADE assay and the modified ADE assay. The standard ADE assay was a 
modification of the assay described by Moren and Halstead.^os This assay is 
considered to be a quantitative assay. The assay was performed by treating a 
constant amount of virus with a series of dilutions of serum. Subsequently, 
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PAM were inoculated with the virus-serum mixtures, and changes in virus yield 
corresponding to each dilution of the serum were monitored. Using this assay, 
ADE of PRRSV infection was shown to be dependent on antibody concentration 
of serum (Figure 1, p.55). This characteristic generated an 'enhancement profile' 
which is characterized by appearance, peak and disappearance of ADE activity 
based on antibody concentration in each dilution of serum.^os 
The enhancement profile is considered to represent total ADE activity that is 
present in a serum. In particular, since the enhancement profile is expressed as a 
polynominal regression curve, the area integrated under the curve may be 
proportional to enhancing activity of serum for a virus. This method was 
applied in this study to evaluating the susceptibility of different PRRSV isolates 
to ADE mediated by antibody raised against a PRRSV isolate. Differences in the 
susceptibility to ADE among the isolates were clearly demonstrated by this 
approach (Figure 2, p.82). 
The modified ADE assay was a variation of the standard ADE assay. The 
assay was conducted in the same maimer as the standard ADE assay with the 
exception that PRRSV was treated with undiluted serum or a specific dilution of 
PRRSV-specific IgG. This assay is considered to be a qualitative test but may be 
practical as compared to the standard ADE assay. In attempting to correlate in 
vitro ADE with an in vivo effect, the method of expressing ADE activity is of 
critical importance. For instance, the presence of enhancing activity in undiluted 
serum of an individual was a significant risk factor for severe dengue illness by 
subsequent DV infection.In the present study, a direct correlation was also 
demonstrated between the presence of ADE activity in undiluted serum of pigs 
which was determined by the modified ADE assay prior to challenge and 
subsequent effect of ADE on the level and the duration of viremia in these pigs 
following challenge (Table 1 and Figure 5, pp.61-62). Consequently, it is likely 
that the modified ADE assay can be used in place of the standard ADE assay in 
assessing ADE activity in sera. 
Yield of progeny virions and infection rates of PAM were determined at 
the end of 48 hour incubation following removal of virus-serum mixtures from 
cultures. This time period was selected because maximum differences in virus 
yield or the infection rate of PAM were observed between treatment and control 
groups in a preliminary study. However, one replication cycle of PRRSV in 
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PAM was reported to be approximately 20 hours when the cells were inoculated 
with a multiplicity of infection (m.o.i.) of 1.244 Consequently, it is not believed 
that progeny virus yields and cell infection rates observed in the study only 
represent the first outcome of replication. 
The mean yield of infectious progeny virions per macrophage was 4.7 and 
11.9 in the absence and presence of virus-specific antibody, respectively. These 
numbers of progeny virions per cell are considered low, regardless of the 
treatment. This low yield is believed to be a reflection of the sensitivity of the 
assay system. Bautista et al. compared the susceptibility of PAM and MA104 cells 
to PRRSV by comparing the frequency that PRRSV was isolated from clinical 
specimens using both cell types. These investigators found that higher rates of 
virus isolation could be achieved using PAM than MA104 cells. In a preliminary 
study, virus titers determined using PAMs were 2 logio higher than virus titers 
determined using MA104 cells (unpublished data). Consequently, if virus assays 
were done using PAM, the virus yield per infected cell would approach 
approximately 500 to 1000 virions per cell which are in a range of virus yield of 
arteriviruses.239 However, MA104 cells were used in place of PAM for virus 
titration in the present study to avoid the potential inconsistency of results due 
to the variation in the susceptibility to PRRSV between lots of PAM because the 
yield of PAM from individual pigs was relatively small. 
The infection rate of PAM in the presence of subneutralizing levels of 
virus-specific antibody approached 1% which is consistent with a m.o.i of 0.01. 
In contrast, the infection rate of PAM was approximately 0.02% in the presence of 
only media. The low infection rate in the absence of antibody might be attributed 
to the presence of high numbers of virus particles which were not capable of 
attaching to PAM through the interaction with viral receptors on the cells. In 
addition, the heterogeneity of the PAM population may also have been 
responsible for the low infection rate. Choi et al. reported that PAM could be 
divided into several subpopulations based on their density.^® The cells of these 
subpopulations varied in their physiological maturity, immunological function, 
and their susceptibility to PRRSV infection. Yields of PRRSV in macrophage 
subpopulations ranged from 1 to 5 logio. 
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Mechanism of ADE of PRRSV infection 
The study demonstrated that both total yield of infectious virions and the 
infection rates of PAM in cultures were increased following treatment of the 
virus with subneutralizing levels of PRRSV-specific antibodies (Figure 1, p. 55). 
The primary mechanism responsible for increased virus yields appears to have 
been due to an increase in the infection rates of PAM which was facilitated by an 
interaction between Fc receptors of PAM and virus-antibody complexes. This 
conclusion is based on two observations. First a direct correlation (r=0.95) was 
observed between increased virus yields and infection rates of PAM (Figure 3, 
p.58). Secondly virus yields were significantly reduced when virus/antibody 
preparations were treated with Protein A prior to exposing PAM to virus (Figure 
4, p. 59). Protein A binds to Fc portion of antibody, which prevents virus-
antibody complexes from attachment to Fc receptor on cells. Similar 
observations have been made by other investigators who studied ADE of 
ADV,158 dV,132 FIPV,225 and West Nile virus (WNV) infection.232 
Additional mechanism(s) may have contributed to the enhancement of 
virus yield in the presence of virus-specific antibody. This possibility is 
supported by the fact that the ratio between increases in virus yield and infection 
rate was greater than 1.4 (Figure 3, p.58). This conclusion is also consistent with 
the observations that not only was the infection rate of PAM increased but also 
the yield of progeny virions from individual PAM (Figure 2, p.57). The increased 
yields of progeny virus in PAM may have been due to increased efficiency of 
virus production. This possibility has been previously reported for other viral 
infections. For example, Robbinson et al. observed higher production of viral 
components in cells that were infected with the human immunodeficiency virus 
in the presence of virus-specific antibody than in the absence of antibody.259 xhe 
mechanism responsible for the enhanced production of viral components in 
individual cells was not determined. However, Collins et al. who studied ADE 
of WNV infection in mouse macrophages presented data which suggested that 
infection of individual cells by several virions could increase virus 
production.106 These investigators found using radiolabeled virus that 
radioactivity count per cell was significantly increased when the cells were 
exposed to the labeled virus in the presence of subneutralizing levels of anti-
WNV antibody. They also observed using nonradiolabeled virus that virus 
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yields were enhanced in the presence of the same concentrations of the antibody. 
The investigators concluded that antibody increased the numbers of WNV 
attached to individual cells which resulted in increased yields of progeny virus. 
It is unlikely that multiple viral infection of individual PAM was responsible for 
the increased efficiency of virus production in the present study because a low 
m.o.i., i.e., 0.01 was used and infection rates were increased in the presence of 
antibody. 
Biological significance of ADE in the pathogenesis of PRRSV 
The preceding study demonstrated that pigs with subneutralizing levels of 
PRRSV-specific antibodies are susceptible to ADE of virus infection, in turn 
resulting in higher level of viremia for longer period (Figure 5, p.62). This 
observation indicates that ADE has the potential to increase the severity of 
disease through amplification of virus replication. The study also revealed that 
the potential of increased susceptibility to ADE exists for a period of 5 to 6 weeks 
in pigs with declining levels of PRRSV-specific antibodies after SVN activity 
drops below detectable levels (Figure 7, p.64). Collectively, these observations 
strongly suggest that ADE of PRRSV infection has the potential to contribute to 
post weaning PRRS in young pigs in which levels of maternal antibodies specific 
for PRRSV are declining. 
In the challenge experiment, it was expected that a marked difference in 
the clinical response would be observed among treatment groups because ADE of 
other virus infection is often manifested by an exacerbation in the severity of 
disease. Disease enhancement in the presence of antibody has been most notably 
demonstrated in humans and cats infected with DV^^s and FIPV,309 respectively. 
Although ADE effect was apparent among treatment groups with respect to the 
duration and the level of viremia, no overt clinical signs of disease were evident 
in infected pigs in any treatment group. Similar observations have also been 
made by Christianson et al. who conducted a study in which fetuses of sows were 
exposed in utero to PRRSV with or without antibody between 40 and 45 days of 
gestation.5® The fetuses were subsequently removed from the sows at day 4 and 
11 postinoculation and examined. No difference in the fetal death rate was 
observed between the 2 groups, but significantly higher virus titers were detected 
in fetuses that were injected with PRRSV-antibody mixtures than fetuses that 
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were only injected with the virus. The lack of clinical signs of disease especially 
with respect to respiratory disease was not completely unexpected because the 
respiratory form of PRRS has not been consistently reproduced under 
experimental conditions, even though respiratory disease is a major component 
of PRRS in the field. It is possible that the lack of clinical manifestations in the 
study may have been due to the challenge route and/or the virus strain used for 
the study. The intramuscular route was used in the study instead of the nasal 
route of exposure which is considered to be the natural route of infection.^i 
Temperature response and virus shedding pattern were not monitored in the 
above study. If these parameters had been monitored, it may have been possible 
to reach a more definitive conclusion with respect to the role of ADE in clinical 
disease. 
The failure to consistently reproduce respiratory disease suggests that this 
manifestation of PRRS may be multifactorial. The apparent failure of antibody 
to contribute to the disease process in the study does not rule out ADE as a 
contributing factor to disease. The contribution of ADE may have been more 
apparent if a heterolgous PRRSV isolate were used as the challenge virus. This 
possibility is supported by the observation that field isolates of PRRSV varied in 
their susceptibility to ADE of infection (Figures 1 and 2, pp.81-82). Another factor 
that has the potential to contribute to the respiratory clinical manifestations of 
PRRS is concurrent infection with bacteria. The PRRSV replicates preferentially 
in PAM, which results in the destruction of these cells. The above study 
demonstrated that infection of PAM by PRRSV is enhanced in the presence of 
virus-specific antibody. Consequently, ADE of PRRSV infection has the potential 
to compromise the local immune defense system of the lung through 
destruction of PAM. It is also conceivable that the function of uninfected PAM 
could be compromised by soluble viral or virus-induced proteins. In turn, the 
loss of the first immune defense mechanism in the lung could increases the 
susceptibility of pigs to infection by other opportunistic respiratory disease 
pathogens, resulting in exacerbation of respiratory disease. Synergistic effects of 
PRRSV infection on the severity of disease by subsequent exposure to bacterial 
pathogens have been demonstrated.i04,i65,274 por example, Gallina et al. 
demonstrated that PRRSV infection predisposed pigs to subsequent infection of 
Streptococcus suis, resulting in increased mortality due to streptococcal 
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meningitis.Similarly, investigators at the Iowa State University observed that 
pigs infected concurrently with PRRSV and Salmonella choleraesuis showed 
severe clinical responses, such as fever, depression, inappetence, while no overt 
clinical signs were observed in pigs infected with either PRRSV or salmonella 
alone (J. Zimmerman, Iowa State University, personal communication). 
The present study indicates that ADE may also be a concern with respect to 
pigs with declining levels of antibodies that were induced by previous exposure. 
Experiments in which the neutralizing and non-neutralizing antibody responses 
of nasally infected pigs were monitored suggests that these antibodies will persist 
in pigs for approximately 280 days and 324 days, respectively (Figure 1, p.lOl). 
Since ADE can only be expressed in vivo in the absence of neutralizing antibody, 
it is conceivable that pigs in the field are susceptible to the effects of ADE for 
approximately 44 days. This potential period of increased susceptibility could be 
an explanation of the cyclic recurrence of PRRS in the field. Field observations 
have suggested that clinical PRRSV infection reoccurs in herds approximately 
every 6 to 10 month following the initial PRRS outbreak.®3,296 Collectively, it 
appears that ADE has the potential to increase the severity of PRRS in the field 
among pigs with declining levels of antibody of maternal or vaccine origin, or 
antibody originally induced by wild type virus infection. 
Significance of the variability in the susceptibility of PRRSV isolates to ADE in 
the development of immunization strategies 
The above study also demonstrated that field isolates of PRRSV vary in 
their susceptibility to ADE of infection. This characteristic of PRRSV was 
dramatically illustrated by the neutralization of isolate ISU-P by a concentration 
of homologous antibody that significantly (p<0,01) enhanced the replication of 12 
of 16 heterologous field isolates tested (Figure lA, p.81). This observation is 
particularly significant with respect to the control of disease by vaccination. For 
example, antibodies induced by vaccine strains of PRRSV could either enhance 
or suppress the replication of wild type PRRSV in vaccinated animals. In 
addition, these findings suggest that the replication of vaccine virus in the host 
could also be enhanced by maternal antibody specific for some field strains of 
PRRSV. Both of these mechanisms could conceivably contribute to the 
exacerbation of PRRS that is occasionally observed in North American swine 
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herds in which vaccine is being used (B Thacker, Iowa State University, Ames, 
lA, personal communication; G. Erickson, Rollins Animal Disease Lab, Raleigh, 
NC). 
Variation in the susceptibility to ADE of infection among virus isolates 
has previously been documented for other viruses, such as DV133,141 and 
FIPV70'225 Iji the case of DV, differences in the susceptibility of DV isolates to 
ADE have been suggested to account for different clinical manifestation of DV 
infection. 128,206 poj. example, the severity of DV infection is much greater in 
individuals with antibodies from previous infection, especially if the previous 
infection was due to a different serotype. ^ 28 Isolates of DV and FIPV have also 
been found to vary in their ability to induce enhancing antibodies.133,225 
variability in the susceptibility to ADE and the ability to induce ADE among 
these viruses have been implicated as important obstacles in the development of 
vaccines and vaccination strategies.^85 The present study also demonstrated the 
potential for ADE of PRRSV infection to interfere with immunization strategies 
for PRRS. These observations suggest that vaccine candidates should be 
evaluated for their ability to induce ADE activity before their use in the field. In 
the present study, PRRSV isolates that were more susceptible to neutralizing 
activity of antibody were shown to be less susceptible to ADE than isolates with 
lower susceptibility to neutralization by the same antibody (Figure 4, p.85). 
Consequently, it may be possible to use the susceptibility of field isolates to 
neutralization by antibody induced by vaccine candidates, as a surrogate marker 
for ADE. Field application of this approach in terms of evaluating vaccine 
candidates needs further work. 
Correlation analysis (Figure 4, p.85) indicates that the degree of 
enhancement mediated by a high concentration of antibody raised against an 
isolate of PRRSV that was capable of neutralizing infection by homologous virus 
was inversely proportional to the ability of this antiserum to neutralize the 
isolates (r=0.92). This observation suggests that the variability in the 
susceptibility of isolates to ADE may be associated with quantitative and/or 
qualitative differences in the antigenic determinants associated with virus 
neutralization. In contrast, a poor correlation (r=0.32) was observed between the 
susceptibility to SVN and ADE mediated by a low concentration of the antibody. 
This lower correlation was because 5 of 17 isolates tested fell outside of the 99% 
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confidence interval. If the 5 isolates were excluded from the analysis, the 
correlation coefficient was 0.91. The apparent lack of correlation between 
susceptibility to SVN and ADE mediated by a low concentration of antibody 
associated with these 5 PRRSV could be a reflection of quantitative and 
qualitative differences in the antigenic determinants of the isolates. These 
observations suggest that ADE can also be mediated by antibody specific for 
antigenic determinants that are only partially associated with SVN or not 
associated at all. 
Role of PRRSV proteins in ADE 
Western immunoblot analysis (WIA) revealed the presence of antibody 
specific for the 15kD nucleocapsid protein and the envelope-associated 26kD 
glycoprotein throughout the period that ADE activity was present in undiluted 
serum of pigs that were injected with polyclonal PRRSV-specific IgG (Table 2, 
p.66). The location of the 26kD protein in the viral envelope suggests that 
antibodies induced by this protein are associated with ADE. Other investigators 
have reported that ADE of other virus infections is also mediated by antibodies 
induced by envelope-associated proteins.173,184 n jg ^Iso possible that other 
envelop-associated proteins of PRRSV that were not detected by assay in the 
present study, such as the 43kD glycoprotein described by Madassi et may 
induce antibodies that contribute to ADE. Because of the internal location of the 
15kD nucleocapsid protein within the virion, it is unlikely that antibodies 
induced by this protein were associated with ADE even through they were 
detected throughout the period that ADE activity was detected in undiluted 
serum. However, it is conceivable that antibody specific for the 15kD protein 
could contribute to in vivo enhancement of PRRSV infection if the integrity of 
the viral envelope is compromised by host defense mechanisms. 
The 26kD protein appears to be also involved in the induction of 
neutralizing activity. This conclusion is based on the observation that no SVN 
antibody was detected in any pig challenged with PRRSV by nasal route until 
after antibodies specific for the 26kD protein were present in serum of infected 
pigs as determined by western immunoblotting (Table 3, p. 105). Consequently, it 
may be possible that the 26kD protein contains antigenic determinants which 
differ in their function: one is primarily associated with virus neutralization and 
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the other is not. Studies of FIPV and DV have revealed the existence of antigenic 
determinants associated with neutralization and ADE on the same 
protein. 141,207,225 these studies, investigators were able to categorize the 
monoclonal antibodies that represent the epitopes of envelope protein into 3 
groups according to their ability to a) only neutralize, b) both neutralize and 
enhance, and c) only enhance virus infection. Consequently, the identification 
of such antigenic determinants associated with ADE on PRRSV proteins and 
their exclusion from vaccines may be beneficial. 
Immunization strategies to avoid the potential adverse affect of ADE 
Antibody dependent enhancement has the potential to contribute to the 
severity of disease and possibly to increase the susceptibility of pigs to infection by 
PRRSV. These possibilities are of particular concern with respect to young pigs 
with declining levels of maternal antibodies since young pigs are especially 
susceptible to respiratory disease induced by PRRSV. Results of this study 
showed that virus replication was significantly suppressed in pigs with virus 
neutralizing antibody titers greater than 3.4 log2 and that ADE activity was not 
detected in undiluted serum until the SVN titers fell below 2 log2 (Figure 5B, 
p.62). Consequently, potential adverse affects mediated by ADE might be avoided 
by designing immunization strategies that maintain high serum virus 
neutralizing activity in young pigs. In addition, the present study also revealed 
that strains vary in the susceptibility to ADE and that such a variation may be 
due to difference in antigenic determinants associated with virus neutralization 
and/or ADE. Consequently, it may be possible to develop a vaccine with low or 
no ADE potential. Such an approach could be accomplished by selecting vaccine 
strains according to their ability to induce enhancing antibody or by genetically 
engineering a vaccine so that antigenic determinants that are strongly associated 
with ADE are excluded. 
Future study 
Results of the proceeding study indicate that ADE of virus infection may 
be a virulence factor in the pathogenesis of PRRSV as well as interefere with 
immunization strategies. It is highly conceivable that ADE may play a significant 
role in the induction of disease in young pigs with circulating maternal antibody 
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specific for PRRSV. This conclusion is based on the following observations. 
First, ADE activity was demonstrated in imdiluted serum of pigs that were 
injected with virus-specific polyclonal antibody. Secondly, subneutralizing 
levels of passively supplied antibodies significantly enhanced the level and 
duration of viremia in pigs following virus challenge. Thirdly, PRRSV isolates 
were shown to vary in their susceptibility to ADE in vitro. 
These observations could be one explanation of the apparent exacerbation 
of clinical PRRSV infection in swine that has been observed in some herds 
following vaccination with RespPRRS® marketed by NOBL Laboratories. 
Therefore, the question of whether or not vaccine-induced antibody can 
contribute to clinical disease in piglets needs to be resolved. Specifically, can the 
injection of live vaccine virus into pigs in the presence of maternal antibody 
specific for a wild type PRRSV increase the level and duration of vaccine virus 
which could conceivably contribute to the disease process? In addition, can low 
levels of vaccine-induced antibody can mediate ADE of infection of wild type 
virus that may be circulating in a herd? For example, the development of 
vaccine-induced antibody in piglets could be impeded in the presence of 
maternal antibody but be sufficient to enhance infection of wild type PRRSV. 
Since previous studies have been done in pigs with passively supplied 
PRRSV-specific antibody, another critical question that needs to be answered is 
whether or not ADE of virus infection can occur in pigs that have been actively 
immunized with vaccine virus. If ADE of infection occurs in pigs with passive 
antibody but not in pigs with active immunity, then emphasis should be directed 
toward developing immunization strategies that induce a strong cell-mediated 
immunity or persistently maintain high levels of SVN antibody. Furthermore, 
if ADE does occur in the presence of active immunity, then efforts should be 
extended to identifying antigenic determinants associated with ADE and 
excluding them from a vaccine virus. 
Since the present study suggests that antibody specific for the 26kD protein 
of PRRSV is responsible for ADE, initial work for the identification of antigenic 
determinants associated with ADE should focus on this protein. However, it is 
possible that other proteins besides the 26kD protein may also be involved in the 
induction of enhancing antibodies. An experimental approach is to generate a 
panel of monoclonal antibodies specific for each viral protein and evaluate each 
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of them for their ability to enhance or neutralize virus infection. This approach 
has been used to identify determinants associated with neutralization and ADE 
for other viruses, most notably FIPV. 70,225 
Differences in the ability of different subclasses of virus-specific IgG to 
mediate ADE of viral infection has been demonstrated with murine monoclonal 
IgG specific for DV and FIPV proteins70'^4i,i45,207 jt is also known that 
polysaccharide antigens induce one type of IgG subclass and polypeptide antigens 
primarily induce the production of a different IgG subclass. There is no reports 
describing differences in the subclasses of antibodies representing antigenic 
determinants of polypeptides, this is an area that should be explored to 
determine if subclass differences are associated with specific antigenic 
determinants associated with ADE. The identification of such antigenic 
determinants could lead to their exclusion from vaccines and further reduce 
ADE activity associated with vaccination. 
The respiratory form of PRRS seen in the field has not been reproduced 
experimentally. Only immunologically naive pigs have been used in these 
studies to date. The failure to reproduce the respiratory manifestation of PRRS 
has led investigators to the speculation that additional factor may be involved. 
One factor that should be investigated is ADE because it increases both the 
infection rate and virus production in PAM. These cells play a critical role in the 
pulmonary immune response, and any disruption in their normal function 
could permit increased virus replication in the lung and increase the lung 
susceptibility to secondary bacterial infection. 
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